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Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological entity that includes a 
spectrum of histological and biochemical anomalies. NAFLD begins with excessive lipid 
accumulation within hepatocytes (hepatic steatosis) and can transition to non-alcoholic 
steatohepatitis (NASH), characterized by hepatic inflammation and injury that can 
render the liver vulnerable to bridging fibrosis, cirrhosis, and hepatocellular carcinoma. 
Dietary cholesterol has been proposed as a potential mediator of the transition from 
steatosis to NASH. Guinea pigs are similar to humans in terms of hepatic cholesterol 
metabolism and were implemented in three studies to explore its contribution to NAFLD. 
In study one male guinea pigs (n = 10/group) were randomly assigned to either a 0.25% 
high-cholesterol (H-Chol) or a 0.04% low-cholesterol diet (L-Chol) for six weeks. H-Chol 
feeding promoted weight loss (p = 0.0009), hypercholesterolemia, elevated plasma 
alanine and aspartate aminotransferases (p = 0.042, p = 0.049 respectively), and 
accumulation of total hepatic cholesterol  (p < 0.0001) and triglyceride (p = 0.002). H-
Chol livers developed moderate steatosis along with evidence of mild inflammation and 
injury. Therefore, these results support the participation of increased dietary cholesterol  
 
 
Ryan Cole deOgburn- University of Connecticut, [2013] 
in promoting NAFLD. Macronutrient composition also influences NAFLD, therefore 
study two sought to determine the impact of feeding a diet low in carbohydrate and high 
in fat (LCD; n = 9) or a high carbohydrate diet (HCD; n = 10) to guinea pigs with 
cholesterol-induced NAFLD. Both groups failed to improve liver histology despite 
greater lipid accumulation in LCD livers. Biochemical liver injury was similar between 
groups, suggesting that both LCD and HCD are unable to improve cholesterol-mediated 
NAFLD. Study three demonstrated that phospholipids (PL) and triglycerides from H-
Chol livers had an increased unsaturated and decreased saturated fatty acid profile. H-
Chol also significantly lowered levels of PL arachidonic acid (p = 0.004). There were no 
differences between LCD or HCD, however both had significant reductions in overall PL 
content (p = 0.001) and similar increases in unsaturated and decreases in saturated 
fatty acid in PL and triglyceride when compared to H-Chol. In conclusion, elevated 
dietary cholesterol participates in NAFLD development and impacts the effectiveness of 
dietary intervention in guinea pigs. 
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 1 
 
GENERAL INTRODUCTION: NON-ALCOHOLIC FATTY LIVER DISEASE 
 
Opening Remarks: 
If one were to select at random a scientific publication concerning non-alcoholic 
fatty liver disease (NAFLD) it would almost invariably contain a rather bland introductory 
statement describing NAFLD as a ‘ spectrum beginning with benign simple steatosis 
and progressing to non-alcoholic steatohepatitis, which ultimately can result in cirrhosis 
and liver failure’. Quite apart from the pervasiveness of these sentiments in academic 
literature, this type of statement is severely misleading in several respects. First, this 
description suggests a relative uniformity in NAFLD pathogenesis amongst all 
individuals regardless of some rather key differences like ethnicity, gender, and 
biological age.  Second, and perhaps somewhat more seriously, this phraseology 
insinuates that fatty deposition and infiltration (herein uniformly referred to as hepatic 
steatosis) is a simplistic process and of minor pathological concern compared to the 
more progressive stages of the disease.  Lastly this description leads one to believe that 
the NAFLD spectrum is unidirectional and culminates inevitably with cirrhosis, in 
essence implying a lack of potential regression or improvement of NAFLD.   
The danger of the aforementioned introductory statement is not the emergence 
of these specific misconceptions themselves, for any sound discussion concerning the 
epidemiology and histopathology of NAFLD would undoubtedly clarify many of these 
issues. What is particularly dangerous is the ubiquity of these vague, uninformative 
phrases throughout the literature and how this reflects a serious lack of critical 
questioning on the part of researchers themselves. Certainly the field of NAFLD 
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research has undoubtedly made enormous progress over the past few decades since 
its initial discovery, fueled by comprehensive experimental approaches in cellular, 
animal, and human studies. It is therefore of great importance to continue moving 
forward, which involves not only performing solid research, but effectively 
communicating the intricacies of such a disease to other scientists and the general 
public as well. Accordingly, the aims of this introduction are two-fold: First, to 
unequivocally correct and summarily dismiss the misconceptions that inevitably arise 
from such a damagingly trite description of a massively complex disease such as this, 
and second, to offer an alternative narrative of NAFLD that is more comprehensive in 
scope and truthful in detail. 
The ensuing chapters of this dissertation place a heavy emphasis on dietary 
considerations- specifically cholesterol and macronutrient composition- in NAFLD 
pathogenesis. Building off of the introductory section, Chapter 1 of the literature review 
follows with an overarching description of cholesterol metabolism, that is its dietary 
absorption, entrance into the liver, intracellular trafficking, and regulatory mechanisms 
governing homeostasis. It then sifts through some key studies that highlight the 
pathophysiological ramifications of excess dietary cholesterol on the liver and how this 
spurs NAFLD progression in animals and humans. It concludes by making a case for 
the guinea pig as an attractive experimental approach for exploring the nuances of 
hepatic cholesterol metabolism and NAFLD. Chapter 2 shifts the attention to 
macronutrients and how dietary carbohydrate and fat elicit changes in hepatic metabolic 
pathways that are prominent in NAFLD. It then proceeds with a discussion of 
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carbohydrate-restricted diets and how, on a biochemical level, this dietary scheme has 
the potential to improve metabolic parameters associated with NAFLD. The dissertation 
then proceeds with three studies, each with a specific research aim designed to build 
upon preexisting evidence in the field. Finally, the project concludes with some closing 
remarks and suggestions for the direction of NAFLD research.  
Nomenclature: Acronyms galore 
More than thirty years have passed since Ludwig et al’s seminal encounter with a 
“hitherto unnamed disease”(1), which they pointedly termed nonalcoholic steatohepatitis 
(NASH).  Unnamed no longer, the histopathological lesions observed by Ludwig’s group 
enjoy distinction today as the leading cause of chronic liver disease in adult and 
pediatric populations the world over, ranging from the United States, South America, 
and Europe in the West to the Middle East, Australia, and Asia in the East.  Considering 
the enormity of societies affected by the emergence of this disease, it stands to reason 
that a uniform nomenclature system exist to appropriately refer to NASH and its 
associated histological spectrum.  At present Ludwig’s original definition of NASH is 
recognized as an entity within the more comprehensive framework of nonalcoholic fatty 
liver disease or NAFLD.  
To those not intimately involved in this research field (as well as to the more 
reflective researchers within it), the very term NAFLD appears to rely more on a lack of 
association with excessive alcohol intake than with any specific underlying pathological 
phenomena. And given that NAFLD is almost universally recognized as the hepatic 
manifestation of the metabolic syndrome (2), this has in turn prompted an outpouring of 
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alternate descriptions such as “metabolic syndrome steatohepatitis (MESH)”, “metabolic 
fatty liver disease”, “insulin-resistance-induced steatohepatitis (IRISH)”, and so on (3). 
While the debate is certain to continue as more studies are published, NAFLD seems 
descriptive enough to remain in use for the foreseeable future; this is fortunate given 
that there are also distinct differences in the pathological progression of NAFLD and 
alcoholic liver disease (ALD).  
A Global Continuum: NAFLD epidemiology in America and abroad 
 
 One often hears or reads today about the global extent of noncommunicable 
diseases such as cardiovascular disease and type 2 diabetes and how these conditions 
reflect an increasingly sluggish lifestyle and poor dietary behaviors that result in 
rampant obesity. The statistics certainly are startling. For example it is currently 
estimated that more than 1.1 billion adults are overweight across the globe, and even 
more depressing is that roughly 300 million adults and at least 155 million children are 
actually classified as obese (4). Obesity itself is reflective of the many metabolic 
derangements such as dyslipidemia and poor glucose tolerance that define the 
metabolic syndrome, thus clinical measures such as plasma lipids, glucose, and body 
mass index are easily obtainable and are the most reliable markers for proper 
diagnosis. There is also a hepatic component to obesity and metabolic syndrome (2) 
that deserves consideration, for the last twenty years have witnessed an increase in the 
prevalence of NAFLD which closely parallels that for obesity (5). Unlike the 
standardized clinical tests that evaluate obesity and metabolic syndrome, there are no 
set standards for evaluating the presence of NAFLD with the exception of a liver biopsy. 
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Typical biochemical measures such as alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and alkaline phosphatase (ALP)-the so called liver enzymes-
are notably unreliable at predicting hepatic steatosis or fibrosis (6). Despite being 
heralded as the ‘gold standard’ for NAFLD diagnosis, a liver biopsy is an intrusive 
procedure fraught with risks of complications, especially for children, and is also quite 
expensive financially. Moreover, biopsies are prone to sampling error as well as 
differences in histopathological interpretation (7). Ultimately these inherent difficulties 
pose significant obstacles to obtaining true estimates of NAFLD prevalence. 
 Despite these pitfalls of NAFLD diagnosis, there is a general consensus that 
NAFLD poses an emerging and formidable public health concern. In the United States 
for example, typical estimates for adults range between 2.8%-46% (8) while 
approximately 10% of all children are estimated to display some features indicative of 
NAFLD (9). Ethnicity has been shown to be influential in terms of susceptibility to 
NAFLD and progression along the histological spectrum. A seminal study in the United 
States conducted by Browning et al (10) found that fatty infiltration or steatosis is 
greatest amongst older men when compared to women, and the frequency is highest 
amongst Hispanics, followed by white, and black populations respectively. This was a 
population-based study and did not speculate on potential mechanisms, but these 
findings, along with others (11,12) suggest that gender and ethnic differences likely play 
prominent roles in determining overall susceptibility to disease progression.  
 NAFLD is also rapidly emerging throughout various global populations, many of 
which live in developing nations that have increasingly adopted a so-called ‘Western’ 
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diet. Data is hard to come by, however the most recent and comprehensive reports 
estimate approximately 20% of the entire global population has some degree of NAFLD 
(8). There are also several estimates that have been published for populations of South 
America (13), Japan (14), Australia (15), northern Europe (16), southern Europe (17), 
and the Middle East (18). Much of this data however is from the 1990’s, therefore 
present-day estimates and population-based studies are eagerly awaited to further 
characterize the epidemiology of NAFLD. Argo et al (19) and Chitturi et al (20) have 
published two very well researched and comprehensive reviews that discuss in detail all 
of the available data to date.  
‘Hepatomania’: A brief appreciation of liver physiology 
The sheer magnitude of physiological functions that the liver is responsible for 
makes it an organ like no other.  It serves as the central hub for virtually all metabolic 
processes and is equipped with a staggering enzymatic arsenal-one can conceive of the 
liver as a kind of biochemical powerhouse, simultaneously coordinating a vast network 
of metabolic pathways that engage nutrients, macromolecules, and xenobiotics alike.  It 
is of course no great surprise that the liver has been a subject of inquiry since the 
earliest civilizations, as Hesiod the eighth century poet attests with his description of 
Zeus’ vengeful punishment of the rebellious Prometheus. This now well known 
capability of the liver for regeneration is interesting from an evolutionary perspective in 
the fact that the liver is the only organ capable of regeneration. This attests to its crucial 
importance in ensuring metabolic homeostasis and general survival of the organism 
itself.  We will not attempt here a thorough description of liver physiology as a whole.  
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Instead the aim is to emphasize how aspects peculiar to the liver, such as its anatomical 
location and diverse cell population ensure smooth and efficient coordination of the 
many basic tasks fundamental for metabolic balance and general survival.   
The liver finds itself constantly exposed to an array of substances, three-quarters 
of which travel through hepatic lobules via transport from the portal vein.  Portal blood 
emanates from the intestine, spleen, pancreas, as well as gallbladder and consequently 
is enriched in nutrients and foreign xenobiotic compounds; the remaining one quarter of 
hepatic blood, supplied by the hepatic artery, is concentrated with oxygen and 
circulating hormones and exit via the terminal arterioles branching throughout the 
hepatic parenchyma. Arterioles, along with the portal venules and major biliary duct are 
extended throughout the liver parallel to one another, forming the conspicuous portal 
triad characteristic of the hepatic lobule. The average human liver consists of 
approximately 100,000 lobules, each about 1 millimeter in diameter. The lobules are 
hexagonally shaped structures with a total of six portal triads present at each corner. 
Situated at the center of the lobules are the central veins which collect the blood 
delivered by the portal vein and hepatic artery and eventually empty into the inferior 
vena cava.  
Hepatocytes represent the overwhelming cell type of the liver, accounting for 
78% of total liver volume (21). These polarized epithelial cells are arranged as cords 
one cell thick and because their surface faces fenestrated sinusoidal endothelial cells, 
they have direct access to both incoming dietary and exogenous substances. They are 
also capable of secreting endocrine substances such as lipoproteins directly into the 
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blood stream. Each hepatocyte is closely bordered by neighboring ones that form tight 
junctions, generating a canaliculus that is responsible for the collection of bile acids and 
salts which travel across the apical hepatocyte surface (22,23). In addition to bile 
secretion hepatocytes are the cell type responsible for a litany of functions that include 
the metabolism of cholesterol, lipids, carbohydrates, proteins, as well as regulation of 
the acute phase response and blood clotting (23).   
Hepatocytes are complimented by a panoply of other distinct cell types. 
Sinusoidal endothelial cells (about 2.5% total volume) are unique cells with distinct 
fenestrations that allow uptake of circulating molecules, sometimes which may be quite 
large (a classic example is chylomicron remnants) and because they lack a basement 
membrane, substances are able to travel to hepatocytes for processing (24). Other cells 
such as cholangiocytes (about 3% of total cell population) control the rate of bile flow 
(23), while still others such as stellate cells (1.4%) are involved in the maintenance of 
the extracellular matrix and storage of vitamin A (25). Kupffer cells ( 2%) are the 
resident macrophage cell of the liver and represent the largest population of 
macrophages of any organ in the human body, making the liver a potent participator in 
immunological processes (26). The diversity of the liver cell population should be kept in 
mind when the discussion turns to the pathological changes that characterize NAFLD. 
For instance, it is the hepatocytes which are prone to excessive lipid accumulation and 
stellate cells which when activated by cytokine stimulation trigger the fibrogenic 
response to injury (see below). It is therefore critical that NAFLD be thought of as a 
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disease of multi-cellular collaboration, which is where the focus of the discussion now 
turns.  
Homogeneous No More: Pathological characteristics of the NAFLD spectrum 
The entire NAFLD pathological spectrum begins with an increased cytoplasmic 
accumulation of lipids (in the form of triglyceride) within various liver cells, 
predominantly hepatocytes, and is referred to as hepatic steatosis.  Steatosis is the sine 
qua non of NAFLD and presents histologically as either large globules with 
displacement of the nucleus to the cellular periphery (macrovesicular) or as smaller 
indentations around the centrally located nucleus, creating a ‘foamy’ cytoplasmic 
appearance (microvesicular) (27).  A mixture of both macrovesicular and microvesicular 
patterns tends to predominate in human NAFLD (27-29) and is typically localized within 
perivenular hepatocytes of zone 3 (30).  In contrast, truly microvesicular steatosis never 
occurs in isolation in NAFLD and when present, usually occurs in a nonzonal 
distribution within contiguous patches of hepatocytes that often harbor 
megamitochondria (31).  Lastly, steatosis that is present without accompanying 
inflammation or liver injury is often incorrectly referred to as ‘simple’ steatosis; there is 
however, nothing actually simple about steatotic development given that it involves a 
complex interplay of molecular, biochemical, and metabolic events both at the level of 
the liver as well as peripheral organs such as adipose and muscle.   
While steatosis is the histological hallmark of NAFLD, this pathological 
abnormality alone is insufficient for a diagnosis of the more inflamed and dangerous 
NASH stage of the spectrum.  In NASH, hepatocytes begin to transition from being 
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merely lipid-engorged to being inflamed and architecturally distorted, thus accurate 
diagnosis of NASH relies on the presence of steatosis, inflammation, and several 
features of hepatic injury (32). In NASH, inflammation can be either lobular or portal in 
nature, although evidence acquired from human liver biopsies suggests that lobular 
inflammatory infiltrates predominate (31).  Typically much of the inflammation occurs in 
zone 3, which anatomically is exposed to lower circulating oxygen and consists of small 
foci of mixed inflammatory infiltrates composed of lymphocytes, eosinophils, 
occasionally polymorphonuclear leukocytes, and aggregates of Kupffer cells (27,30,31).  
Clusters of Kupffer cells are referred to as microgranulomas or pigmented Kupffer cells 
and form as a result of their migration from their normal periportal location in zone 1 to a 
perivenular zone 3 position where they engulf and phagocytose apoptotic and necrotic 
hepatoyctes (33). As the resident macrophages of the liver the participation of Kupffer 
cells in hepatic inflammation is unsurprising, however it is interesting that very little 
attention has been paid to Kupffer cell aggregation as a pathological entity of NAFLD, 
although there are some exceptions (27). When hepatic macrophages contain 
noticeable lipid droplets they are referred to as lipogranulomas that may be observed in 
either perivenular, portal, or lobular areas. It should be emphasized that the 
inflammatory pattern of NASH is drastically different from that typically observed in other 
severe liver diseases such as chronic hepatitis or cholestasis, in that NASH 
inflammation is generally mild and tends to occur primarily within the lobules rather than 
portal areas (34). 
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Concomitant with inflammation are features of hepatic injury that can include 
ballooned hepatocytes, Mallory-Denk bodies (MDB), megamitochondria, glycogenated 
nuclei, acidophil bodies, and spotty necrosis (27,28,30).  Ballooning degeneration of 
hepatocytes is one of the most crucial determinants of NASH diagnosis and refers to 
the enlargement or swelling of hepatocytes, most often in zone 3 in the midst of 
surrounding steatotic hepatocytes (27).  Morphologically, ballooned hepatocytes have a 
loss of their normal hexagonal shape, are larger, and retain rarified cytoplasm that may 
be due to intracellular fluid accumulation (32).  It is worth mentioning here that 
histological identification of ballooned hepatocytes can be quite challenging and it is not 
uncommon for pathologists to have to distinguish these lesions from swollen, glycogen-
rich hepatocytes (29).  Additionally, ballooned hepatocytes are often one of the most 
difficult lesions to consistently reproduce in animal studies of NAFLD.  MDB, which are 
dense eosinophilic intracytoplasmic perinuclear inclusions, are often found within 
ballooned hepatocytes and result from impaired proteosomal degradation of 
cytoplasmic proteins, mainly those that bind to ubiquitin (28,30).  Often this type of 
lesion is found within cells of zone 3 and can be detected through 
immunohistochemistry using monoclonal antibody staining specific to either cytoplasmic 
filaments or ubiquitin itself (35).  
Distorted organelle morphology can also be present in NASH and often this 
involves the mitochondria.  Megamitochondria are observed as intracellular eosinophilic 
inclusions often in hepatocytes with microvesicular steatosis (29) and ultrastructurally 
present as multi-lamellar membranes with paracrystalline inclusions, often with an 
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apparent loss of cristae (28).  Whether these mitochondrial abnormalities reflect a 
progressive adaptation to cellular stress (30) or indeed implicate NASH as a disease of 
the mitochondria themselves as has recently been proposed (36), is still relatively 
unclear. 
All cells retain the requisite molecular machinery to engage in a program of 
calculated self destruction referred to as apoptosis (37). Existence of such a dramatic 
pathway offers protection to the tissue and organism itself from the far more deleterious 
consequences of uncontrolled release of cytoplasmic contents and unwarranted 
activation of the immune system, which are features characteristic of a not so 
coordinated type of cell death, necrosis (33). A thorough description of the molecular 
details in both modes of cell death will not be attempted here, but thankfully there is a 
relative abundance of informative reviews available, much of which emanates from 
research conducted by Gregory Gores and colleagues (38-41). Germane to the current 
discussion is that in NASH, hepatocytes undergo both forms of death, creating unique 
histological features. Activation of the apoptotic signaling cascade, either through the 
extrinsic, death receptor mediated pathway or the intrinsic, intracellular organelle 
pathway results in the collapse and shrinking of individual hepatocytes along with 
distinctive chromatin condensation and nuclear fragmentation, culminating in the 
‘blebbing’ of the plasma membrane into small vesicles termed apoptotic bodies (40,42). 
In NASH, the presence of these bodies tends to correlate with the severity of apoptosis 
itself (43). Whereas apoptosis represents a metabolically active form of cell death, 
oncotic necrosis occurs in situations when cellular energy in the form of adenosine 
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triphosphate (ATP) is limited and thus represents a form of uncontrolled cell death 
(38,39). Hepatocyte swelling, loss of membrane integrity, rupture, and release of 
cytoplasmic components are distinctive features of oncotic necrosis that typically trigger 
a robust hepatic inflammatory response. Histologically this can be observed in foci of 
Kupffer cell aggregates that surround single hepatocytes within the sinusoid (43), 
however often times both features of cell death coexist in liver pathology. Thus in the 
pathophysiological setting of NASH it is likely that both apoptosis and necrosis occur, 
especially considering they share several of the same initiating factors and signals (33). 
There comes a point in the NAFLD spectrum, as in other chronic liver diseases, 
when the liver seeks to protect itself from these previously enumerated onslaughts by 
enacting a wound-healing response; this is done in an attempt to encapsulate the 
existing injury and is accomplished through accelerated deposition of extracellular 
matrix components which collectively give rise to the hepatic scar (44). Such 
components include a vast array of proteins that include fibril-forming collagens, 
proteoglycans, and fibronectin and their accumulation reflects both increased synthesis 
as well as decreased degradation (44,45); here it should be pointed out that the extent 
of extracellular matrix remodeling which occurs in fibrosis is a chronic process, typically 
over the course of several years, sometimes even decades, which is in stark contrast to 
organs such as kidney and lung which have a much more rapid fibrotic progression 
course (46). These differences are likely due to the unparalleled regenerative capacity 
of the liver. Accordingly, the liver is quite resilient to the early pathological changes that 
accompany fibrosis and if the source of injury is eliminated, fibrosis can potentially 
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reverse course (44). Cirrhosis on the other hand, represents the most advanced stage 
of fibrosis, is not reversible, and is characterized by even greater hepatic scarring along 
with the distortion of the hepatic parenchyma and the formation of nodules of 
regenerating hepatocytes. These alterations to hepatic architecture culminate in 
impeded blood flow and portal hypertension that substantially increase the risk of overall 
hepatic failure (46).  
The evolution of fibrosis is not surprisingly, quite complex and involves a multi-
cellular collaborative effort, which for brevity’s sake will not be further delineated here, 
although the interested reader should consult the litany of insightful reviews composed 
by Scott Friedman that have greatly facilitated current molecular and clinical 
conceptions of this process (44,46-48). The work by Friedman and colleagues 
throughout the years has demonstrated that the principal mediator of fibrosis is the 
stellate cell (49), which normally resides in the Space of Disse as a quiescent, inactive 
cell. When stimulated by appropriate stimuli, be it reactive oxygen species (ROS) due to 
oxidative stress, apoptotic bodies that are engulfed by Kupffer cells, cytokines or other 
soluble mediators, stellate cells undergo activation which results in several phenotypic 
changes that include increased proliferation, contractility, altered matrix degradation, 
and inflammatory signaling (46).  
In general, despite varying etiologies (viral hepatitis, alcohol abuse, iron or 
copper overload for example) fibrotic development tends to retain several of the same 
general cellular and molecular features. This does not mean however that the pattern or 
relative distribution of fibrotic tracts within the lobules themselves are similar in all 
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instances. A case in point is NASH. NASH has a uniquely distinctive fibrotic signature 
compared to other chronic liver diseases like hepatitis and cholestatic diseases in that 
the initial collagen deposition begins within the pericellular or along the perisinusoidal 
spaces, predominantly within zone 3 (27,29,31,32,34,43). This so-called ‘chicken wire’ 
type of fibrosis tends to extend and radiate outward from the central veins. As the 
collagen fibers begin to form bridges across the parenchyma, hepatocytes become 
trapped and form islands, resulting in seriously distorted hepatic architecture and not 
surprisingly, impaired functioning of the liver itself (34). 
Having discussed, albeit somewhat briefly, the vast extent of pathological 
changes visited upon the liver during NAFLD, the focus now shifts inwards towards the 
cellular pathways that, on a molecular and biochemical level, strongly govern these 
hepatic alterations. The attentive researcher should nonetheless be aware of the 
necessity of both fields of study; that is, one cannot simply focus on the style or pattern 
of pathological lesions nor solely on mechanistic data and hope to produce a 
comprehensive picture of NAFLD pathogenesis. A deeper understanding instead 
requires an appreciation for both pathology and biochemistry alike.  
A Not So ‘Simple’ Spectrum: Pathological and biochemical anomalies in hepatic 
steatosis 
 
In situations of macronutrient abundance, such as immediately after a meal or 
during situations of prolonged caloric overload, cells such as adipocytes and 
hepatocytes store surfeit metabolic energy in the form of triglycerides (TG). These inert, 
highly reduced lipid molecules reside within the hydrophobic core of lipid droplets (LD), 
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specialized organelles designed to, among other functions, shelter neutral lipids like TG 
as well as cholesterol esters (CE) away from the aqueous cytoplasm (50,51). When 
circumstances dictate, the stored lipid can be hydrolyzed and released as fatty acids 
where they can then serve as intermediates in the synthesis of various lipid species or 
as bioactive ligands by binding to key nuclear hormone receptors like peroxisome-
proliferator activated receptor α (PPARα), which in turn elicits key changes in overall 
hepatic lipid metabolism (52). Thus by regulating the flux of lipid in cells, LDs serve as 
crucial components of lipid metabolism, with increasing evidence suggesting a 
prominent role for these organelles during times of health as well as disease itself (see 
reference 53 for a recent review).  
There is also another side to LDs, which is their participation in the development 
of steatosis.  Mechanistically this occurs when TG begins to be stored in amounts that 
exceed mechanisms of export and breakdown and clinically manifests when lipid 
content exceeds 5% of the liver by weight. Normally the liver contains only relatively 
small amounts of stored lipids, yet in the face of excessive fatty acids hepatocytes can 
enact several mechanisms that effectively funnel incoming fatty acids towards pathways 
responsible for TG production, and ultimately, LD incorporation.    
At the level of the liver, TG content is reflective of fatty acid uptake (either from 
circulating fatty acids or dietary lipoproteins), endogenous synthesis, fatty acid 
oxidation, and secretion in the form of very-low density lipoprotein (VLDL). The latter 
two mechanisms are the major means hepatocytes use to reduce hepatic TG content 
(54). Donnelly et al (55), using stable isotope methodology found that the overwhelming 
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majority, or 60%, of hepatic TG were derived from the plasma fatty acid pool. 
Approximately 26% of liver TG were accounted for through endogenous production or 
de novo lipogenesis (DNL), while 15% was shown to come from the diet. Thus in this 
key study the major sources in humans with NAFLD seem to come principally from 
peripheral fatty acids and DNL. Among some of the offered explanations for steatotic 
development aside from increased fatty acid uptake and lipogenic production is possible 
impairments in the mitochondrial oxidation of fatty acids and defective hepatic VLDL 
assembly and release (56). Available evidence, at least in humans, largely seems to 
indicate that fatty acid oxidation is normal, or even increased in patients with steatosis 
as demonstrated by Sanyal et al (57). Using nondiabetic patients with steatosis  or 
NASH, Sanyal et al found that serum beta-hydroxybutyrate levels were greater in both 
groups compared to non-obese control subjects, although the highest rates were 
observed in the NASH group. Impaired VLDL assembly or secretion on the other hand, 
does in fact seem to be implicated in generating fatty liver in humans (58,59). For 
instance, Charlton et al (58) evaluated the absolute synthesis rate of apoB-100 using 
stable isotope methodology and found a marked decrease in apoB-100 synthesis in 
patients with steatosis and NASH compared to controls. Thus while the study by 
Donnelly et al (55) indicates elevated DNL and uptake of circulating fatty acids as the 
prime culprits in promoting steatosis it is important to keep in mind the potential 
participation of impaired mobilization of VLDLs, which is now starting to garner more 
intensive interest in the field.  
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Assaults from All Angles: The folly of the two-hit hypothesis in the steatosis to 
NASH transition 
 
 Metabolism in its barest sense represents the totality of all biochemical reactions 
that enable survival. Of the over 8,700 reactions and 16,000 metabolites documented in 
the Kyoto Encyclopedia of Genes and Genomes (www.genome.jp/kegg/pathway.html) 
three core processes predominate: 1) the construction of simple or more complex 
macromolecules (anabolism); 2) the degradation of molecules for generation of energy 
(catabolism); and 3) the elimination of reactive and harmful biochemical intermediates 
(disposal).  As the field of biology itself continues to splinter into more refined sub-
disciplines with increasing precision and refinement of experimental techniques, there 
has been a call for a more comprehensive understanding of the nuances of metabolism 
as it relates to disease. DeBerardinis et al are quite correct in their perspective of the 
impossibility to view metabolism “merely as a self-regulating network operating 
independently of other biological systems” (60).  Certainly any perturbation within a 
particular metabolic pathway will affect the performance of other metabolic routes in a 
particular physiological context. Pathological conditions such as diabetes, insulin 
resistance, cardiovascular dysfunction, and NAFLD, among others, are poignant 
illustrations of distinct disturbances within the metabolic web that wreak havoc both 
locally within cells and globally throughout the organism. Thus, just as ripples in a pond 
extend beyond the pebble, interruptions in metabolic nodes create ripples throughout 
the entire biological network leaving no system unscathed.  
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 This comprehensive approach to metabolism and how it factors into the genesis 
of disease seems an appropriate philosophy to adopt towards NAFLD, whose 
pathophysiology involves multiple derangements within several distinct, but 
interconnected hepatic pathways.  Accelerated flux of metabolites (glucose, fructose, 
certain amino acids) through the lipogenic pathway, dysregulated synthesis of VLDL 
particles, inefficient decarboxylation and oxidation of fatty acids (both mitochondrial and 
peroxisomal), and inappropriate handling and storage of fatty acid pools are the primary 
mechanisms at the level of the liver that are responsible for steatosis, the sine qua non 
of NAFLD.  External to the liver are adipocytes that through alterations in their own 
signaling pathways are unable to respond to insulin’s suppressive effect on lipolysis, 
producing high levels of unesterified fatty acids that mobilize to the liver.  The situation 
becomes even more daunting during the inflammatory transition of steatosis to NASH. 
Here, metabolically stressed organelles like the mitochondria and endoplasmic 
reticulum (ER) react to a variety of cellular insults by engaging pro-inflammatory 
mechanisms such as apoptosis, ER stress, and the unfolded protein response (UPR) 
that promote organelle destruction and cellular death, excessive release of dangerous 
pro-inflammatory mediators, alterations in nutrient utilization and energy production, and 
most seriously, distort liver architecture to produce the conspicuous inflammatory 
infiltrates, ballooned hepatocytes and cross-linked fibrotic tracts that define NASH.  
 So, not only does one have to be cognizant of metabolic interruptions within the 
liver in understanding the emergence of NAFLD-we would also do well here to 
remember the diversity of the liver cell population and that these metabolic ripples 
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extend throughout hepatocytes as well as stellate and Kupffer cells alike- but also within 
the adipose and to some extent, skeletal muscle as well.  To gain some insight as to 
why a broader, more encompassing metabolic perspective is better suited towards the 
study of NAFLD we need to first revisit those earlier conceptions articulated by 
Christopher Day and Oliver James in what has come to be known as the “two-hit” 
hypothesis (61). 
 In reflecting on the years following Ludwig et al’s publication of NASH as a 
distinct, pathological phenomena it seems fair to say that by the late 1990’s, research 
had come to somewhat of a crossroads.  For instance it was understood that many 
patients with severely fatty liver often never progressed to steatohepatitis (62). 
Somewhat counter intuitively, it was also known that despite varying etiologies, the 
progression of steatohepatitis could be characterized by several of the same histological 
features. This prompted researchers to ask whether there was the existence of some 
unifying mechanism that could sufficiently explain both the tendency of certain 
individuals to progress beyond steatosis as well as histological similarities that present 
during different clinical situations. 
  In 1998, Day and James in an editorial published in the journal 
Gastroenterology (61), posited that one such unifying mechanism linking steatosis to 
hepatic inflammation and fibrosis was lipid peroxidation.  Citing data produced by 
Dominique Pessayre’s lab in which rat liver mitochondria, hepatocytes, or rats 
themselves were exposed to drugs capable of producing so called ‘classical’ 
steatohepatitis (cationic amphiphilic amines) (63), Day and James hypothesized that 
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lipid peroxidation potentially “explains most, if not all, of the diverse histological features 
observed in this condition”.  In Berson et al’s study, the administration of these drugs 
inhibited mitochondrial β-oxidation and respiratory capacity and increased the 
production of various reactive oxygen species (ROS), triggering a 5-10 fold increase in 
lipid peroxidation. The appeal of these data for Day and James was that they 
convincingly demonstrated that a cellular insult capable of initiating lipid accumulation, 
in this case the inhibition of fatty acid oxidation, could serve as a first “hit”.  The 
impairment of mitochondrial respiration and function that followed could then 
theoretically serve as a second “hit” in which free radicals emanating from the 
mitochondria were free to attack susceptible fatty acid chains of membrane 
polyunsaturated fatty acids (PUFA).  According to this hypothesis the capability of 
certain bi-products of peroxidation could in turn initiate many of the cellular processes 
such as apotosis, necrosis, and pro-inflammatory cytokine signaling characteristic of 
lesion formation, thus offering a unifying framework of steatohepatitis progression. 
 It may help to consider for a moment the ‘lipocentric’ nature of the “two-hit” 
hypothesis.  Lipids, as fatty acids are here needed first to secure the development of 
steatosis which emerges from an overload of the oxidizing systems responsible for fatty 
acid deconstruction.  Such an overabundance of fatty acids in turn increases the 
availability for them to serve as substrates for the principal microsomal cytochrome 
P450 enzymes, CYP2E1 and CYP4A.  Normally these enzymes function to hydroxylate 
and convert non-polar substrates, including fatty acids, to more polar compounds for 
eventual conjugation or excretion.  As their catalytic activity is dependent on oxygen 
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however, there are a great many harmful metabolites produced from this system and it 
is these superoxide anions (O2._), hydrogen peroxide (H2O2), and hydroxyl radicals (-
OH), that when produced in amounts exceeding antioxidant species lead to a state of 
cellular oxidative stress (64).  ROS can also be produced from complexes of the 
mitochondrial respiratory chain and because of their fairly short half-life, many of the 
cellular effects occur in a close proximity to mitochondria themselves; these local effects 
include the depletion of adenosine triphosphate (ATP) and nicotinamide dinucleotide 
(NAD), damage to cellular macromolecules such as DNA, protein denaturation, and not 
surprisingly the reduction of antioxidant defenses, in particular glutathione (65).  Here 
again is where lipids come into play. With limited capacity for cellular defense free 
radicals (in particular the hydroxyl radical) are able to migrate unopposed into 
membrane lipid bilayers and attack vulnerable unsaturated side chains of membrane 
PUFAs, owing to their decreased carbon to hydrogen bond strength.  This in turn 
creates lipid hydroperoxides that release aldehyde bi-products, of which 4-hydroxy-2-
nonenal (4-HNE) and malondialdehyde (MDA) are of considerable importance in 
biological systems (66).  Longer lived than free radicals, 4-HNE and MDA pose a much 
greater cytotoxic risk to cells as they can readily diffuse from membranes and attack 
distant intracellular or extracellular targets (66); these attacks can include the covalent 
modification of cellular proteins into adducts and the disruption of organelle membrane 
integrity.  Lipid peroxidation itself also acts as an amplifier of free radical and aldehyde 
generation, further depleting antioxidant capacity and thereby exacerbating the state of 
oxidative stress (67).  Lastly, aside from impairing organelle function, aldehydes such as 
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4-HNE and MDA can directly induce the production of cytokines, in particular tumor 
necrosis factor-α (TNF-α), which in turn acts as a chemoattractant for neutrophils 
leading to chemotaxis, inflammation, and eventually apoptotic-mediated cell death. 
Hepatic stellate cells, the principal mediators of liver fibrosis can also be directly 
activated following membrane lipid peroxidation through the production of transforming 
growth factor β (TGF-β) (68,69).  
 Though the ‘two-hit’ hypothesis has commandeered the attention of researchers 
of NAFLD there are several emerging issues that have caused this framework to be 
requestioned. As discussed in detail in chapter 1 of the upcoming literature review, the 
concept that liver TG accumulation is a necessary condition for the transition from 
steatosis to NASH is in need of a serious re-evaluation in light of powerful studies which 
demonstrate quite the opposite (70-72). In fact, TG accumulation likely serves a 
hepatoprotective function by sheltering bioactive fatty acids in the TG molecule and it is 
only when the fatty acids are mobilized from TG that they have the opportunity to serve 
as signaling molecules in lipotoxic processes. Examples of such species include non-
esterified fatty acids (primarily saturated) which trigger apoptotic activation (71), 
diacylglycerols which interfere with insulin signaling (73-75), and cholesterol, specifically 
in its free form (FC) (see following chapter).  
Of Mice, Men, and Everything in Between: Animal models in NAFLD research 
 Because of the inherent difficulty and ethical considerations involved in obtaining 
a liver biopsy, research in animals provides an advantageous approach to studying 
different facets of NAFLD. For example, dietary (76) and genetic manipulations (77-86) 
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can be combined or studied separately in order to tease apart the many manifold events 
in NAFLD propagation. Much of the work to date is centered around the mouse or rat, 
which provide the overwhelming source for much of the genetic manipulations currently 
available, though studies using non-genetically modified rabbits are starting to emerge 
as viable alternatives, especially with regard to liver disease and excessive dietary 
cholesterol (87,88). Even less utilized and appreciated is the guinea pig, an animal that 
more closely resembles humans with regards to lipoprotein metabolism and which also 
handles hepatic cholesterol similarly (see next section). Currently there are very few 
publications utilizing guinea pigs to study NAFLD, though it appears the tide may be 
turning (89,90). It has even been proposed that guinea pigs, rather than being 
appropriate models for atherosclerosis, are in fact much more appealing for liver 
diseases, NAFLD in particular (91).   
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LITERATURE REVIEW: CHAPTER 1 
 
Key aspects of cholesterol homeostasis, the interaction of cholesterol, 
phospholipids, and triglycerides, and emerging role in NAFLD progression 
 
Cholesterol. What does one think of when confronted with this seemingly loaded 
word? For some, particularly biophysicists and biochemists, thoughts presumably turn 
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to the crucial biophysical properties of this molecule in cellular membrane physiology 
and eukaryotic cell survival. Nutritional scientists on the other hand, likely direct their 
attention to the essentiality of cholesterol in dietary lipid absorption and capacity to 
serve as precursors for the production of key vitamins and reproductive hormones, 
while still others like clinicians, focus on the pathophysiological ramifications of excess 
cholesterol in human disease. Indeed, cholesterol is responsible for a vast realm of 
biological functions, so it is no wonder that it spurs such intense scientific inquiry in so 
many diverse research fields. It is puzzling though, how such a molecule so crucial to 
survival itself can also simultaneously pose such severe physiological and 
pathophysiological risks, and how this nefarious aspect of cholesterol’s identity tends to 
predominate in the minds of many scientists as well as the lay masses themselves. 
While certainly dysregulated cholesterol metabolism is of major importance to the 
emergence of many devastating disease states, atherosclerotic vascular disease in 
particular, it should be kept in mind that these pathophysiological ramifications take 
years, sometimes decades, to develop and only after a myriad of regulatory 
mechanisms governing uptake, synthesis, and transport are eventually overwhelmed. 
Evolution it seems, has equipped cells with quite the armamentarium to handle this 
essential, yet potentially dangerous lipid.  
The sheer magnitude of biological functions that cholesterol is responsible for is 
staggering. As a conspicuous component of cellular membranes, cholesterol’s presence 
influences membrane fluidity, modulates the functions of integral membrane proteins, 
and enables the formation of lipid raft regions critical for membrane signaling cascades 
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(1-4).  It is involved in the conductance of neurotransmissions along neuronal axons as 
a rich lipid component of myelin (5). Along with these membrane effects, the fused, rigid 
four-ringed steroid backbone can undergo a series of oxidative cyclizations and 
demethylation reactions to yield valuable bioactive molecules, notably bile acids, 
cholecalciferol (vitamin D), and steroid hormones, which in turn can participate in such 
critical processes as dietary lipid absorption, calcium metabolism, and hormonal 
regulation of reproduction (1). Given the breadth of detail involved, these processes will 
not be further expanded upon, however the interested reader is directed to several 
erudite reviews that discuss thoroughly the physiology of cholesterol (6,7). In particular, 
Ira Tabas’ perceptive perspective (1) offers one of the most insightful reads into the 
uniqueness of the cholesterol molecule itself.  
Because cholesterol is now increasingly being recognized as a major culprit in 
diseases other than atherosclerosis and cardiovascular disease (CVD), particularly 
those of hepatic and neurological origin, it seems as urgent a time as ever to 
understand the regulatory schemes fundamental for maintenance of cholesterol 
homeostasis. Knowledge of the intricacies surrounding this unique and often 
underappreciated molecule will likely begin to help clarify as to how it participates in the 
progression of these other diseases, of which NAFLD is of particular salience. Therefore 
it is the aim of this chapter to briefly describe the major aspects of cholesterol 
metabolism; that is, the uptake of exogenous (dietary) cholesterol by the intestine and 
liver, the hepatic uptake of endogenous cholesterol from plasma-derived lipoproteins, 
and finally, the molecular regulation of cellular cholesterol homeostasis. A brief 
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discussion then follows of studies that illustrate the role of elevated cholesterol in 
NAFLD and NASH pathogenesis. Lastly, the chapter will conclude by emphasizing the 
guinea pig as an experimental approach to understanding the nexus between 
disturbances in hepatic cholesterol metabolism and NAFLD progression. 
Deliverance: Intestinal and hepatic cholesterol acquisition  
 Higher eukaryotes such as mammals are endowed with the ability to absorb 
dietary sterols, including cholesterol, from the luminal environment of the small intestine. 
There is however, no actual dietary requirement for cholesterol itself as virtually all cells 
can construct the molecule de novo from a single precursor, acetate. The routine of 
dietary cholesterol absorption can be conceived of as three distinct phases (8). The first, 
or intraluminal phase, involves a coordinated release of pancreatic lipases and 
esterases which attack incoming lipid emulsions containing dietary cholesterol, 
triglycerides, and phospholipids. Much of the cholesterol acquired from the diet exists in 
its free, unesterified form (FC), with less than 15% existing in its esterified form (CE) (9). 
Pancreatic cholesterol esterase acts upon any CE molecules, cleaving the fatty acid 
from the A ring creating FC. Because of the near absolute insolubility of FC in pure 
aqueous environments, the molecule requires rapid solubilization in order for efficient 
absorption and this is provided through the detergency of bile acids. These amphipathic 
compounds aggregate spontaneously, forming simple micelles when their concentration 
exceeds the critical micellar concentration. While thermodynamically stable these 
aggregates can only solubilize a small amount of cholesterol, however when they 
combine with various fatty acids, monoglycerides, and lysophospholipids, mixed 
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micelles are formed. These are larger aggregates whose formation greatly enhances 
the solubility of cholesterol (within the hydrophobic core) and which also enable dietary 
lipid transport through a formidable diffusion barrier, the unstirred water layer, which lies 
at the interface between the water phase of the intestinal lumen and the apical 
membrane of the enterocyte (9). The obligatory nature of bile acids in promoting 
efficient intestinal cholesterol absorption should not be understated (10).  Following 
transport the mixed micelles then disaggregate, dispersing lipid contents that include 
significant amounts of FC which is then ready for uptake by the intestine. It should also 
be pointed out that intestinal cholesterol uptake refers to the actual entry of FC and CE 
into enterocytes from the lumen. This is distinct from intestinal cholesterol absorption, 
which as previously defined (9), refers to the transfer of luminal cholesterol to the 
lymphatic system throughout the entirety of the small intestine although the majority 
occurs in the duodenum and proximal jejunum. 
 The second phase of intestinal lipid absorption involves the uptake of cholesterol, 
the vast majority of which is unesterified, across the enterocyte brush border. Until 
2004, intestinal sterol influx was largely perceived of as a passive diffusion process with 
the incoming hydrophobic cholesterol passing down a concentration gradient through 
the enterocyte plasma membrane (8,10), although evidence did exist that collectively 
suggested the existence of an elusive sterol transport protein (11). Moreover, 
heterogeneous responses and interstrain differences in humans and rodents, 
respectively, pointed to the likelihood of genetic regulation in this process. Using a 
genomic-bioinformatics approach with intestinal scrapings from rat, Altmann et al 
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successfully identified Niemann-Pick C1 Like 1 (NPC1L1) as the putative intestinal 
cholesterol transporter (12). Not only was NPC1L1 enriched and localized to the 
enterocyte epithelial layer bordering the luminal space, but NPC1L1 null mice also had 
a 69% reduction in the absorption of radiolabeled cholesterol and did not respond when 
treated with a known pharmacological inhibitor of intestinal and biliary cholesterol, 
ezetimibe. Following the identification of NPC1L1, it was shown subsequently that this 
transporter not only was responsible for the uptake of cholesterol, but also the 
structurally related plant sterols, campesterol and sitosterol, as their plasma 
concentration in NPC1L1 null mice were reduced by more than 90% as compared to 
wild type mice (13). Genetic inactivation of NPC1L1 in mice also was found to 
dramatically reduce circulating plasma cholesterol on a high cholesterol, high-fat Paigen 
diet and prevented NPC1L1 null mouse livers and gallbladders from cholesterol-induced 
hepatic steatosis and cholestasis respectively (14). Interestingly this same study also 
demonstrated through messenger ribonucleic acid (mRNA) profiling experiments that 
humans and mice differ strikingly in the tissue expression of NPC1L1, with humans 
exhibiting the greatest expression in both the small intestine, as well as liver. In 
contrast, murine NPC1L1 is expressed primarily in the small intestine only (14). Direct 
biochemical (15) and molecular (16) evidence later emerged which unequivocally 
established NPC1L1 as the target of ezetimibe and hence as the bona fide intestinal 
cholesterol transporter. 
 The cellular basis for NPC1L1-mediated cholesterol transport has recently begun 
to be unraveled and provides an interesting insight as to how intestinally derived 
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cholesterol travels into enterocytes (see references 11 and 17 for detailed reviews that 
cover this process). Although not completely understood it appears that NPC1L1 
functions in a cholesterol-sensitive endocytotic pathway (18); under conditions of 
cellular cholesterol depletion, NPC1L1 travels from the endocytotic recycling 
compartment to the apical plasma membrane where it binds and facilitates cholesterol 
uptake. The polytopic NPC1L1 then disappears from the plasma membrane and 
localizes to intracellular compartments where it releases its cholesterol load, therefore 
able to return to the cell surface when cholesterol is again limited. Ge et al (19) further 
demonstrated that FC promotes the internalization of NPC1L1 and that this requires 
microfilaments and the clathrin complex, which is important for endocytosis itself. 
Importantly, NPC1L1 transports only FC, not CE, which makes this pathway distinct 
from other membrane cholesterol receptors, particularly the low-density lipoprotein 
receptor (LDLR) and the scavenger class B type 1 receptor (SR-B1) which transport 
newly uptaken CE (11). 
 The third and final phase of cholesterol absorption involves the trafficking and 
incorporation of absorbed FC into chylomicrons, massive macromolecular spherical 
complexes composed of amphipathic phospholipids, apolipoproteins, triglycerides, and 
cholesterol. As mentioned previously, the overwhelming majority of cholesterol entering 
enterocytes is FC which if not handled properly, can elicit severe cytotoxic effects in 
cells (20). Fortunately cells have an efficient buffering system in place to prevent such 
occurrences, and this is mediated by acyl-CoA cholesterol acyltransferase (ACAT), 
which enzymatically transfers monounsaturated fatty acids (MUFA) such as 
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palmitoleate or oleate to the hydroxyl group on the third carbon of FC forming an 
esterified, and ultimately more hydrophobic molecule. In the major lipoprotein producing 
cells, that is, enterocytes and hepatocytes, ACAT-2 is the major isoform and is present 
as an ER-bound membrane protein (21). ACAT-mediated esterification enables the 
newly formed CE to package with newly synthesized triglycerides, phospholipids, and 
the substantially complex apolipoprotein B (apoB), lipidating and inflating the 
prechylomicron particle until it is ready for eventual egress into the lymphatic system. 
Exactly how the incoming FC is directed to the ER is still not defined, though it is likely 
that some form of vesicular or non-vesicular transport mechanisms exist. Dietary-
derived cholesterol represents only a small fraction of chylomicrons, with FC and CE 
constituting 1% and 3% by weight respectively and this is due to the rich concentration 
of triglycerides which make up about 85% of the total weight of the particle. Because CE 
cannot intercalate into lipid membranes it is found stored within the huge hydrophobic 
core whereas the FC is scattered about the surface, helping to stabilize the spherical 
structure. The itinerary that enterocytes use to synthesize these gigantic particles is 
complex (see references 22-24 for informed discussions), yet at least for cholesterol it 
seems that ACAT-mediated esterification is the pivotal step in determining how much 
dietary-derived cholesterol gets packaged and ultimately, secreted from the intestine. 
For instance, mice that are genetically manipulated to have an intestinal-specific 
knockout of ACAT-2 have blunted cholesterol absorption and reduced plasma 
cholesterol, yet increased concentrations of total and free cholesterol along with a 
pronounced reduction of CE in intestinal segments (25,26). These findings would seem 
 40 
 
to indicate that inhibition of cholesterol esterifcation at the level of the intestine is 
sufficient to prevent cholesterol accretion in other compartments such as plasma and 
liver and has prompted some (25) to speculate that ACAT-2 inhibition may be 
atheroprotective. One could contend however that limiting CE formation at the expense 
of increasing cellular FC concentration is a dangerous trade-off given the ramifications 
of excess FC accumulation (20).  
 To get to the liver, dietary cholesterol must first travel through the lymphatic 
vessels and venous circulation, sheltered within the core of chylomicrons. The myriad 
events that occur during chylomicron transport have been well studied and defined and 
for brevity’s sake will not be further discussed. (Two indispensible reviews (27,28) that 
explain beautifully the lipoprotein transport system and its intricacies are provided by 
Michael Brown and Joseph Goldstein, the proverbial ‘pioneers’ of cholesterol 
metabolism and discoverers of the LDLR). The focus here instead is the uptake of 
chylomicron delivered cholesterol by the liver.  
 Within the capillaries of adipose and muscle tissues lipoprotein lipase (LPL) 
depletes chylomicrons of their triglyceride cargo by liberating free fatty acids and 
monoglycerides, thereby forming a chylomicron remnant. This remnant, though smaller 
than the original particle (300-800 angstroms as compared to 800-5000 angstroms) is 
still quite large and must somehow traverse the fenestrated endothelial cells that line 
the hepatic sinusoids. This is provided through direct binding of the apolipoprotein E 
component to various heparan sulfate proteoglycans lining the Space of Disse (28), or 
alternatively, the remnants can be uptaken directly by the LDLR (via recognition of the 
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apolipoprotein E component). Hepatic LDLRs are the primary conduit for lipoprotein 
entrance into the liver and they function by plucking circulating lipoprotein particles from 
plasma (27), and are integral to the regulation of plasma cholesterol concentrations. To 
enter into hepatocytes, chylomicron remnants and other lipoprotein species including 
VLDL remnants, and LDL particles must first be internalized; by binding to the LDLR, a 
series of events is enacted in which the particle and receptor become internalized via a 
process known as receptor-mediated endocytosis (2). In terms of the particles’ 
cholesterol cargo, both the free and esterified molecules are liberated and travel 
through a coordinated organelle system known as the endosomal system, eventually 
entering into acidic lysosomes, and finally, traverse the lysosomal membrane and exit 
towards the ER (2). It is at this critical organelle that cholesterol exerts its homeostatic 
mechanisms through a remarkable sequence of molecular and cellular events, and 
where the spotlight is now directed.  
Keeping the Peace: Mechanisms of hepatic cholesterol homeostasis 
Cellular cholesterol concentrations are meticulously controlled by an array of 
membrane bound sterol sensing proteins that coordinate cholesterol biosynthesis and 
uptake through a highly regulated feedback system. This system functions at 
transcriptional and post-transcriptional levels, revealing an exceedingly complex cellular 
program devoted to maintain cholesterol and lipid homeostasis. Pivotal to the 
maintenance of cellular cholesterol concentrations are the ER-membrane embedded 
SREBP transcription factors which upon proteolytic cleavage travel to the Golgi complex 
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and then the nucleus to initiate transcription of genes involved in cholesterol 
biosynthesis and uptake.   
 In the mammalian genome three SREBP isoforms are present as SREBP-1a, 
SREBP-1c, and SREBP-2. Both SREBP-1a and 1c are produced through alternative 
transcription start sites on exon 1 whereas SREBP-2 is encoded by a separate gene 
located on human chromosome 22 (29). The physiological roles of the SREBP isoforms 
differ, with SREBP-1a being a strong activator of all SREBP target genes and SREBPs-
1c and 2 confined to more restricted roles. SREBP-1c preferentially activates 
transcription of genes involved for fatty acid synthesis whereas SREBP-2 enhances 
genes required for cholesterol synthesis (29). Tissue and organ analysis have revealed 
that SREBPs-1c and 2 are primarily localized to the liver and several other cholesterol 
dependent tissues whereas in cultured cell lines SREBPs-1a and 2 are the predominant 
isoforms (30). 
 Immediately after their synthesis, SREBPs are anchored to ER membranes as 
inactive precursors through two membrane spanning helices and adopt an orientation in 
which both the amino-terminal and carboxy-terminal domains face the cytoplasm. All 
SREBP precursors consist of 1,150 amino acids and are organized into an amino-
terminal domain which contain a bHLH-Zip crucial for binding to DNA and a carboxy-
terminal regulatory domain of roughly 590 amino acids. The two transmembrane 
domains are separated by a small loop of 30 amino acids which projects into the ER 
lumen. SREBPs remain anchored to the ER membrane through an interaction between 
the regulatory carboxy-terminal domain of the SREBP and the cytosolically-oriented 
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carboxy terminal domain of the polytopic membrane protein SREBP-cleavage-activating 
protein (Scap). The carboxy terminal of Scap consists of multiple tryptophan and 
aspartate repeats (WD repeats) which foster protein-protein interactions (31). 
To serve as a transcription factor, SREBPs must first exit the ER membrane 
bound to Scap and then travel to the Golgi complex where two sequential proteolytic 
cleavages occurs. Once the Scap/SREBP complex enters the Golgi, the complex 
dissociates and the SREBP becomes embedded in the Golgi membrane where it 
encounters two membrane bound proteases designated as Site-1 (S1P) and Site-2 
(S2P). S1P is a serine protease that cleaves the SREBP in the luminal membrane 
spanning loop, thereby cleaving the SREBP in half (32). The amino terminal half of 
SREBP then serves as the substrate for the S2P, a zinc metalloproteinase that cleaves 
at a site within the membrane spanning helix thereby releasing the active amino-
terminal domain located within the cytoplasm (33). The amino-terminal domain is 
designated nSREBP which then enters the nucleus and binds to sterol response 
elements (SREs) composed of the E-box inverted DNA repeat (5’-CANNTG-3’) as well 
as the direct DNA repeat (5’-TCACNCCAC-3’) (29).   
Transport of the Scap/SREBP complex from the ER is a process highly regulated 
by cholesterol and oxysterols, potent cholesterol derivates with additional hydroxyl or 
keto groups at the 7-position on the B ring or at several positions on the side chain.  
When cellular concentrations of sterols decline, Scap escorts the SREBP from the ER 
and travels to the Golgi for proteolytic processing, thereby enabling nSREBP to bind to 
SREs located within promoter/enhancer regions of specific genes dedicated to 
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cholesterol synthesis and uptake including HMG-CoA reductase, the rate-limiting 
enzyme of cholesterol biosynthesis which converts HMG-CoA to mevalonate, and 
LDLRs. Conversely, if cellular sterol concentrations are elevated, Scap serves as a 
sterol sensor and retains the SREBP within the ER membrane thereby inhibiting 
Scap/SREBP transport to the Golgi, formation of the transcriptionally active amino 
terminal SREBP fragment, and transcription of SREBP target genes. Scap exhibits dual 
roles in maintaining cellular cholesterol balance, both as an escort protein and as a 
sterol sensor and therefore represents a crucial feature of this highly regulatory system.   
 Scap is a polytopic ER membrane protein composed of approximately 1,277 
amino acids which contain two domains of between 600-700 amino acids each. The 
amino-terminal domain embeds the protein in ER membranes through a series of eight 
transmembrane helices, each of which are separated by hydrophilic loops. The carboxy 
terminal domain is composed of multiple copies of a tryptophan and aspartate (WD) 
repeat sequence, which serves to bind the carboxy terminal domain of SREBPs, 
thereby retaining SREBPs within the ER membrane (31). Within the amino terminal 
domain, transmembrane helices 2-6 represent the intramembrane sterol-sensing 
domain (SSD), a sequence of five transmembrane helices consisting of roughly 180 
amino acids which play essential roles in controlling lipid homeostasis and facilitating 
lateral membrane protein movement (34, 35). Originally identified in Scap (34), SSDs 
have been identified in several other polytopic membrane proteins including HMG-CoA 
reductase, the Niemann Pick C1 protein (NPC1), a lipid transport protein involved in the 
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intracellular trafficking of cholesterol, and 7-dehydrocholesterol reductase, one of the 
final enzymes catalyzing the formation of cholesterol (36).   
 The dual roles of Scap as both a sterol sensor and escort protein were originally 
established in studies of mutant Chinese hamster ovary cells (CHO) that displayed 
defects in the regulation of cholesterol synthesis (37). In cells engineered to lack Scap, 
SREBPs are retained in the ER membranes and the cells require exogenous 
cholesterol administration for growth (38). Cells that contain point mutations in Scap, 
specifically at amino acids D443N or Y298C display sterol resistance in which the Scap 
sterol sensing function is diminished and the mutant Scap escorts SREBPs to the Golgi 
complex even in the presence of elevated cellular cholesterol (39). This ultimately leads 
to a situation of endogenous cholesterol overproduction and cellular overloading.  
These point mutation experiments, along with others (39) occur within the SSD of Scap 
and solidified this region of Scap as a bona fide SSD. Thus, in the presence of sterols, 
Scap remains bound to SREBP in the ER membrane, access to proteolytic cleavage is 
denied, and transcription of cholesterol synthesizing enzymes declines.   
 In situations when cellular cholesterol levels are elevated, Scap remains 
embedded in the ER membrane bound to SREBPs and cholesterol biosynthesis is 
abolished; this inhibition is contingent on the sterol-sensing function of Scap as well as 
binding of the Scap/SREBP complex to Insigs, newly characterized ER retention 
proteins (40). Two Insig isoforms, Insig-1 and Insig-2 have been successfully identified 
as Scap binding proteins (41) and are central to the suppression of SREBP Golgi 
transport and nuclear import; remarkably these proteins also serve a crucial role in the 
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sterol-mediated ubiquitination and degradation of HMG-CoA reductase, also embedded 
in the ER membrane (42). Cholesterol binds to the SSD of Scap and triggers a 
conformational change thereby enabling its binding to Insigs (41) however cholesterol 
does not participate in HMG-CoA degradation; it appears that lanosterol, a cholesterol 
precursor, is a much more potent stimulus for this degradation. Elevated lanosterol 
concentrations are presumed to interact with the SSD of HMG-CoA reductase which in 
turn triggers the binding of the enzyme to Insig proteins, which ultimately facilitate the 
degradation process (43). Why lanosterol is the primary regulator of this process is 
relatively unknown, however it may be due to the cytotoxic nature of lanosterol itself 
(44). By stimulating the degradation of the reductase, lanosterol inhibits its own 
production farther along the cholesterol synthetic pathway and thus prevents excessive 
accumulation. Cells can then efficiently metabolize lanosterol, thereby avoiding the 
detrimental effects of this molecule (43,44). 
 The understanding that eukaryotic cells regulate cholesterol and lipid 
homeostasis by the coordinated movement of ER membrane bound transcription factors 
to the Golgi and eventually to the nucleus has fostered intense research efforts 
dedicated to understanding the molecular events by which this process occurs.  
Elevated concentrations of cholesterol and oxysterols in cells selectively inhibit this 
process by facilitating Scap/SREBP binding to Insig-1, thus retaining this complex 
entirely within ER membranes. When cells are depleted of cholesterol, the Scap/SREBP 
complex exits the ER by clustering laterally along with other proteins into COPII-coated 
vesicles, which then bud from the ER (45, 46). COPII binding begins with the 
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attachment of Sar1, a small GTP binding protein which attaches to ER membranes by 
exchanging GTP for GDP. The now membrane bound Sar1 subsequently attracts the 
Sec23/24 complex. The Sec23 component of this heterodimer can recruit additional 
proteins, notably the Sec13/31 complex, which forms the coat of the COPII vesicle (47).  
Binding of Scap to these vesicles is accomplished through an interaction between 
Sec24 and a MELADL (methionine, glutamate, leucine, alanine, aspartate, leucine) 
hexapeptide sequence of Scap, which is located in the cytoplasmic loop between the 
transmembrane helices 6 and 7, beginning at amino acid residue 447 and ending at 
residue 452 (48). This sequence was identified through several mutagenesis studies in 
which it was determined that mutations within this sequence abrogate Sec23/24 binding 
to Scap and thus inhibit Scap/SREBP incorporation into COPII vesicles for export to the 
Golgi (49). As cells begin to build up cholesterol, Scap undergoes a conformational 
change causing it to bind to Insig-1. The binding of Scap to Insig-1 precludes the 
binding of the Sar1/Sec23/24 complex to Scap and the Scap/SREBP complex ultimately 
remains in the ER membrane bound to Insig-1. While many aspects of this regulatory 
scheme remain to be answered, it is clear that that cells employ a remarkable spectrum 
of regulation and feedback control in monitoring cellular cholesterol levels. The 
elucidation of these molecular mechanisms provides a stunningly comprehensive 
picture that helps explain the long recognized ability of cells to inhibit cholesterol uptake 
and synthesis when concentrations are elevated.   
Agents Provocateurs: Hepatic free cholesterol, ER stress, and organelle 
dysfunction in NASH progression 
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Experiments conducted in cells have shown convincingly that cholesterol loading 
induces cytotoxicity of the ER (50), depletes mitochondrial glutathione content and 
sensitizes cells to cytokine-mediated NASH (51). Additionally, a recent metabolomic 
assessment concluded that dietary cholesterol was a causal factor in both steatosis and 
hepatic inflammation (52). Moreover, there exists now an abundance of evidence from 
animal studies that has shown that hepatic accumulation of cholesterol aggravates 
hepatic histology by dysregulating homeostatic mechanisms (53) and through 
synergistically interacting with dietary fats (54,55). Dietary cholesterol also further 
distorts hepatic architecture and promotes injury in hypercholesterolemic mouse models 
such as LDLR and ApoE knockout mice (56,57). Most importantly human studies have 
also demonstrated a resounding connection between dysregulated hepatic cholesterol 
metabolism and the severity of NAFLD progression (58). In fact, the very appearance of 
hepatic cholesterol crystals in both mice and humans appears to distinguish between 
steatosis and NASH as shown by Ioannou et al (59). In a very recent study the group of 
Geoffrey Farrell showed quite convincingly that in an insulin-resistant, obese genetic 
mouse model (foz/foz), NASH was successfully induced by feeding a cholesterol-rich 
diet, and perhaps more significantly, was completely abolished when pharmacological 
cholesterol-lowering agents (ezetimibe/atorvastatin) were administered (60). Musso et 
al (61) have compiled the most comprehensive review to date regarding the molecular 
and biochemical events initiated by excess cholesterol in NAFLD pathogenesis. It is 
anticipated that more publications will emerge in the near future, considering the 
mounting evidence that now exists against excessive dietary cholesterol. Now is the 
 49 
 
time for serious investigations into other ramifications of excess cholesterol, beyond the 
arterial wall.  
The ‘Common’ Guinea Pig: Opportunities for investigating hepatic cholesterol 
and NAFLD 
The gamut of animal models for NAFLD is extensive and involves an array of 
both genetic and dietary models, the majority of which are mice and rats (62,63).  
Genetically altered models of hepatic steatosis often display increased hepatic 
lipogenesis (PEPCK-n-SREBP-1α mice) or decreased hepatic fatty acid oxidation 
(PPARα -/- mice).  Models like the ob/ob mouse and fa/fa rat have naturally occurring 
mutations in the synthesis of leptin, a satiety hormone produced predominantly by white 
adipocytes, and in the gene encoding the leptin receptor respectively. As a 
consequence these animals exhibit severe disturbances in energy metabolism and 
develop hyperphagia, hyperinsulinemia, hyperglycemia, dyslipidemia, and 
spontaneously fatty livers (62) thereby making them a worthy model for NAFLD etiology. 
Phenotypically normal rodents have also been utilized to investigate the effects of 
dietary composition and individual nutrients on hepatic steatosis. Rodent diets high in 
fat, sucrose, or fructose have been developed to enhance hepatic lipogenesis while 
methionine- and/or choline deficient diets are often implemented to impair fat oxidation.  
Taken together, these genetic and dietary rodent models constitute the conceptual 
framework for our current understanding of the molecular and metabolic processes 
germane to steatosis and NAFLD.   
The reality however, is that mice and rats differ substantially from humans in the 
genetic expression and activity level of several genes involved in hepatic lipid and 
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cholesterol metabolism, thus the pathogenesis of this disease in these animals does not 
appropriately emulate that of the human situation. Rather than relying solely on the tools 
of molecular biology to procure transgenic or genetic knock-out animals researchers 
must also direct their efforts towards identifying species that naturally replicate human 
metabolism. An ideal model should exhibit similar genetic and enzymatic programs 
related to the pathway(s) of interest and respond to dietary, exercise, or 
pharmacological treatments in a manner analogous to that of human interventions.  
Indeed, the guinea pig is perhaps the most excellent representation of such a model 
with regards to hepatic and whole body trafficking and processing of lipids and 
cholesterol and may represent a novel template for elucidating the true mechanisms 
implicated in human steatosis and NAFLD. 
The most drastic difference between guinea pigs and rodents is that the majority 
of cholesterol is transported within LDL particles (64), an observation which has made 
guinea pigs the ultimate animal model for human lipoprotein metabolism (65); this does 
not hold true for rats or mice which predominantly carry cholesterol in HDL particles 
(66). Furthermore, similar to humans, guinea pigs display a high LDL-to-HDL ratio (67) 
and possess several key enzymes involved in the intravascular processing of 
lipoproteins, notably CETP, lecithin cholesterol acyltransferase (LCAT), and LPL (65).  
These inherent similarities between guinea pigs and humans implicate this animal as a 
bona fide model for lipoprotein metabolism yet may also expand current knowledge 
pertaining to NAFLD and cardiovascular disease. NAFLD has been proposed as the 
hepatic manifestation of the metabolic syndrome (68) and is also closely linked to 
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cardiovascular dysfunction (69,70). Given the striking similarities between humans and 
guinea pig lipoprotein metabolism, in conjunction with recent research that has 
suggested guinea pigs as a suitable model to evaluate inflammation and atherosclerosis 
(71), it appears feasible that guinea pigs may represent an innovative approach to 
discerning the mechanisms by which NAFLD contributes to the pathophysiology of 
cardiovascular disease.   
Guinea pigs also resemble humans in the synthesis, storage, and catabolism of 
cholesterol in the liver. This observation is particularly relevant for hepatic steatosis and 
NAFLD, as emerging research has suggested cholesterol as a central molecule in the 
transition from hepatic steatosis to NASH. Although excessive cholesterol storage may 
not solely cause hepatic steatosis per se, the accumulation of free cholesterol may 
exacerbate the degree of steatosis and hepatocellular dysfunction in humans. Both 
humans and guinea pigs exhibit higher concentrations of hepatic free cholesterol versus 
esterified cholesterol (72) as well as similar enzyme activities of ACAT, the ER-localized 
enzyme that esterifies cholesterol, and HMG-CoA reductase (73). Moreover, guinea 
pigs demonstrate moderate rates of hepatic cholesterol synthesis (67) and catabolism 
(74) comparable to humans. While it remains unclear as to whether the expression and 
activity of enzymes involved in hepatic fatty acid synthesis and combustion correlate 
between guinea pigs and humans, the striking similarities in hepatic cholesterol 
metabolism warrant the use of this animal as a novel model for elucidating the role of 
cholesterol in the progression of hepatic steatosis and the transition to more advanced 
stages of NAFLD. Lastly, guinea pigs have been repeatedly demonstrated to respond to 
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dietary interventions, particularly carbohydrate restriction, in a manner analogous to 
humans (75,76) and given the potential therapeutic role of carbohydrate restriction in 
attenuating NAFLD (see following chapter), guinea pigs may represent the most 
appropriate means to evaluate the role of dietary composition on NAFLD, thus standing 
at the crossroads between laboratory research and clinical application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW: CHAPTER 2 
Carbohydrates and fats in hepatic lipid accumulation and dietary modulation of 
NAFLD 
 
Glucose Fattens Up: De novo lipogenesis and hepatic steatosis 
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The biochemical transformations of carbohydrates, notably the aldo- and 
ketohexoses glucose and fructose to varying fatty acid species for cellular storage as 
TG-a tightly choreographed process referred to as de novo lipogenesis (DNL)-offers a 
unique insight into metabolic regulation as a whole. Engaging glycolysis, the 
tricarboxylic acid (TCA) cycle and fatty acid biosynthesis, the lipogenic program 
responds to numerous regulatory signals emanating from dietary macronutrients and 
hormones whose effects are mediated by a selective group of nuclear receptors and 
transcription factors-all of which are intimately involved in the preservation of 
carbohydrate and lipid homeostasis. Certain nutritional scenarios particularly excessive 
carbohydrate consumption markedly enhance DNL within the liver and as the primary 
lipogenic organ in humans accelerated hepatic DNL represents a significant contributory 
mechanism to cytoplasmic TG accumulation and the development of hepatic steatosis. 
Appreciation of the nutritional and metabolic cues responsible for DNL requires an 
understanding of the critical enzymes involved and the molecular factors governing their 
expression and activity. 
Under situations in which hepatic glycogen stores are replete, monosaccharides 
such as glucose and fructose enter hepatocytes and are directed towards the glycolytic 
pathway to be utilized in a series of sequential energy-yielding catabolic reactions. 
Phosphorylation of glucose and fructose via glucokinase (GK) and fructokinase 
respectively effectively traps the sugars within hepatocytes and represents the initial 
glycolytic step forming glucose-6 (G-6P) and fructose-1 phosphate (F-1P). Fructose 
metabolism occurs much more rapidly than glucose presumably due to a higher affinity 
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of fructokinase for fructose (77) as well as its circumvention of the first committed 
glycolytic enzyme phosphofructokinase-1 (PFK-1). Subsequent conversion of F-1P to 
dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3 phosphate effectively 
avoids the complex allosteric regulation aimed at PFK-1; these differences enable 
fructose to be considerably more lipogenic than glucose.  Glycolysis proceeds with the 
formation of several intermediates, culminating in the substrate-level phosphorylation of 
phosphoenolpyruvate (PEP) to pyruvate via liver-type pyruvate kinase (L-PK).  Newly 
formed pyruvate then enters into the mitochondrial matrix where it undergoes an 
oxidative decarboxylation through the multi-enzyme pyruvate dehydrogenase (PDH) 
complex yielding acetyl-CoA.  Rather than enter into the TCA cycle for complete 
oxidation acetyl-CoA condenses with the four-carbon oxaloacetate to form the six-
carbon citrate which then exits the mitochondria and into the cytosol where it 
immediately undergoes an ATP-dependent cleavage to oxaloacetate and acetyl-CoA 
through the enzyme citrate lyase (ACL). This reaction is of considerable importance as 
it links carbohydrate catabolism to the energetically expensive biosynthesis of fatty 
acids. The newly liberated acetyl-CoA is then able to serve as a substrate for the rate-
limiting enzyme in lipogenesis, acetyl-CoA carboxylase (ACC) which catalyzes the 
formation of malonyl-CoA, an important molecule that serves as both a carbon donor in 
fatty acid synthesis and a potent inhibitor of the carnitine-palmitoyl transferase (CPT) 
system and hence mitochondrial fatty acid oxidation (78). Two isoforms of ACC (ACC1 
and ACC2) and distinct cellular pools of malonyl-CoA are responsible for these 
contrasting phenomena; ACC1 located in the cytosol generates the malonyl-CoA 
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necessary for lipid synthesis while the close proximity of ACC2 to the mitochondrial 
membrane generates the malonyl-CoA required for CPT inhibition (79). Following a 
series of condensation and reduction reactions catalyzed by fatty acid synthase (FAS), 
the malonyl-CoA molecule is extended to ultimately form the sixteen carbon saturated 
palmitate, the end product of FAS and the first fatty acid formed through DNL.  
As a precursor to other various long-chain fatty acid species palmitate is a 
valuable substrate for the elongation and desaturation systems designed to produce 
longer chain saturated fatty acids (SFA) as well as mono- (MUFA) and polyunsaturated 
fatty acids (PUFA). Numerous endoplasmic reticulum (ER) membrane bound 
elongases, desaturases and acyltransferases participate in these coordinated reactions, 
the majority of which will not be discussed here (see (80) for a recent comprehensive 
review). Two critical enzymes, the elongase ELOVL-6 (elongation of very-long-chain 
fatty acid) and stearoyl-CoA desaturase 1 (SCD-1) deserve particular attention as both 
are known to be transcriptionally regulated in a manner similar to other enzymes 
involved in DNL (see next section). ELOVL-6, a member of the microsomal elongase 
family catalyzes the elongation of long chain (typically C12-C16) SFA and MUFA and 
relevant to TG synthesis ELOVL-6 elongates palmitate to stearate (81). SCD-1 is a 
delta-9 desaturase which introduces a single double bond into both palmitate and the 
eighteen-carbon stearate forming the MUFAs palmitoleate (16:1) and oleate (18:1) 
respectively and therefore serves as the rate-limiting reaction in endogenous MUFA 
synthesis. As a result of these two enzymes palmitate is successfully elongated to 
stearate as well as desaturated to palmitoleate and oleate. Finally, a series of 
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sequential acyltransferase reactions culminates in the production of diacylglycerol which 
in the final reaction catalyzed by diacylglycerol acyltransferase (DGAT) is covalently 
joined to a fatty acyl-CoA thereby forming TG (for an insightful and historical account of 
the major TG biosynthetic pathways and biochemical reactions see a recent review, 
(82)).  
The extraction and storage of nutrient-derived energy represents a distinct 
survival mechanism exploited by nearly all organisms, the vast majority of which tend to 
store cellular energy as TG due to its highly reduced and concentrated nature; at more 
than 38 kJ/g TG yield the greatest energy content of all nutrients. In humans nutrient 
storage becomes crucial during times of nutrient scarcity such as fasting and starvation 
yet troublesome during caloric overindulgence and physical inexertion, behaviors that 
afflict a staggering proportion of the national and global populations. As just described, 
excessive intake of nutrients especially carbohydrate signals the liver to increase 
hepatic DNL to appropriately convert and store this incoming energy as TGs through the 
participation of several lipogenic enzymes. Understanding the manner in which these 
reactions are coordinated however, requires an investigation of the molecular factors 
responsible for the induction of hepatic DNL.  
 The liver X receptors α (LXRα) and β (LXRβ) are members of a subgroup of 
nuclear receptors termed the “adopted orphan” receptors  (83) that serve as cellular 
sterol sensors through their binding of cholesterol derivatives or oxysterols. Accordingly 
LXRs regulate the expression and transcription of genes pivotal to cellular cholesterol 
efflux, reverse cholesterol transport, and hepatic cholesterol catabolism via bile acid 
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synthesis and biliary excretion (see 84,85 for reviews). Despite promising anti-
atherogenic effects upon LXR pharmacological activation, valid concerns exist with 
regard to the lipogenic effect mediated by LXRs. An earlier study by Grefthorst et al (86) 
was one of the first to demonstrate that oral administration of an LXR agonist to wild-
type C57BL/6J mice resulted in massive hepatic steatosis, a phenomenon associated 
with a sharp induction in the mRNA of Fas, Acc1 and the lipogenic transcription factor 
sterol regulatory element binding protein 1c (SREBP-1c). These observations were in 
agreement with previous promoter studies that identified two functional LXR response 
elements (LXREs) within the mouse SREBP-1c promoter region, both of which are 
essential for LXR regulation (87,88). Moreover, selective deficiency of Srebp-1c in mice 
was shown to result in a blunted response to a fasting/refeeding treatment and an 
approximately 50% reduction in the rate of hepatic fatty acid synthesis (89). 
Mechanistically it is still not entirely clear as to how LXR activation induces SREBP-1c 
transcription and subsequent lipogenesis although in vitro experiments with isolated rat 
hepatocytes have suggested a collaboration with insulin (90). Alternatively, Hegarty et al 
(91) demonstrated that while LXR activation resulted in increased SREBP-1c induction, 
insulin proved a much more potent stimulus in the induction and cleavage of the mature 
SREBP-1c protein, thereby proposing that the full activation of the transcriptionally 
active SREBP-1c is absolutely dependent on insulin. Lastly it is important to note that 
LXR can directly activate lipogenic gene expression, particularly Fas independent of the 
SREBP-1c (92). Even more striking was the fairly recent finding by Ji-Young Cha and 
Joyce Repa (93) that the carbohydrate-sensitive transcription factor, carbohydrate-
 58 
 
response element-binding protein (ChREBP) (see below) is an apparent target gene of 
LXR. LXR agonists administered to wild-type mice significantly increased hepatic 
ChREBP mRNA compared to LXRα/β double knock-out mice. Particularly exciting was 
that the mRNA of L-PK failed to increase in the double knock-out mice, a noteworthy 
finding given that L-PK expression is absolutely dependent on ChREBP transcriptional 
activity. These latest findings appear to further solidify LXR as a bona fide master 
regulator of lipogenesis.  
As just discussed, the SREBP-1c transcription factor maintains a central role in 
mediating the lipogenic response to LXR and insulin action due to its ability to activate 
nearly all the genes pertinent to fatty acid synthesis notably GK, ACL, ACC, FAS, 
ELOVL6, and SCD1 (94). SREBP-1c is one isoform of the well-characterized SREBP 
family of ER membrane-located transcription factors governing fatty acid and 
cholesterol biosynthesis (see 94,95 for comprehensive reviews on each respectively). 
SREBP-1c transcription is dramatically enhanced by insulin in cultured hepatocytes 
(96), an in vitro observation that nonetheless appears to correspond to insulin’s potent 
anabolic effects. Thus in response to carbohydrate-mediated insulin secretion SREBP-
1c expression and activity increase leading to an induction of lipogenic enzymes and 
the eventual storage of carbohydrate as TG. The overexpression of SREBP-1c in the 
livers of ob/ob mice results in both an increased mRNA expression of lipogenic genes 
as well as a grossly fatty liver, illustrating the significance of this transcription factor in 
DNL and liver physiology (97). 
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 The discovery of ChREBP as a carbohydrate-responsive transcription factor (98) 
provided a crucial insight as to how simple carbohydrates such as glucose impact and 
coordinate gene expression. It also confirmed the suspicions of several laboratories that 
SREBP-1c was not the sole transcription factor responsible for the induction of 
lipogenesis. Subsequent in vivo experiments in mice utilizing a global ChREBP 
knockout (99) demonstrated an impairment in glycolysis and a 60% reduction in the rate 
of hepatic fatty acid synthesis after administration of a carbohydrate load while the 
generation of liver-specific ChREBP knockout mice (100) showed a marked 
improvement in hepatic steatosis, primarily through a decreased rate in hepatic DNL 
and expression of ACC, FAS and SCD-1. Perhaps one of the more intriguing aspects of 
ChREBP-mediated transcription is the identity of the carbohydrate molecule which 
activates ChREBP: xyulose-5 phosphate (Xu-5P) (101), an intermediate in the pentose 
phosphate pathway whose concentration increases in response to an enhanced influx 
of glucose. Phosphorylation of glucose by GK, a transcriptional target of SREBP-1c 
enables glucose to engage the glycolytic pathway while some of the glucose is directed 
towards the pentose phosphate pathway leading to Xu-5P, ChREBP activation and 
increased ChREBP-mediated lipogenesis. Thus SREBP-1c and ChREBP appear to 
coordinate DNL in response to hormonal and nutritional cues, the former via insulin and 
the latter through dietary carbohydrate in the form of Xu-5P. 
 
Food for Thought: Consideration of nutrient composition in the promotion and 
regression of NAFLD 
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From a nutritional perspective a critical component of any dietary intervention is 
the macronutrient composition.  Physiologically, carbohydrate in the form of glucose 
serves as the most potent stimulator of pancreatic insulin release, thus it seems logical 
that in the context of impaired insulin action, this dietary stimulus should be lessened to 
minimalize insulin release and thereby improve sensitivity.  Furthermore in humans the 
liver is the organ most actively involved in lipid synthesis, a process predominately 
stimulated via insulin through transcriptional activation of SREBP-1c and through 
glucose activation of ChREBP. The catabolic actions of glucagon oppose these effects, 
therefore dietary measures which increase the glucagon to insulin ratio would abrogate 
such anabolic processes as lipid and glycogen synthesis and promote energy 
expenditure, effectively decreasing hepatic lipid content. 
Several investigators have observed a strong association between excessive 
carbohydrate intake and an increased severity of hepatic steatosis and the inflammatory 
NASH (102,103) in humans.  In a recent prospective study, Kang et al (103) evaluated 
91 patients with clinically suspected NAFLD and characterized 31 patients (34%) as 
having metabolic syndrome.  Those patients with metabolic syndrome were shown to 
consume significantly more carbohydrate (p =0.03) and less fat (p =0.01) and displayed 
higher histological severity scores for steatosis (p =0.004) and NASH (p =0.0006) 
compared to patients without metabolic syndrome.  This particular study is noteworthy 
as it recapitulates current evidence which demonstrates a strong link between 
excessive carbohydrate consumption and the development of physiological factors 
associated with metabolic syndrome as elegantly described by Volek et al (104).  A 
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carbohydrate restricted dietary intervention was recently conducted in an obese female 
patient diagnosed with NAFLD (105) that presented with abnormal plasma ALT levels 
and a hepatic triglyceride content of 44.6% as assessed by 1H MRS. The patient was 
instructed to follow for 2 weeks a ketogenic diet composed of 5: 41: 54 % carbohydrate: 
fat: protein respectively.  At 5 weeks after the initiation of the diet, there was a complete 
correction of plasma ALT values and remarkably, a dramatic four-fold reduction in 
hepatic triglyceride content to 11.9%.  While long-term controlled human studies 
designed to evaluate the role of carbohydrate restriction on improvements in NAFLD are 
sparse, the available evidence does indeed support a beneficial role for this dietary 
intervention in ameliorating the associated clinical and histological abnormalities 
inherent in this disease.  In an interesting animal study (106) two groups of mice were 
fed diets high in carbohydrate (68%) that differed in starch composition in order to 
examine the effects of rapidly absorbed carbohydrate on hepatic steatosis.  One group 
consumed a diet composed of 100% amylopectin, a highly branched chain glucose 
polymer which is rapidly metabolized within the small intestine, whereas the other group 
consumed 60% amylose and 40% amylopectin; amylose due to its linear structure, is 
hydrolyzed at a slower rate and therefore predicted to contribute to less severe hepatic 
steatosis.  Indeed, histological examination indicated the presence of mixed hepatic 
steatosis in mice fed the rapidly absorbed carbohydrate and a two-fold greater hepatic 
triglyceride content (20.7 + 9.4 mg/g vs 9.6 + 4.9 mg/g; p =0.01) when compared to the 
mice that consumed the slower absorbed carbohydrate.  Again, long term clinical 
studies which examine the relationship between carbohydrate and NAFLD in humans 
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are warranted, however this study clearly points to the potential benefit(s) of reduced 
carbohydrate or low glycemic index diets as a novel dietary treatment for reversing the 
progression of hepatic steatosis. 
To date, there have been relatively few long-term controlled studies investigating 
the role of dietary composition, in particular, carbohydrate and carbohydrate restriction 
on NAFLD although several lines of evidence suggest that limited carbohydrate 
consumption may be beneficial towards improved liver function.  In a one year 
prospective study, Solga et al (102) found that a higher carbohydrate intake was 
significantly associated with higher odds of hepatic inflammation whereas a higher fat 
intake was associated with significantly lower odds of inflammation in morbidly obese 
patients with NAFLD.  In addition, the authors observed a trend toward lower odds of 
steatosis and fibrosis in the highest tertile of fat intake suggesting that the presence of 
fat may improve NAFLD histopathology. The underlying mechanism(s) pertaining to 
carbohydrate-induced hepatic inflammation have yet to be clarified.  A more recent 
study by Tendler et al (107) found that a low carbohydrate, ketogenic diet (< 20 g/day 
carbohydrate) significantly improved steatosis, inflammation, and fibrosis in NAFLD 
patients within a 6 month period concomitant with weight loss and lowered plasma 
insulin and glucose levels.  These results support the prevailing notion that insulin 
resistance and hyperglycemia play salient roles in enhancing hepatic DNL and 
triglyceride synthesis thus diets aimed to reduce insulin release may mitigate 
carbohydrate-stimulated lipogenesis.   
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Dietary fat, in particular PUFAs are known to exert hypotriglyceridemic effects 
and are a potentially important dietary treatment in reducing cardiovascular disease risk. 
Evidence is also accumulating that suggests they may also exert various 
hepatoprotective effects. These fatty acids are well known regulators of hepatic gene 
expression with regard to carbohydrate and lipid metabolism, suppressing L-PK in the 
glycolytic pathway as well as several key lipogenic enzymes (see (108) for a brief 
review). Impressively, SREBP-1c is potently inhibited by PUFAs and although the 
mechanistic details require further studies, it has been demonstrated that PUFAs 
reduce SREBP-1c transcription, enhance SREBP-1c mRNA turnover and directly 
interfere with the proteolytic cleavage of the transcriptionally mature SREBP-1c protein 
(108). It has also been recently demonstrated that PUFAs, specifically linoleate (18:2), 
eicosapentanoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6) effectively 
inhibit ChREBP activity in mice, thereby decreasing expression of both L-PK and FAS 
(109). A recent study investigating the potential therapeutic effects of omega-3 FAs in 
patients clinically diagnosed as having hepatic steatosis (110) found that those 
receiving 2.7 grams daily of concentrated EPA for twelve months had significantly 
reduced plasma values of ALT and AST and a regression of steatosis as assessed by 
histological analysis. An eight week trial in patients with elevated hepatic TG content (as 
assessed by proton magnetic resonance spectroscopy) who received 9 grams/day of 
fish oil showed a 46% reduction in plasma TG, a 21% reduction in plasma VLDL and 
IDL cholesterol and a 15% decrease in plasma apolipoprotein B, yet no improvement in 
hepatic TG content (111). It must be mentioned that the sample population for this study 
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was fairly small (n=17) and included mainly African-Americans, who tend to accumulate 
less intraperitoneal fat and differ from other ethnic groups such as Hispanics and 
Caucasians in terms of the prevalence of steatosis (112).   
Nutritional modulation of hepatic anomalies such as steatosis and the more 
severe NASH through carbohydrate restriction as well as increased unsaturated fatty 
acids are beginning to show promise as front-line dietary defenses.  Although the 
evidence is still fairly limited for these approaches the metabolic basis for them seem 
fundamentally sound. Reduced dietary intake of carbohydrate, particularly rapidly 
absorbed sources such as refined grains and starches restricts insulin release and 
shifts metabolism towards a state of energy-deficit, prompting the oxidation of stored 
carbohydrate, as glycogen and fat, as adipose TG. Dietary unsaturated fatty acids 
appear to function at the molecular level to antagonize the transcriptional regulators 
responsible for inducing the lipogenic program. While drugs such as insulin sensitizers 
and nuclear receptor agonists are valuable in their own right, it is time for nutritional 
strategies to emerge as viable therapeutic modalities for diseases of metabolic origin.  
Given the strategic role of the liver in managing incoming dietary components, this 
seems a logical place to start. 
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STUDY 1: Hypercholesterolemia, hepatic steatosis, and liver injury in 
guinea pigs with cholesterol-induced non-alcoholic fatty liver disease 
 
Abstract: 
 
 Evidence from numerous animal and human studies have implicated dietary 
cholesterol as a lipotoxic mediator in the transition of hepatic steatosis to non-alcoholic 
steatohepatitis (NASH), a critical event in the progression of nonalcoholic fatty liver 
disease (NAFLD). Here, we sought to examine the impact of a dietary cholesterol 
challenge on NAFLD progression in phenotypically normal guinea pigs, an animal that 
more closely approximates humans in terms of hepatic cholesterol handling and 
metabolism than other commonly utilized animal models. Young (3-month) male Hartley 
guinea pigs (n =10/group) were subjected to either a high-cholesterol (H-Chol) diet 
containing 0.25% dietary cholesterol or a control, 0.04% low-cholesterol (L-Chol) diet for 
six weeks and evaluated by metabolic and histopathological parameters. Interestingly, 
H-Chol fed guinea pigs had lower final body weights (p = 0.002) and decreased daily 
food intake (p < 0.0001) compared to the L-Chol group.  Compared to L-Chol controls, 
H-Chol guinea pigs developed marked hypercholesterolemia (284 vs 48 mg/dL; p = 
0.0001) and elevated plasma activity of ALT and AST, which are biochemical indicators 
of hepatic injury (p < 0.05 for both) while displaying no differences in plasma glucose, 
non-esterified fatty acid, or triglyceride (TG). Plasma total cholesterol was shown to be 
correlated with plasma ALT activity (r = .78, p = 0.02) in the H-Chol group only. H-Chol 
feeding resulted in increased hepatic accumulation of TG (p = 0.002) along with total, 
free, and esterified cholesterol (p < 0.0001 for all), resulting in modest hepatic steatosis. 
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Moreover, features of hepatic inflammation and injury such as single cell necrosis were 
evident in livers of H-Chol fed guinea pigs. These results demonstrate that a dietary 
cholesterol challenge is sufficient to elicit not only steatosis, but more advanced 
features of hepatic injury in guinea pigs over a six week period. As these are the first 
studies to document histological changes in guinea pigs fed H-Chol, they add to the 
growing list of studies which implicate dietary cholesterol as a causative factor in 
NAFLD development and progression. 
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STUDY 1: Introduction 
 
 In situations of macronutrient abundance, such as immediately after a meal or 
during situations of prolonged caloric overload, cells such as adipocytes and 
hepatocytes store surfeit metabolic energy in the form of triglycerides (TG). These inert, 
highly reduced lipid molecules reside within the hydrophobic core of lipid droplets (LD), 
specialized organelles designed to, among other functions, shelter neutral lipids like TG 
as well as cholesterol esters (CE) away from the aqueous cytoplasm (1,2). When 
circumstances dictate, the stored lipid can be hydrolyzed and released as fatty acids 
where they can then serve as intermediates in the synthesis of various lipid species or 
as bioactive ligands by binding to key nuclear hormone receptors like peroxisome-
proliferator activated receptor α (PPARα), which in turn elicits key changes in overall 
hepatic lipid metabolism (3). Thus by regulating the flux of lipid in cells, LDs serve as 
crucial components of lipid metabolism, with increasing evidence suggesting a 
prominent role for these organelles during times of health as well as disease itself (see 
reference 4 for a recent review).  
Given the massive amount of TG and CE that can be stored within LDs it should 
be of no surprise that their accumulation leads to excessive lipid deposition, which in the 
liver manifests itself as hepatic steatosis. This condition is of clinical significance as it 
represents the initial stage and histological hallmark of non-alcoholic fatty liver disease 
(NAFLD), a clinicopathological entity that represents a spectrum of histological 
abnormalities typically observed during conditions of excessive alcohol intake (5). 
Steatosis that accompanies hepatic inflammation and features of injury like ballooned 
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hepatocytes and apoptotic bodies is referred to as non-alcoholic steatohepatitis 
(NASH), the development of which represents a critical transition in the continuum of 
NAFLD (6). NASH livers from animal models and humans are prone to further 
alterations to liver architecture that include bridging fibrosis, cirrhosis, and in some 
cases hepatocellular carcinoma, culminating eventually with liver failure (7). Exactly 
what mechanisms mediate the transition from pure steatosis to NASH is a research 
question of fundamental importance, but has yet to be convincingly answered. At the 
forefront of proposed explanations has been the ‘two-hit’ hypothesis (8) which posits 
that excess hepatic lipid accumulation brought about by metabolic derangements such 
as insulin resistance and obesity is an initial insult to the liver. Rendered vulnerable by 
the presence of steatotic hepatocytes, the liver then experiences an onslaught of 
secondary hits in the form of oxidative injury and inflammatory pathways that enable 
hepatic inflammation and injury to ensue (9). According to this hypothesis the capability 
of certain bi-products of lipid peroxidation could in turn initiate many of the cellular 
processes such as apotosis, necrosis, and pro-inflammatory cytokine signaling 
characteristic of lesion formation, thus offering a unifying framework of steatohepatitis 
progression. 
A noticeable shift has emerged recently however that suggests disagreement 
with this hypothesis in NASH development (10-12). Rather than focus solely on the 
magnitude of fatty deposition as a crucial effector of disease progression, many 
investigators are instead directing their attention to the nature of the lipid species 
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themselves (13,14). The search is on now for the so called lipotoxic mediators of 
hepatic injury, of which excessive dietary cholesterol is a prime culprit (15,16). 
Experiments conducted in cells have shown convincingly that cholesterol loading 
induces cytotoxicity of the ER (17), depletes mitochondrial glutathione content and 
sensitizes cells to cytokine-mediated NASH (18). Additionally, a recent metabolomic 
assessment concluded that dietary cholesterol was a causal factor in both steatosis and 
hepatic inflammation (19). Moreover, there exists now an abundance of evidence from 
animal studies that has shown that hepatic accumulation of cholesterol aggravates 
hepatic histology by dysregulating homeostatic mechanisms (20) and through 
synergistically interacting with dietary fats (21,22). Dietary cholesterol also further 
distorts hepatic architecture and promotes injury in hypercholesterolemic mouse models 
such as LDLR and ApoE knockout mice (23,24). Most importantly human studies have 
also demonstrated a resounding connection between dysregulated hepatic cholesterol 
metabolism and the severity of NAFLD progression (25). In fact, the very appearance of 
hepatic cholesterol crystals in both mice and humans appears to distinguish between 
steatosis and NASH as shown by Ioannou et al (26). 
Thus the available evidence to date not only hints at, but affirms the importance 
of cholesterol as a lipid mediator of NAFLD progression in a variety of experimental 
settings. These data led to the current study which sought to investigate how 
challenging guinea pigs with excess dietary cholesterol influences NAFLD. The animal 
was chosen purposefully, given its close similarities with humans in terms of hepatic 
cholesterol handling (27).   
 81 
 
STUDY 1: Materials and experimental methodology 
 
Study design: 
Male Hartley guinea pigs (n =39) approximately 3 months of age (Charles River 
Laboratories, Wilmington, MA) were housed in the biology vivarium in the School of 
Pharmacy at UConn. Guinea pigs were housed in cages in groups of two or three on a 
12 hour light-dark cycle in a temperature and humidity controlled room. All guinea pigs 
were acclimated to the facility for one week prior to the experimental period and were 
fed standard rodent chow. Guinea pigs were then randomized to consume either a 
0.04% low-cholesterol control diet (L-Chol) (n =10) or a 0.25% high-cholesterol diet (H-
Chol) (n =29) for six weeks. Both diets were prepared by Research Diets (New 
Brunswick, NJ: L-Chol, D01013102; H-Chol, D01013101) and were identical in terms of 
macronutrient and ingredient composition with the only exception being the cholesterol 
content (Table 1.1). The level of dietary cholesterol in the L-Chol group is equivalent to 
300 mg/day for humans whereas the H-Chol diet is equivalent to the daily consumption 
of 1800 mg for humans. Therefore the H-Chol diet represents a true dietary cholesterol 
challenge. Vitamin and micronutrient composition were formulated to meet the National 
Research Council requirements for guinea pigs and all experimental protocols were 
approved by the Institutional Animal Care and Use Committee (IACUC) at UConn. 
Throughout the six week study period guinea pigs consumed diets and water ad 
libitum. Animal body weight was measured at the beginning of every week on a digital 
scale and recorded in grams. Food intake per cage was calculated as the difference 
between the original amount offered and the amount remaining in the hopper and was 
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measured every two days. At the conclusion of the six week study period guinea pigs 
were fasted overnight for 12 hours and then anesthetized under isoflurane vapors 
followed by cardiac puncture.  Whole blood and livers were then subsequently collected 
for analysis.  For the current study, a total of 10 guinea pigs from the H-Chol group were 
randomly selected for sacrifice, while the remaining 19 guinea pigs were transitioned to 
a separate dietary intervention (see study 2 of this dissertation).  Therefore all 
experimental data obtained in the current study represents a sample of n = 10 for L-
Chol and n = 10 for H-Chol. It must be noted here that with regards to plasma 
measurements, data could only be analyzed in five of the L-Chol guinea pigs due to 
unintended hemolysis of blood following cardiac puncture; while the hemolyzed samples 
were still assessed for plasma parameters, the results differed dramatically from the 
non-hemolyzed samples and thus were excluded from final analyses due to their 
unreliability. 
Plasma metabolite analysis: 
Whole blood was obtained through cardiac puncture and collected into EDTA-
containing 50 mL screw tubes and immediately centrifuged at 2000 x g for 20 minutes 
(Beckman Model TJ-6) to separate plasma from red blood cells.  To prevent proteolytic 
degradation a preservation cocktail composed of sodium azide (0.1 mL/100 mL) and 
aprotinin (0.5 mL/100 mL) was added to plasma following centrifugation.  Plasma was 
aliquoted and stored at -80°C for subsequent analysis.  All plasma metabolites, with the 
exceptions of free cholesterol and non-esterified fatty acids (see below) were analyzed 
using the Cobas c111 analyzer (Roche Diagnostics, Indianapolis, IN). 
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Total cholesterol (TC)  
 Plasma TC was analyzed using an enzymatic and colorimetric method where 
cholesterol esters (CE) are first cleaved to free cholesterol and fatty acids via 
cholesterol esterase.  The cholesterol molecule is then acted upon by cholesterol 
oxidase and undergoes oxidation to cholest-4-en-3-one and hydrogen peroxide.  The 
reaction proceeds with hydrogen peroxide oxidatively coupling 4-aminoantipyrine and 
phenol in the presence of peroxidase, yielding a quinone-imine chromophore.  The 
resulting red color intensity is directly proportional to the concentration of TC in the 
sample. Results are expressed as mg/dL. 
High-density lipoprotein cholesterol (HDL-C) 
 Plasma HDL-C was measured directly with a homogeneous enzymatic 
colorimetric automated procedure. This method is based on the formation of water-
soluble complexes of dextran sulfate and LDL, VLDL, and chylomicrons in the presence 
of divalent cations, particularly magnesium ions (28).  Briefly, a HEPES buffer 
containing 1.5g/L dextran sulfate was added to plasma aliquots followed by the addition 
of a working solution of HEPES buffer containing polyethylene glycol (PEG)-modified 
cholesterol esterase and cholesterol oxidase.  The modification of these enzymes by 
PEG (attached to the amino groups) causes them to show selective catalytic activities 
towards the various lipoprotein particles with the greatest reactivity towards HDL.  
Furthermore, LDL, VLDL, and chylomicrons are resistant to the actions of PEG-modified 
enzymes, thus the measured cholesterol corresponds to that within the HDL particle 
only.  CE are then converted to FC and fatty acid following the action of PEG-modified 
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cholesterol esterase with subsequent oxidation of the FC to ∆4-cholestenone and 
hydrogen peroxide through the action of cholesterol oxidase.  Hydrogen peroxide then 
reacts with 4-aminoantipyrine and a sodium complex (sodium N-(2-hydroxy-3-
sulfopropyl)-3,5-dimethoxyaniline), yielding water and a purple-blue chromophore 
whose intensity is directly proportional to the concentration of cholesterol within the HDL 
particles. Results are expressed as mg/dL. 
Low-density lipoprotein cholesterol (LDL-C) 
 The concentration of LDL-C was calculated indirectly according to the Friedwald 
equation as shown here; LDL-C = TC – [HDL-C + (TG/5)].  As the plasma triglyceride 
levels were not markedly elevated (table 1.2) the use of this formula to estimate LDL-C 
was considered appropriate. LDL-C concentration is expressed as mg/dL. 
Free cholesterol (FC) 
 Plasma FC was quantitatively determined according to an enzymatic method as 
per the instructions of the manufacturer (Wako Diagnostics, Richmond, VA).  The 
principle of this test is the enzymatic oxidation of FC by cholesterol oxidase to ∆4-
cholestenone with the simultaneous production of hydrogen peroxide.  The hydrogen 
peroxide produced along with the presence of peroxidase enables a oxidative 
condensation reaction between 3,5-dimethoxy-N-ethyl-N-(2-hydroxy-3-sulfopropyl) 
aniline sodium (DAOS) and 4-aminoantipyrine producing a blue pigment whose 
absorbance is then measured at 600 nm and reflects the concentration of FC present in 
the sample, expressed as mg/dL. The reaction scheme is shown here:  
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Triglyceride (TG) 
 Plasma TG was measured using an enzymatic colorimetric method in which 
lipoprotein lipase hydrolyzes the TG molecule generating three fatty acids and the 
glycerol moiety.  Glycerol kinase then phosphorylates glycerol to produce adenosine 
diphosphate and glycerol-3-phosphate, which then undergoes oxidation to 
dihydroxyacetone phosphate via glycerophosphate oxidase.  This reaction step also 
yields hydrogen peroxide that reacts with 4-aminophenazone and 4-chlorophenol and, 
in a peroxidase-catalyzed reaction, results in the production of a red dyestuff, 4-(p-
benzoquinone-monoimino)-phenazone. The resultant intensity of the red dyestuff is 
directly proportional to the TG concentration and is measured photometrically in the 
Cobas c111 analyzer.  Plasma TG is expressed as mg/dL. 
Non esterified fatty acid (NEFA) 
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 To quantitatively determine plasma NEFA concentration an enzymatic 
colorimetric method was employed (Wako Diagnostics, Richmond, VA) and conducted 
in accordance with the manufacturer’s instructions.  This method relies on the acylation 
of coenzyme A by fatty acids in the presence of acyl-CoA synthetase and adenosine 
triphosphate (ATP).  This acylation results in the formation of thiol esters in the form of 
acyl-CoA along with adenosine monophosphate (AMP) and pyro-phosphate as 
byproducts.  The procedure proceeds with the oxidation of the acyl-CoA in the presence 
of added acyl-CoA oxidase, producing hydrogen peroxide, which, in the presence of 
peroxidase, then enables the oxidative condensation of 3-methyl-N-ethyl-N-(β-
hydroxyethyl)-aniline (MEHA) with 4-aminoantipyrine to form a purple-colored 
chromophore.  The concentration of NEFA is then determined from the optical density of 
the chromophore when measured at 550 nm.  The results are expressed as mEq/L. The 
overall reaction scheme is represented here: 
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Glucose 
 Plasma glucose was quantitatively determined photometrically by monitoring the 
rate of NADPH formation.  Glucose was first phosphorylated to glucose-6-phosphate 
(G6P) by hexokinase in the presence of ATP and then oxidized to gluconate-6-
phosphate following G6P-dehydrogenase activity.  In this second reaction, the oxidation 
of G6P proceeds with the reduction of NADP+ to NADPH, the rate of which is directly 
proportional to the plasma glucose concentration.  It is worth noting that glucose is the 
only carbohydrate oxidized in this assay. Results are expressed as mg/dL. 
Alanine aminotransferase (ALT) activity 
 Hepatic injury was assessed biochemically by measuring the enzymatic activity 
level of ALT in plasma.  The assay relies on the enzymatic transfer of the amino group 
from L-alanine to 2-oxoglutarate, catalyzed by ALT, with subsequent formation of 
pyruvate and L-glutamate.  Nicotinamide adenine dinucleotide (NADH) then reduces 
pyruvate to L-lactate in a reaction catalyzed by lactate dehydrogenase.  The rate of 
NADH oxidation to NAD+ is directly proportional to the catalytic activity of ALT and is 
determined by measuring the decrease in absorbance.  Importantly, this assay includes 
pyridoxal phosphate (PLP) which functions as a coenzyme in the transfer of amino 
groups and therefore ensures full enzymatic activation of ALT.  Results are expressed 
as U/L. 
Aspartate aminotransferase (AST) activity 
 Plasma AST activity is also utilized as a biochemical assessment of hepatic 
injury and is measured by the Cobas c111 analyzer in a manner similar to ALT. In the 
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first transfer reaction, AST catalyzes the transfer of the amino group from L-aspartate to 
2-oxoglutarate, forming oxaloacetate and L-glutamate.  The assay proceeds with the 
reduction of oxaloacetate by NADH and in the presence of malate dehydrogenase 
forms L-malate and NAD+.  AST activity reflects the rate of NADH oxidation and is 
determined by measuring the decrease in absorbance.  Full AST activation was 
ensured by the presence of PLP in the assay reagents.  Results are expressed as U/L. 
Hepatic lipid analysis:   
 Whole livers were excised and immediately weighed on a digital scale and their 
weights recorded in grams. Livers were photographed with a Canon PowerShot A720 IS 
digital camera and then approximately 1 g of tissue from the left sublobe of the quadrate 
lobe was sliced with a razor, placed in a 1 mL snap tube and immediately stored at -
80°C for hepatic lipid extraction.  Once all tissue had been removed for lipid and 
histological analysis (see below) the remnant liver mass was tightly wrapped in 
aluminum foil and stored at -80°C for future analysis.  The concentration of hepatic 
lipids are expressed as mg/g liver with the exception of phospholipid, which is 
expressed as µg/g liver. 
Hepatic TG 
  The procedure for lipid extraction from liver is based on the original protocol 
published by Folch et al (29) with some minor variations.  Approximately 1 g of liver was 
finely sliced with a razor blade and added to 50 mL screw-top glass test tubes 
containing 10 mL of Folch solution (2:1 chloroform:methanol).  Tubes were then 
capped, vortexed, and left to incubate for 24 hours in a dark room at room temperature.  
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The homogenate was then filtered gravimetrically with Whatman grade #1 filter paper, 
added to a separatory funnel, mixed with 3 mL 0.05% sulfuric acid, and left to incubate 
for 1 hour or until adequate phase separation took place.  The lower phase, which 
contains the pure lipid extract, was collected into 30 mL glass screw-top tubes and the 
total volume was adjusted to 10 mL by adding Folch solution followed by vortexing.  
Then a 2 mL aliquot was collected into 10 mL glass screw top test tubes, combined with 
500 µL of sulfuric acid, vortexed, and left uncapped overnight at room temperature.  The 
following day the upper layer was removed and the total volume adjusted to 2 mL with 
chloroform.  Next, a 200 µL aliquot was added to 13 x 100 mm glass tubes and 
evaporated under a steady stream of nitrogen gas.  Samples were rehydrated with 
approximately 1 mL of 1% triton X-100 (triton/water) and then stored in the dark at 4°C 
prior to analysis.  Hepatic TG were measured enzymatically using a commercially 
available assay (Pointe Scientific Inc, Canton, MI) which sequentially hydrolyzes, 
oxidizes, and condenses the TG molecules into a red colored quinoneimine that is 
measured spectrophotometrically at 500 nm.  The TG concentration in the liver sample 
is directly proportional to the intensity of the red chromophore. 
Hepatic TC 
 The isolation of TC from the liver followed the same steps as that detailed for 
liver TG until the phase separation step (see above).  Once the final volume of the lipid 
extract was adjusted to 10 mL with Folch solution, a 200 µL aliquot was transferred in 
triplicate to 13 x 100 mm glass test tubes and allowed to evaporate overnight uncapped.  
Samples were resuspended in 200 µL ethanol, vortexed, and analyzed using a 
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commercially available assay (Pointe Scientific Inc, Canton, MI).  The assay utilizes the 
peroxidase, phenol, and 4-aminoantipyrine color system in which the intensity of the red 
colored quinoneimine is measured at 500 nm and directly proportional to the 
concentration of liver TC. 
Hepatic FC 
 Steps for the extraction and isolation of hepatic FC are identical to that for 
hepatic TC.  Once samples were rehydrated with 200 µL ethanol they were then 
analyzed according to the manufacturer’s instructions (Pointe Scientific Inc, Canton, 
MI).  This assay is the same used to measure plasma FC (see above for reaction 
scheme). 
Hepatic cholesterol ester (CE) 
 The amount of cholesterol stored as CE within the liver was determined indirectly 
by calculating the difference between liver TC and FC; CE = TC – FC. 
Hepatic phospholipid (PL) 
 Total PL concentration was quantified in the liver through capillary gas 
chromatography (see study 3 materials and experimental methodology).  
Liver pathology: 
 To evaluate whether H-Chol impacts liver pathology, approximately 1-2 g of 
tissue from the left lobe or the medial sublobe of the right lobe were sliced with a razor 
blade and submerged in 10% neutral buffered formalin solution. Formalin is an example 
of an aqueous aldehyde solution and contains approximately 4% weight/volume (w/v) 
formaldehyde in water at a neutral buffered pH of 7.2-7.4.  All samples remained 
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immersed for approximately 1 week in order for full stabilization of histological structure 
to occur and were then delivered to the Histology section of the Connecticut Veterinary 
Medical Diagnostic Laboratory in the Department of Pathobiology and Veterinary 
Science for processing, sectioning, and staining.  It must be mentioned here that the 
selection of the left lobe or medial sublobe for representative histology was done in an 
attempt to avoid any interpretive difficulties resulting from a phenomenon known as 
tensional lipidosis.  This can occur when liver tissue that is in close proximity to the gall 
bladder is removed and this can often exaggerate the degree of hepatosteatosis 
present. 
A note on histological methods 
 The ultimate aim of histological staining is to examine the structural framework of 
tissue with as minimal alteration as possible to the original structural and chemical 
composition. This requires considerable vigilance when it comes to preparation and 
handling of microscopic samples as well as an appreciation for certain technical 
difficulties that inevitably arise during the course of tissue procurement, fixation, 
embedding, sectioning, and staining. 
All freshly isolated tissues are chemically and physically unstable and need to be 
stabilized in order to arrest post-mortem decay. Moreover, many histological staining 
methods will only succeed when this process, referred to as fixation, is implemented.  
The most obvious result of fixation is the hardening of tissue which enables the eventual 
slicing of the samples into sections. However, often unbeknownst to the researcher, 
common fixation methods that rely on liquid fixatives also introduce chemical and 
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structural artifacts due to swelling and shrinking of tissue. Complicating matters further 
is that these physical changes often do not affect all regions of the tissue equally, 
resulting in visibly noticeable ‘empty spaces’ that one must take into account when 
selecting the most appropriate section(s) for analysis.  
In order for embedding to successfully occur, specimens must be equilibrated 
with a solvent that is miscible with wax (typically, but not always, this is paraffin). This is 
accomplished by replacing the natural water present in the specimen first with alcohol 
and then with a paraffin solvent (also referred to as a clearing agent), often xylene. 
Molten paraffin wax is then allowed to infiltrate the tissue, which is eventually embedded 
(blocked out) in solidified paraffin blocks that are used for sectioning. Physical changes 
are continually visited on tissues till the time of embedding, such that the volume of 
paraffin-embedded specimen is typically 60-70% that of what it was at the time of 
excision. One should also be cognizant of the potential loss of some lipid constituents, 
which invariably dissolve out during the dehydration and embedding process. If lipids 
are of significant interest experimentally then quick freezing of tissue via immersion in 
liquid nitrogen followed by sectioning on a cryostat can significantly minimize loss of 
tissue lipid constituents. Germane to histology, this type of freezing technique limits ice 
crystal formation which is known to distort tissue architecture by appearing as series of 
meaningless holes scattered throughout the section.  
Paraffin blocks are then sliced into thin sections (typically 5-10 µM), floated on warm 
water to remove wrinkles and mounted on glass slides. The slides are dried in warm air 
and then immersed in xylene or other clearing agents to dissolve the wax and to 
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equilibrate the tissue with the clearing agent itself. Slides are then exposed to a series 
of graded mixtures of alcohol and water before the stain of interest is applied. 
Hematoxylin and eosin (H&E) stain 
 Five µM sections were mounted onto glass slides, dried in warm air, and placed 
on a Leica Autostainer for automated H&E staining. The slides were placed in two 
changes of xylene for approximately four minutes each followed by two changes of 
100% ethanol for four minutes each. Slides then were rinsed in tap water for two 
minutes, placed in Harris Hematoxylin for 6 minutes and washed in running tap water 
for two minutes. They were then dipped twice in decolorizing acid alcohol solution, 
washed in running tap water for two minutes, placed in 1% ammonia water for 10 
seconds, washed in running water for another two minutes, and placed in 95% ethanol 
for one minute. The final stage involved placing the slides in eosin stain for three 
minutes, followed by four changes of 100% ethanol for one minute each, and two 
changes of xylene for one minute each. Lastly, a coverslip with synthetic resin was 
placed on the slides.  The cellular components can be identified based on the color 
imparted by the H&E; all nuclei are stained blue and the cytoplasm is colored in various 
shades of pink. 
Trichome stain 
 The term ‘trichome’ indicates a staining method where two or more anionic dyes 
are used in combination with a heteropolyacid, which is a water- and alcohol-soluble 
crystalline compound. There are several variations of trichome staining, notably 
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Masson’s and Mallory’s techniques, all of which enable the identification of collagenous 
and reticular fibers, basement membranes, and secretory granules. 
 Five µM sections from paraffin-embedded liver blocks were mounted on glass 
slides then deparaffinized and hydrated in distilled water. Hydrated sections were then 
placed in Bouin’s solution overnight at room temperature. Following overnight 
incubation, slides were rinsed in tap water until colorless and then placed in working 
Weigert’s iron hematoxylin solution (2.5g hematoxylin, 250 mL 95% alcohol, 4 mL 29%  
aqueous ferric chloride, 95 mL distilled water, 1 mL HCL) for 10 min. Slides were then 
rinsed in tap water till clear, placed in Gomori’s 1-step trichome with Aniline blue 
(#1816, Poly Scientific R&D) for 15 minutes and then rinsed again in tap water till clear. 
Slides were placed in 5% acetic acid (5 mL glacial acetic acid, 100 mL distilled water) 
for 2 minutes and then dehydrated in 95% ethanol followed by 100% ethanol and finally 
cleared in xylene and covered with a coverslip with synthetic resin.  With the trichome 
stain, collagen fibers are recognized as distinct bright blue colorations against a 
background of red-colored cytoplasm and black nuclei. 
Oil Red O (ORO) stain 
 
 ORO is a member of the solvent (azo) class of dyes which are characterized by 
their largely non-polar groups and reduced capacity for hydrogen bonding. These dyes 
function by moving from polar solvents into somewhat less polar (more hydrophobic) 
domains such as lipids with typical examples of solvent dyes including Sudan III, IV, and 
ORO. ORO is more hydrophobic and intensely colored than the Sudan dyes thereby 
allowing for greater resolution of microvesicular lipid droplets.  
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 The preparation of livers for ORO staining differs from those sections subjected 
to H&E or trichome staining in that the samples require freezing.  Following removal of 
the whole liver, approximately .1-.5 g of freshly excised liver tissue from the left lobe or 
the medial sublobe of the right lobe were immediately placed in 24x24x5 mm cryomolds 
(American MasterTech) and filled with optimal cutting temperature (OCT) compound. 
The cryomolds were then placed in a metal bowl containing a small amount of 2-
methylbutane (#270342-IL, 99.5% HPLC grade) for 1-2 minutes atop dry ice. Cryomolds 
were wrapped in parafilm and aluminum foil, and placed immediately in -80°C until 
sectioning 
 A saturated solution of ORO was developed by adding excess dye powder to a 
99% isopropyl alcohol solution and allowed to stand for 2-3 days prior to use. Two 
volumes of a 1% dextrin in water solution was added to 3 volumes of the ORO stock 
solution, mixed, and allowed to stand for two days before being filtered through 
Whatman #4 filter paper, thereby forming the working solution. 
Frozen sections were sliced at 4 µM using a cryostat and collected onto slides 
and then rinsed in 60% ethanol, stained with the working solution of ORO for 10-20 
minutes, rinsed in 60% ethanol followed by four changes of water, and then 
counterstained with an alum-hematoxylin solution. The sections were finally washed in 
one more exchange of water and mounted in an aqueous medium.  
Ultimately the process results in hydrophobic lipids, especially the neutral 
triglyceride species, being stained red with small intracellular microvesicular droplets 
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also clearly visible. The more hydrophilic lipids are also stained, albeit weaker and 
orange-red in color.  
Parameters of hepatic steatosis  
 Histological evaluation of hepatic steatosis for H&E-stained guinea pig liver 
sections from L-Chol (n =10) and H-Chol (n =10) was performed by a board-certified 
pathologist, Joan A Smyth (JAS) of the Department of Pathobiology and Veterinary 
Science, according to the scoring system originally proposed by Brunt et al (30) and 
validated by Kleiner et al (31). The grading system of hepatic steatosis is based on the 
percentage of lobule and parenchyma involved as follows (31): 
 Grade 0: Minimal fat accumulation in <5% of hepatocytes. 
 Grade 1:  Mild fat accumulation in 5-33% of hepatocytes. 
 Grade 2: Moderate fat accumulation in 34-66% of hepatocytes. 
 Grade 3: Severe fat accumulation in >66% of all hepatocytes. 
 Additionally, steatosis was evaluated with regard to the pattern-type of lipid 
droplets and noted as either microvesicular, macrovesicular, or mixed macro and 
microvesicular steatosis. All photomicrographs of liver sections stained with H&E, 
trichome, and ORO are the courtesy of JAS. 
Statistical analysis: 
 All data were analyzed using the Prism statistical program from GraphPad 
Software version 5.0c (San Diego, CA).  Two-tailed independent student’s t-tests were 
performed when comparing the differences between L-Chol and H-Chol groups.  An 
unpaired t-test with Welch’s correction was used in cases where variances were 
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significantly different as determined by the F-test.  All data are expressed as the mean + 
standard error of the mean (SEM).  An α-level of p < 0.05 was chosen to denote 
statistical significance.     
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STUDY 1: Results 
 
Increased dietary cholesterol does not impact body weight or adiposity 
 
 Following a one week acclimatization period, guinea pigs were randomly 
assigned to consume either a low-cholesterol diet containing .04% dietary cholesterol 
(L-Chol) or a high-cholesterol diet containing .25% cholesterol (H-Chol) for 
approximately 6 weeks. Both diets were identical in macronutrient and micronutrient 
composition with the sole difference being the cholesterol content; .04% is equivalent to 
300 mg cholesterol/day for humans whereas .25% is equivalent to the consumption of 
1800 mg cholesterol/day for humans (32). Thus the H-Chol constitutes an exorbitant 
source of cholesterol and represents a true cholesterol challenge. A complete 
composition of the diets is listed in Table 1.1. 
Initial body weights (in grams, g) at week one did not significantly differ between 
groups (369 + 4.5 vs 372 + 15, p = 0.86; Figure 1.1) with the heaviest animal (490g) 
being in the H-Chol group.  Both groups gained weight over the course of six weeks yet 
surprisingly the L-Chol guinea pigs weighed significantly more at week 6 compared to 
the H-Chol group (639 + 17 vs 555 + 17, p = 0.002; Figure 1.1) with the heaviest guinea 
pig weighing 749g and 663g in L-Chol and H-Chol respectively. The increased weight 
gain of L-Chol guinea pigs can be explained by an increased daily consumption of the 
diet (grams/day) relative to the H-Chol group (57 + 1.8 vs 45 + 1.9, p = <0.0001; Figure 
1.2). Despite the differences in body weight, there were no differences in the degree of 
adiposity between L-Chol and H-Chol animals according to adipose weight (g) (10 + 1.2 
vs 7 + 1.2, p = .085).  In the L-Chol group, the heaviest animal had the second heaviest 
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adipose weight whereas in the H-Chol group, the greatest body weight and adipose 
mass corresponded to the same guinea pig.  
H-Chol feeding induces hypercholesterolemia but does not affect other plasma 
metabolic parameters 
 
 Of the various plasma parameters measured in the current study the most 
noticeable difference between the L-Chol and H-Chol groups resided in total 
cholesterol. H-Chol guinea pigs displayed significantly higher total cholesterol than the 
L-Chol controls (p = 0.0001).  Consonant with these data, plasma free cholesterol was 
also significantly elevated in H-Chol guinea pigs relative to the L-Chol group (p 
<0.0001). LDL-C (p = 0.0003) as well as HDL-C (p = 0.0003) were also greatest in H-
Chol group compared to L-Chol group (figure 1.3).  The cholesterol profile of L-Chol 
and H-Chol guinea pigs demonstrated that the majority of the cholesterol in plasma is 
transported in the LDL fraction, which as discussed previously is one of the most 
conspicuous features of guinea pigs that mimics human lipoprotein metabolism.  
Accordingly, linear regression analysis demonstrated a strongly positive correlation 
between plasma total cholesterol and LDL-C in L-Chol (r = 0.9, p = 0.03), H-Chol (r = 
0.96, p <0.0001), and both L-Chol and H-Chol together (r = 0.98, p <0.0001; figure 1.4).  
 Interestingly, H-Chol feeding appeared to have little to no effect on circulating 
levels of triglycerides (p = 0.75), non-esterified fatty acids (p = 0.84), or glucose (p = 
0.86) compared to the L-Chol controls.  Table 1.2 provides the results for all plasma 
metabolites measured in this study.    
Feeding H-Chol for six weeks increases biochemical indices of liver injury 
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 Plasma concentrations of liver transaminase enzymes, in particular ALT and 
AST, serve as clinical markers of hepatic injury and are often referred to as liver 
function tests (LFTs).  The rationale for measuring ALT and AST (along with alkaline 
phosphatase, ALP) is that when hepatocytes are exposed to some injurious insult they 
become damaged and leak these enzymes into the hepatic and eventually, general 
circulation.  In general, the greater plasma concentration of these enzymes indicates 
more severe liver injury, although several (valid) concerns have been raised about their 
clinical accuracy and reliability. 
 Guinea pigs in the H-Chol group displayed significantly elevated plasma 
concentrations of ALT (p = 0.042) and AST (p = 0.049) compared to the L-Chol controls 
(table 1.2, figure 1.5) indicating that excessive cholesterol feeding does induce some 
form of hepatic injury.  In support of this we noted a strong positive correlation between 
ALT and plasma total cholesterol in the H-Chol group only (r = 0.78, p = 0.02; figure 
1.6).   
H-Chol does not impact liver weight but increases the liver to body weight ratio 
 
 To determine whether there were differences in liver size and gross morphology 
whole livers were excised, immediately weighed on a digital scale, and photographed.  
Surprisingly the livers from H-Chol guinea pigs were similar to L-Chol livers in wet 
weight (p = 0.103; figure 1.7), yet there were striking differences morphologically. 
Whereas L-Chol livers were smooth and displayed a dark red-brown complexion H-Chol 
livers were paler, with an almost cloudy white appearance and a rough, tumescent 
texture (see histological figures).  
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 While organ wet weight does provide important information, a much more reliable 
measurement is the ratio of the organ to body weight as a whole.  Indeed, despite no 
differences in total liver weight, the liver to body weight (liver/body weight) ratio was 
significantly greater in the H-Chol group (p = 0.001), constituting almost 4% compared 
to 3% in L-Chol (figure 1.8). Thus H-Chol livers constitute a greater proportion of total 
body weight following the six week dietary period. Table 1.3 provides the results for all 
the hepatic parameters assessed in the current study. 
Six week dietary cholesterol challenge promotes accrual and storage of 
triglycerides and cholesterol in liver 
 
 A well-documented, yet incompletely understood phenomenon in rodents, 
including guinea, pigs fed cholesterol-enriched diets is the accumulation of hepatic 
triglycerides (TG), often resulting in fatty liver.  Why excessive dietary cholesterol 
promotes hepatocellular storage of TG has still not been sufficiently explained at the 
molecular level, although it is tempting that a cooperative relationship exists between 
TGs and cholesteryl esters (CEs) in governing lipid accumulation.  
We also observed an increase in liver TG content of H-Chol livers compared to L-
Chol controls (p = 0.002; figure 1.9) and this occurred with a concomitant accumulation 
of hepatic cholesterol, both total (p = <0.0001; figure 1.10) and free (p = 0.0004).  As 
TGs constitute the major stored neutral lipid in cells, it was particularly surprising to see 
hepatic cholesterol concentration exceed that of TG. For instance in the H-Chol group 
total cholesterol equaled 14 mg/g whereas liver TG was around 12 mg/g while L-Chol 
livers contained similar quantities of these two lipids (table 1.3).   
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Lastly hepatic phospholipids were shown to be similar between L-Chol and H-
Chol groups (p = 0.21).  It was interesting that total phospholipid concentration was 
slightly higher in the L-Chol group (table 1.3) suggesting possible disturbances in 
hepatic phospholipid balance (see study 3 of this dissertation). 
Six weeks of H-Chol induces moderate steatosis and successfully provokes 
development of hepatic lesions characteristic of NASH 
 
 A trained pathologist (JAS) who was blinded to the study evaluated liver sections 
from each guinea pig to assess the degree of fatty infiltration, inflammatory features, 
and fibrosis.  Relevant here is that all sections were examined twice and at different 
time points, thereby ensuring an unbiased evaluation.  Additionally, only steatosis was 
quantified and assigned a score according to the system of Kleiner et al. (31),  while 
features such as inflammatory infiltration and fibrosis were noted and photographed 
during the course of analysis.  With regard to the L-Chol group, nine out of ten livers 
had very minimal fatty deposition and were classified as grade 0 while one liver 
presented with fine microvesicular steatosis of unknown origin and was classified as 
grade 2.  In contrast, all H-Chol livers presented some degree of steatosis with the 
majority (60%) being assigned a grade of 2 resulting in a significantly greater steatosis 
score compared to L-Chol (p <0.0001; figure 1.11).  All H-Chol livers displayed a 
pattern of mixed microvesicular and macrovesicular steatosis and there was little 
variation in the distribution of fatty change throughout zones 1, 2, or 3 of the lobule as 
evidenced by both H&E and ORO staining (figure 1.12 B,D,F). 
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 Mild lobular inflammation was a feature common to all H-Chol livers and several 
displayed pronounced inflammatory foci scattered throughout the parenchyma.  In 
addition to inflammatory infiltrates NASH diagnosis relies on the simultaneous presence 
of more insidious forms of liver injury, with the cardinal feature being ballooned or 
degenerated hepatocytes.  As the description suggests, hepatoyctes that undergo this 
morphological change typically become swollen and disfigured such that they lose their 
classic hexagonal shape and contain rarified, foamy cytoplasm, presumably the result of 
increased accumulation of intracellular fluid.  We noted ballooning change in several H-
Chol livers, though not surprisingly the extent of this lesion throughout the lobule was 
considerably variable and there were some sections devoid of any ballooned 
hepatocytes, consistent with the results of many rodent models of NAFLD.  
 Aside from ballooning, hepatic injury in NASH is characterized by hepatocellular 
death which presents histologically as acidophil (apoptotic) bodies or spotty necrosis 
(6).  Single-cell necrosis was evident in livers of H-Chol guinea pigs (figure 1.13 A, 
arrowhead) and this likely contributed to the emergence of the observed inflammatory 
infiltrates given the invariable immune response that the presence of necrotic cells 
initiates. One other notable histological lesion that was observed in H-Chol livers was 
the presence (albeit relatively minor) of glycogenated nuclei (figure 1.13 B, arrow), 
which are vacuolated hepatocytes with diffuse cytoplasmic glycogen accumulation 
typically observed in individuals with glycogen storage disease or with poorly controlled 
type 1 diabetes (7).  Like megamitochondria, Mallory-Denk bodies (MDB), or acidophil 
bodies, glycogenated nuclei are unique lesions indicative of some underlying liver injury, 
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which, in this particular study, seems to be the bombardment of the liver with excessive 
dietary cholesterol. 
 Overall these histological findings support our study hypothesis that dietary 
cholesterol promotes not only fatty liver, but also is capable of provoking the transition 
to NASH.   
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Table 1.1: Dietary composition of .04% low-cholesterol (L-Chol) and .25% high-
cholesterol (H-Chol) diets 
 
Macronutrient L-Chol H-Chol 
 % gram % kcal % gram % kcal 
Protein 22.3 23 22.2 23 
Carbohydrate 40.6 42 40.5 42 
Fat 15.1 35 15.1 35 
Ingredient L-Chol H-Chol 
 grams grams 
Soy protein 200 200 
L-methionine 5 5 
Corn starch 125 125 
Maltodextrin  25 25 
Sucrose 214 214 
Cellulose 100 100 
Guar gum 25 25 
Olive oil 33.36 33.36 
Palm kernel oil 68.11 68.11 
Safflower oil 37.53 37.53 
Mineral mix1 75 75 
Vitamin mix1 10 10 
Cholesterol  0.37 (.04%)2 2.3 (.25%)3 
Caloric density (kcal/g) 3.87 3.88 
1Mineral and vitamin mixes were formulated to meet the National Research Council requirements for 
guinea pigs. 
2.04% is equivalent to approximately 300 mg cholesterol/day for humans. 
3.25% is equivalent to approximately 1800 mg cholesterol/day for humans. 
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Figure 1.1: Initial and final body weights along with average body weight change 
of L-Chol and H-Chol guinea pigs 
 
 
 
 
Figure 1.2: Average daily food consumption of guinea pigs fed L-Chol or H-Chol 
 
 
 
 
Figure 1.3: Plasma cholesterol profile of L-Chol and H-Chol fed guinea pigs 
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Figure 1.4: Plasma total cholesterol as a function of LDL-C  
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Table 1.2: Plasma characteristics of guinea pigs fed .04% and .25% cholesterol for 
six weeks 
 
Metabolite L-Chol (n = 5) H-Chol (n = 10) p-value 
Total cholesterol 
(mg/dL) 48 + 4.8 284 + 36.6 0.0001* 
Free cholesterol 
(mg/dL) 21 + 1.4 99 + 10 < 0.0001* 
*LDL-C (mg/dL) 32 + 6.2 201 + 29  0.0003* 
HDL-C (mg/dL) 4 + 1.4 72 + 11.6 0.0003* 
Triglycerides  
(mg/dL) 58 + 9.8 61 + 6 0.75 
Non-esterified 
fatty acids 
(mEq/L) 
0.5 + .03 0.5 + .04 0.84 
Glucose (mg/dL) 186 + 12 184 + 9.4 0.86 
ALT (U/L) 86 + 23.2 196 + 30.8 0.042* 
AST (U/L) 213 + 71.7 472 + 72.6 0.049* 
All data presented as mean + standard error of the mean (SEM) 
Abbreviations: LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density 
lipoprotein cholesterol, ALT; alanine aminotransferase, AST; aspartate 
aminotransferase 
*LDL-C calculated according to Friedwald equation. 
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Figure 1.5: Plasma activity level of liver enzymes in L-Chol and H-Chol guinea 
pigs 
 
Figure 1.6: Plasma ALT as a function of plasma total cholesterol in H-Chol fed 
guinea pigs 
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Figure 1.7: L-Chol and H-Chol guinea pig liver weights      
 
 
Figure 1.8: Ratio of liver to final body weight in L-Chol and H-Chol 
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Table 1.3: Hepatic characteristics of guinea pigs fed .04% and .25% cholesterol 
for six weeks 
 
Liver parameter L-Chol (n = 10) H-Chol (n = 10) p-value 
Liver weight (g) 19.3 + .8 21.9 + 1.3 0.103 
Liver/body weight 
(%) 3 + .1 3.9 + .2 0.001* 
Triglycerides  
(mg/g) 6 + .4 11.6 + 1.3 0.002* 
Phospholipids*  
(ug/g) 29557 + 1359 27026 + 1216 0.21 
Total cholesterol 
(mg/g) 5.1 + .4 14 + 1.3 <0.0001* 
Steatosis score .2 + .2 1.8 + .2 <0.0001* 
All data presented as mean + standard error of the mean (SEM) 
* For phospholipid analysis, n = 6 for L-Chol and n = 5 for H-Chol 
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Figure 1.9: Hepatic triglyceride content of L-Chol and H-Chol guinea pigs 
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Figure 1.10: Hepatic total cholesterol content of L-Chol and H-Chol guinea pigs 
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Figure 1.11: Liver steatosis scoring for L-Chol and H-Chol fed guinea pigs 
 
 
 
 
 
 
 
 
Figure 1.12: Gross morphology and histology of livers from L-Chol and H-Chol 
guinea pigs  (see following page) 
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Figure 1.13: Features of liver injury characteristic of NASH in H-Chol guinea pigs 
 
 
 
 117 
 
STUDY 1: Discussion 
 
 In the current study we have presented evidence that supports a causative 
relationship between cholesterol-enriched dietary feeding and the emergence and 
progression of NAFLD in non-genetically modified guinea pigs. Over the course of six 
weeks guinea pigs fed a diet containing 0.25% cholesterol (H-Chol) developed marked 
hypercholesterolemia, displayed biochemical evidence of hepatic injury, and 
accumulated copious amounts of triglyceride and cholesterol species in the liver 
causing moderate steatosis.  Accompanying this fatty infiltration was the presence of 
several histological features characteristic of NASH, including mild lobular inflammation, 
hepatocyte ballooning, single cell necrosis, and glycogenated nuclei. Altogether, these 
data demonstrate that manipulating dietary cholesterol content may prove a useful 
experimental approach in understanding the pathophysiology of NAFLD.  
To our knowledge, this is the first study to investigate the impact of high 
cholesterol on liver pathology in guinea pigs, which may serve as a possible alternative 
to the mouse or rat models that have long commandeered the field of NAFLD research. 
Previous studies in our lab have demonstrated that guinea pigs accumulate significant 
amounts of triglyceride and total, free, and esterified cholesterol when fed cholesterol-
enriched diets (32). This same study also demonstrated that feeding 0.25% cholesterol 
for 12 weeks impacted several key regulatory mechanisms involved in hepatic 
cholesterol metabolism. Specifically, guinea pigs fed the high cholesterol diet had 
lowered hepatic mRNA abundance of 3-hydroxy-3-methylglutaryl-CoA reductase  
(HMGR) and increased activity of acyl CoA cholesterol acyltransferase (ACAT) when 
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compared to low-cholesterol fed guinea pig controls (32). Hepatic cholesterol 
homeostasis is governed by a highly coordinated feedback system. When cholesterol 
availability is increased, such as during a high-cholesterol diet, cells enact a sequence 
of events designed to reduce their cholesterol content; this involves a down-regulation 
of the low-density lipoprotein receptors (LDLR) which are the major entrance points of 
extracellular cholesterol, as well as degradation and reduced transcription of HMGR, a 
major regulatory point in cholesterol synthesis (33). Though these experiments were not 
conducted in the current study, we think it likely that similar changes are also at play. 
Guinea pigs from the H-Chol group displayed hypercholesterolemia, indicating that 
there was a reduction in hepatic clearance of plasma cholesterol. It was interesting that 
only plasma cholesterol and not circulating triglyceride, non-esterified fatty acids, or 
glucose was impacted by the H-Chol feeding although mice and rabbits that have been 
fed just a cholesterol-enriched diet also have no changes in plasma lipids compared to 
controls (22,34). We should also point out that the hepatic pathological changes that 
occurred in the H-Chol group did so in the absence of weight gain or hyperglycemia. 
This suggests that different metabolic factors are at play depending on the species, or 
alternatively that glucose metabolism and perhaps insulin resistance are not major 
players in the context of cholesterol-induced liver injury. The evidence supporting this 
notion is still relatively conflicted, with one study showing a reduction in plasma glucose 
and insulin in Japanese white rabbits with advanced fibrosis that were fed a 0.75% 
cholesterol diet for 9 months (35). Another study in Syrian golden hamsters showed that 
the addition of 0.05-0.25% cholesterol to a 40% high sucrose diet aggravated insulin 
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resistance and that the severity of changes were cholesterol concentration dependant 
(36).  
An interesting observation from the present study was that H-Chol guinea pigs 
accumulated more hepatic cholesterol than triglyceride (TG). Though TG is the major 
storage form of lipid within cells, they are known to be influenced by the level of cellular 
cholesterol. The connection between cholesterol and TG likely centers around the 
endoplasmic reticulum embedded enzyme, stearoyl-CoA desaturase 1 (SCD-1), which 
is the enzyme responsible for the conversion of saturated fatty acids to 
monounsaturated species (MUFA) (37). MUFA are the preferred substrates for 
incorporation into both TG as well as cholesterol esters, thus conditions that influence 
SCD-1 activity such as cholesterol excess likely impact the metabolism of both lipids 
(38).  
One of the features that makes guinea pigs attractive for studying cholesterol’s 
involvement in NAFLD is that they, like humans, contain most of the cholesterol within 
the liver in the free, unesterified form (27). We also observed an overwhelming 
proportion of the liver cholesterol to be free in H-Chol guinea pigs. As free cholesterol 
has been shown to accumulate extensively in obese diabetic mice leading to NASH 
(20), it was anticipated that the H-Chol group would experience similar pathological 
changes. Indeed, hepatic free cholesterol was significantly greater in the H-Chol livers, 
although it should be mentioned that guinea pigs with the highest concentrations of free 
cholesterol did not always have the fattiest livers nor greatest extent of hepatic injury. 
That said, the guinea pig that was classified as having the greatest histological evidence 
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of inflammation did have the highest free cholesterol content as well as the highest 
average plasma glucose and interestingly, the greatest concentration of HDL-C. 
Therefore it seems that the hepatic response to increased accumulation of free 
cholesterol varies individually in guinea pigs.  
To summarize, we observed that feeding non-genetically modified male guinea 
pigs a diet with the cholesterol equivalent of 1800 mg per day for humans resulted in 
hypercholesterolemia, moderate mixed micro-and macrovesicular liver steatosis and 
mild inflammation, with some guinea pigs displaying single cell necrosis and 
glycogenated nuclei. Importantly, these changes occurred despite guinea pigs losing 
weight and having similar glucose metabolism to controls. These effects were diet-
specific as the low-cholesterol fed guinea pigs displayed none of these changes and 
had overall normal liver histology. The extent of steatosis in H-Chol guinea pigs seems 
to depend more on hepatic cholesterol content than triglyceride and this could be useful 
in future studies that investigate whether there exist any potential differences between 
hepatic lipids in steatotic development.  
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STUDY 2: Metabolic and pathological impact of carbohydrate-
restricted and carbohydrate-enriched diets on cholesterol-induced 
NAFLD 
 
 
Abstract: 
  
 Cholesterol-induced non-alcoholic fatty liver disease (NAFLD) occurs in guinea 
pigs when fed diets containing 0.25% dietary cholesterol, yet whether or not dietary 
manipulation can improve the state of disease in guinea pigs is not yet well known. 
Because guinea pigs respond to dietary intervention such as carbohydrate restriction in 
a manner resembling humans, we sought to explore the metabolic effects of 
manipulating dietary fat and carbohydrate content in guinea pigs with pre-existing 
NAFLD and determine whether these interventions could improve histological features 
characteristic of this disease. Accordingly, after a six week period of a high-cholesterol 
diet, guinea pigs were randomized to consume either a diet enriched in both fat and 
carbohydrate (herein referred to as a high-carbohydrate diet, HCD) or a diet restricted in 
carbohydrate but plentiful in fat (a low carbohydrate diet, LCD). Both diets contained 
equivalent cholesterol (0.04% w/w). Both HCD and LCD were consumed for six weeks 
and guinea pigs were evaluated for metabolic parameters and liver histology to 
determine any dietary effects. Plasma cholesterol species were elevated in LCD 
compared to HCD guinea pigs, yet only cholesterol associated with HDL (HDL-C) 
reached statistical significance (p = 0.044). Circulating triglyceride (TG) was slightly 
though not significantly (p = 0.28) greater in LCD versus HCD, while there were no 
differences in circulating levels of glucose (p = 0.85), non-esterified fatty acids (p = 
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0.97), nor plasma activity of the liver enzymes ALT (p = 0.59) or AST (p = 0.75). Plasma 
ketone bodies were only slightly elevated in the LCD group as compared to the HCD (p 
= 0.07), though this may be partially explained by the variable responses of guinea pigs 
fed the LCD. Levels of hepatic TG (p = 0.01), total cholesterol (p = 0.034), and free 
cholesterol (p = 0.02), but not cholesterol ester (p = 0.45) were increased in guinea pigs 
fed LCD compared to HCD, indicating increased retention of these lipids under a LCD. 
Remarkably, despite the increased lipid content of LCD livers, there were similar 
histological findings between both groups, with guinea pigs fed LCD or HCD displaying 
evidence of bridging fibrosis. There was also evidence of biliary hyperplasia in the HCD 
group, although this response was not uniform throughout the group. These findings 
collectively suggest that feeding either a LCD or HCD following a dietary cholesterol 
challenge fails to improve liver histopathology, possibly indicating that dietary 
cholesterol loading renders livers unresponsive to dietary macronutrient manipulation.  
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STUDY 2: Introduction 
 
To date, there have been relatively few long-term controlled studies investigating 
the role of dietary composition, in particular, carbohydrate and carbohydrate restriction 
on NAFLD although several lines of evidence suggest that limited carbohydrate 
consumption may be beneficial towards improved liver function. 
Several investigators have observed a strong association between excessive 
carbohydrate intake and an increased severity of hepatic steatosis and the inflammatory 
NASH (1,2) in humans.  In a recent prospective study, Kang et al (2) evaluated 91 
patients with clinically suspected NAFLD and characterized 31 patients (34%) as having 
metabolic syndrome.  Those patients with metabolic syndrome were shown to consume 
significantly more carbohydrate (p =0.03) and less fat (p =0.01) and displayed higher 
histological severity scores for steatosis (p =0.004) and NASH (p =0.0006) compared to 
patients without metabolic syndrome.  This particular study is noteworthy as it 
recapitulates current evidence which demonstrates a potent link between excessive 
carbohydrate consumption and the development of physiological factors associated with 
metabolic syndrome as elegantly described by Volek et al (3).  A carbohydrate restricted 
dietary intervention was recently conducted in an obese female patient diagnosed with 
NAFLD (4) that presented with abnormal plasma ALT levels and a hepatic triglyceride 
content of 44.6% as assessed by 1H MRS. The patient was instructed to follow for 2 
weeks a ketogenic diet composed of 5: 41: 54 % carbohydrate: fat: protein respectively.  
At 5 weeks after the initiation of the diet, there was a complete correction of plasma ALT 
values and remarkably, a dramatic four-fold reduction in hepatic triglyceride content to 
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11.9%.  While long-term controlled human studies designed to evaluate the role of 
carbohydrate restriction on improvements in NAFLD are sparse, the available evidence 
does indeed support a beneficial role for this dietary intervention in ameliorating the 
associated clinical and histological abnormalities inherent in this disease.  In an 
interesting animal study (5) two groups of mice were fed diets high in carbohydrate 
(68%) that differed in starch composition in order to examine the effects of rapidly 
absorbed carbohydrate on hepatic steatosis.  One group consumed a diet composed of 
100% amylopectin, a highly branched chain glucose polymer which is rapidly 
metabolized within the small intestine, whereas the other group consumed 60% 
amylose and 40% amylopectin; amylose due to its linear structure, is hydrolyzed at a 
slower rate and therefore predicted to contribute to less severe hepatic steatosis.  
Indeed, histological examination indicated the presence of mixed hepatic steatosis in 
mice fed the rapidly absorbed carbohydrate and a two-fold greater hepatic triglyceride 
content (20.7 + 9.4 mg/g vs 9.6 + 4.9 mg/g; p =0.01) when compared to the mice that 
consumed the slower absorbed carbohydrate.  Again, long term clinical studies which 
examine the relationship between carbohydrate and NAFLD in humans are warranted, 
however this study clearly points to the potential benefit(s) of reduced carbohydrate or 
low glycemic index diets as a novel dietary treatment for reversing the progression of 
hepatic steatosis. 
Dietary fat, in particular PUFAs are known to exert hypotriglyceridemic effects 
and are a potentially important dietary treatment in reducing cardiovascular disease risk. 
Evidence is also accumulating that suggests they may also exert various 
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hepatoprotective effects. These fatty acids are well known regulators of hepatic gene 
expression with regard to carbohydrate and lipid metabolism, suppressing L-PK in the 
glycolytic pathway as well as several key lipogenic enzymes (see (6) for a brief review). 
Impressively, SREBP-1c is potently inhibited by PUFAs and although the mechanistic 
details require further studies, it has been demonstrated that PUFAs reduce SREBP-1c 
transcription, enhance SREBP-1c mRNA turnover and directly interfere with the 
proteolytic cleavage of the transcriptionally mature SREBP-1c protein (6). It has also 
been recently demonstrated that PUFAs, specifically linoleate (18:2), eicosapentanoic 
acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6) effectively inhibit ChREBP 
activity in mice, thereby decreasing expression of both L-PK and FAS (7). A recent 
study investigating the potential therapeutic effects of omega-3 FAs in patients clinically 
diagnosed as having hepatic steatosis (8) found that those receiving 2.7 grams daily of 
concentrated EPA for twelve months had significantly reduced plasma values of ALT 
and AST and a regression of steatosis as assessed by histological analysis. An eight 
week trial in patients with elevated hepatic TG content (as assessed by proton magnetic 
resonance spectroscopy) who received 9 grams/day of fish oil showed a 46% reduction 
in plasma TG, a 21% reduction in plasma VLDL and IDL cholesterol and a 15% 
decrease in plasma apolipoprotein B, yet no improvement in hepatic TG content (9). It 
must be mentioned that the sample population for this study was fairly small (n=17) and 
included mainly African-Americans, who tend to accumulate less intraperitoneal fat and 
differ from other ethnic groups such as Hispanics and Caucasians in terms of the 
prevalence of steatosis (10). 
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Lastly, feeding ketogenic diets that are very low in carbohydrate content have 
been shown to induce a unique metabolic state in mice by improving glucose 
homeostasis, insulin sensitivity, plasma liver enzyme levels, and significantly reducing 
weight gain (11). They have also been demonstrated to prevent hepatic steatosis by 
reducing hepatic levels of palmitate (16:0), the end product of DNL (12). Therefore an 
intervention based on manipulating the macronutrient content may prove a valuable 
therapeutic modality in NAFLD. This possibility is the subject of investigation in the 
current study, in which guinea pigs were assigned to a diet either enriched in fat and low 
in carbohydrate (LCD) or a diet enriched with carbohydrate and fat (HCD). Importantly 
these diets were administered after six weeks of high-cholesterol feeding to determine 
the metabolic and pathological impact of each diet on guinea pigs with established liver 
damage.   
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STUDY 2: Materials and experimental methodology 
 
Study design: 
 As demonstrated in study 1, guinea pigs fed H-Chol for six weeks are 
hypercholesterolemic and develop hepatic steatosis and histological features 
characteristic of NASH.  To ascertain whether manipulating dietary macronutrient 
composition could potentially improve these metabolic and pathological abnormalities, 
we randomly selected nineteen guinea pigs after six weeks of H-Chol feeding and 
further randomized them to consume either a low-carbohydrate diet (LCD, n = 9) or a 
high-carbohydrate diet (HCD, n = 10).  Both diets were prepared by Research Diets 
(New Brunswick, NJ: LCD, D10030306; HCD, D10030305) and diets and water were 
consumed ad libitum for a total of six weeks.  Importantly, both the LCD and HCD 
contained similar amounts of dietary cholesterol (0.04% and 0.05% for LCD and HCD 
respectively) which was equivalent to an intake of 300 mg/day for humans (Table 2.1).  
All guinea pigs were housed in the biology vivarium in the School of Pharmacy under 
identical conditions to those as study 1. Weekly body weight measurements and 
assessment of food intake were performed identical to study 1. Vitamin and 
micronutrient composition were formulated to meet the National Research Council 
requirements for guinea pigs and all experimental protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) at UConn. 
 At the conclusion of the six week study period all guinea pigs were fasted for 12 
hours overnight and then anesthetized under isoflurane vapors.  Following cardiac 
puncture, whole blood and livers were collected for analysis as described in study 1.  
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Our original power calculations determined that a sample size of 10 guinea pigs/group 
would be sufficient to determine statistical significance, however one animal from the 
LCD had to be euthanized due to focal necrosis, colon rupture, and acute peritonitis of 
the abdominal cavity.  These morphologic findings were unrelated to any effects from 
the diet itself.  Thus all analyses of the LCD group were performed with a sample size of 
nine guinea pigs. 
Plasma metabolite analysis: 
 Whole blood and plasma separation was performed identical to study 1. Plasma 
analytes were identical to those measured in study 1 and will not be described here 
(see materials and experimental methodology section of study 1 for assay descriptions 
and principles).  An additional plasma metabolite that was measured in the current 
study was ketone bodies, the details of which are provided below.  
Ketone bodies  
   The plasma ketone bodies acetoacetone (AcAc) and 3-hydroxybutyrate (3-HB) 
were measured using a commercially available kit (Wako Diagnostics, Richmond, VA) 
according to the manufacturer’s instructions. The assay is based on a series of cyclic 
enzymatic reactions in which AcAc and 3-HB are converted to 3-HB and AcAc 
respectively.  The reactions proceed in the presence of 3-hydroxybutyrate 
dehydrogenase, NADH, and thio-NAD and by measuring the rate of thio-NADH 
production spectrophotometrically it is possible to determine the concentration of ketone 
bodies in plasma.  After mixing sample plasma with the appropriate reagents, readings 
were taken every 30 seconds for two minutes at 405nm.  The plasma concentration of 
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AcAc and 3-HB were calculated by multiplying the concentration of a calibrator by the 
per minute change in optical density of the sample and dividing by the change in 
calibrator optical density per minute.  Results are expressed as µmol/L. A schematic of 
the reaction sequence is shown here: 
 
Hepatic lipid analysis: 
 Liver extraction and selection of tissue samples was conducted as described in 
study 1.  Protocols for lipid extraction and biochemical measurements of lipid species is 
identical to study 1.  
Hepatic glycogen: 
 To determine the metabolic impact of a LCD or HCD on liver glycogen storage, 
approximately 1 g of liquid nitrogen frozen liver was homogenized in a small amount of 
distilled water (dH20) using a Tissue Tearor homogenizer (model 985370, Biospec 
Products Inc).  Each homogenized liver sample was then taken to a final content of 30-
50% in 30% potassium hydroxide (KOH), heated at 100°C for 2 hours, and cooled.  
Next, two volumes of 95% ethanol was added to precipitate the crude glycogen. 
Samples were then centrifuged and the precipitates collected.  Precipitates were then 
suspended in a minimal amount of dH20 and acidified to a pH of 3 with 5N hydrochloric 
acid (HCL), followed by re-precipitation with 1 volume of ethanol.  The 
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wash/acidification/precipitation process was repeated a total of three times and the 
precipitates were finally washed with ethanol and dried in a speed vac.  Treating the 
precipitates in this manner ultimately removes a great majority of glucose with minimal 
effect on tissue glycogen.   
 After weighing the dried material, samples were ready to be analyzed with a 
direct enzymatic procedure in accordance with the manufacturer’s instructions (Abcam 
Inc, Cambridge, MA).  The assay is based on an enzymatic procedure in which 
glucoamylase first hydrolyzes glycogen to free glucose.  Next, glucose oxidase and 
peroxidase act on the free glucose, generating a product capable of reacting with a 
color probe that, when measured spectrophotometrically at 570 nm, provides the 
glycogen concentration present in the liver sample.  To correct for any potential 
background concentration of glucose, an aliquot of each sample was used as a glucose 
control in which no hydrolysis enzyme mix was added.  The level of glucose background 
in each sample was then subtracted from the glycogen readings.  In addition to 
measuring hepatic glycogen in LCD and HCD guinea pigs, a small sample (n = 4) of L-
Chol livers were included as controls to observe how glycogen content changes under 
different dietary conditions.  Results were obtained as µg/µL and then converted to µg/g 
liver. 
Liver pathology: 
 Selection of liver samples for histological staining and pathological evaluation 
followed the same procedure as described for study 1.  Parameters for grading hepatic 
steatosis were also identical to study 1.  A trained pathologist (JAS) was responsible for 
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histological evaluation of all liver sections as well as photomicrographs of representative 
lesions. 
Statistical analysis: 
 All data were analyzed using the Prism statistical program from GraphPad 
Software version 5.0c (San Diego, CA).  Two-tailed independent student’s t-tests were 
performed when comparing the differences between LCD and HCD groups.  In the case 
of unequal variances, an unpaired t-test with Welch’s correction was used.  To compare 
differences between H-Chol, LCD, and HCD, a one-way analysis of variance (1-way 
ANOVA) was used followed by Tukey’s post-hoc multiple comparisons test.  In the case 
of unequal variances as determined by Bartlett’s test, data were analyzed with Kruskal-
Wallis test followed by Dunn’s post-hoc multiple comparisons test All data are 
expressed as the mean + standard error of the mean (SEM).  An α-level of p < 0.05 was 
chosen to denote statistical significance. 
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STUDY 2: Results 
 
LCD and HCD guinea pigs show similar weight gain despite increased daily food 
consumption in HCD group 
 
 Following a one week acclimatization period, guinea pigs who had previously 
been fed a H-Chol diet for six weeks were randomized to consume either a LCD or HCD 
with normal dietary cholesterol (0.04%) for an additional six week period.  Nutritionally, 
the LCD consisted primarily of dietary fat and protein, with the least amount of calories 
coming from carbohydrate sources (65:25:9 % kCal from fat, protein, and carbohydrate 
respectively) while the HCD consisted primarily of carbohydrate, followed by fat and 
protein (54:30:15 % kCal).  Table 2.1 provides the complete composition and table 2.2 
lists the percentage distribution of dietary fatty acid classes for both diets.   
 There were no significant differences in initial body weights between LCD and 
HCD (613 + 37 vs 643 + 22; p = 0.48), nor were there any differences in the final body 
weights at week 6 (707 + 45 vs 748 + 29, p = 0.45; figure 2.1 a).  It is possible that a 
significant difference could exist between final body weights of LCD and HCD were it 
not for one guinea pig that weighed over 1 kilogram (figure 2.1 b).  Accordingly, both 
groups displayed a similar change in body weight (p = 0.77) over the course of six 
weeks.  These changes occurred despite HCD animals being more hyperphagic, as 
they had significantly greater daily food consumption (p = 0.0002).  This effect is likely is 
due to the greater overall caloric density of the LCD compared to the HCD (table 2.1).  
These data indicate that LCD and HCD have similar effects on body weight over the 
course of six weeks.  Typically LCDs initiate greater weight loss in guinea pigs 
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compared to HCDs, however these results were observed with longer feeding durations 
such as 12 weeks (13), thus the current six week study may have been insufficient for 
these changes to occur.  
Carbohydrate restriction tends to increase plasma cholesterol 
 Reducing dietary carbohydrate is known to have several profound effects on 
lipoprotein metabolism.  For example greater dietary consumption of saturated fats and 
cholesterol that can occur on a LCD raises plasma total cholesterol, but interestingly, 
much of this increase is attributed to cholesterol contained within the HDL particles. 
 In the current study we observed a trend for higher concentrations of plasma TC, 
FC, and LDL-C in LCD compared to HCD (figure 2.3).  Interestingly the only parameter 
that differed significantly was plasma HDL-C and this was greatest in LCD compared to 
HCD (p = 0.044).  A clue to understanding these data may be the degree of variability 
observed within the LCD.  Figure 2.4 depicts the individual plasma TC responses, which 
in the HCD are closely centered around the mean while values are much more variable 
in the LCD group.  Similar variability was seen in the individual plasma FC, LDL-C, and 
HDL-C responses (data not shown).  The cholesterol profile of both LCD and HCD 
demonstrated that LDL particles transport the majority of cholesterol, which is unique 
amongst other experimental rodent models such as the rat or mouse that maintain very 
elevated concentrations of HDL particles.  Linear regression analysis revealed a strong 
positive correlation between plasma TC and LDL-C in LCD (r = .99, p = < 0.0001), HCD 
(r = .98, p = < 0.0001), and LCD and HCD together (r = .99, p < 0.0001; figure 2.5 a).  
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Finally, this relationship also persisted when L-Chol, H-Chol, LCD, and HCD groups 
were analyzed together (r = .99, p < 0.0001; figure 2.5 b). 
 The average plasma TC of both LCD and HCD it should be noted, were 
significantly lower as compared to the H-Chol group according to ANOVA (p < 0.0001). 
In fact, all plasma cholesterol parameters of LCD and HCD differed significantly from H-
Chol (see table 2.5 at the end of this section which lists the ANOVA results of all 
plasma and hepatic parameters between H-Chol, LCD, and HCD).  This implies that 
removal of exaggerated amounts of dietary cholesterol improves hypercholesterolemia 
whether guinea pigs were on a LCD or HCD. 
LCD and HCD produced similar effects on plasma metabolic parameters 
 One of the most commonly observed features of either very-low or moderate 
LCDs is a pronounced reduction in VLDL-associated triglycerides.  In the present study 
however this was not observed as both LCD and HCD had similar levels (p = 0.28).  
Furthermore, we could not detect any statistical differences in other routine plasma 
parameters such as NEFA (p = 0.97) and glucose (p = 0.85) between LCD and HCD. 
Table 2.3 provides the results for all the plasma metabolites measured and figure 2.6 
depicts the individual responses for plasma triglyceride (a), NEFA (b), glucose (c), and 
ketone bodies (d).  One of the most interesting results concerned plasma ketone 
bodies, which tended to be higher in LCD but did not reach statistical significance at the 
0.05 level.  This result was particularly surprising given the overwhelming reliance of 
dietary fat as opposed to carbohydrate in the LCD group, conditions that favor ketone 
body synthesis and utilization. This may partially be explained by the individual 
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responses of LCD guinea pigs which are highly variable compared to those of the HCD 
(figure 2.6, d).  Likely, carbohydrate restriction elicits unique individual metabolic 
responses whose importance may lie in their variability rather than the totaled group 
average of certain plasma parameters.  
Feeding a LCD or HCD for six weeks fails to improve biochemical indices of liver 
injury 
 
 Both LCD and HCD guinea pigs displayed similar plasma activity levels of the 
liver enzymes ALT (p = 0.59) and AST (p = 0.75), indirectly indicating a similar degree 
of hepatic injury (table 2.3, figure 2.7).  Interestingly, despite a trend for lower plasma 
FC in the HCD group, AST activity level was positively associated with this plasma 
variable (r = .8, p = 0.009).  This correlation hints at a relationship between plasma FC 
and liver injury that occurs only in the context of a HCD.  Most importantly neither 
plasma ALT (p = 0.82) or AST (p = 0.66) differed significantly from those of the H-Chol 
group as determined by ANOVA (table 2.5).  These results imply that a LCD or HCD is 
unable to improve these markers of biochemical injury following a period of H-Chol 
feeding, a finding which conflicts with our original study hypothesis. 
Feeding a LCD for six weeks does not significantly reduce hepatic glycogen 
compared to HCD 
 
 Liver glycogen depletion is a well known metabolic effect of carbohydrate 
restriction while feeding a carbohydrate-enriched diet is known to stimulate 
glycogenesis thereby increasing hepatic glycogen stores.  In the current study however, 
both LCD and HCD livers contained similar concentrations of glycogen (p = 0.12; figure 
2.8 a, table 2.4).  The lack of statistical significance could be the result of the 
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considerable variability of the HCD group.  Contrary to other experimental measures, 
liver glycogen was fairly consistent between LCD animals and centered around the 
mean.  There is also the possibility that this particular carbohydrate-restricted diet 
formulation was not low enough in carbohydrate content to elicit glycogenolysis, or 
glycogen breakdown.  For a comparison, we also measured the glycogen content of a 
small sample (n = 4) of L-Chol controls and found that both LCD and HCD displayed 
greater glycogen storage.  This is the first study that we are aware of that has measured 
this parameter in guinea pigs therefore additional studies need to be conducted to gain 
insight as to how glycogen content changes according to diet.   
 Despite similar concentrations, glycogen content was shown to be positively 
correlated with liver weight (r = .63, p = 0.05) in HCD animals only.  Even more 
intriguing was the positive correlation between glycogen and plasma ALT activity (r = .7, 
p = 0.04; figure 2.8 b) in the HCD group-although one cannot infer causality from 
regression analysis, this relationship suggests that increased glycogen content may be 
an important contributor to plasma ALT levels, at least in the context of a HCD.  
LCD livers show increased retention and storage of hepatic triglycerides, total, 
and free cholesterol without any difference in organ weight 
 
 Previously it was observed that guinea pigs fed a LCD in conjunction with 0.25% 
dietary cholesterol develop severe hepatomegaly compared to guinea pigs fed the 
same cholesterol concentration on a HCD (13).  In the present study where both the 
LCD and HCD have normal cholesterol content, there was no difference in organ weight 
between the groups (p = 0.36; figure 2.9).  The results for all hepatic parameters is 
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provided in table 2.4.  Liver weight was shown to be correlated with final body weight 
for both LCD and HCD (figure 2.10 a,b), although the relationship appears strongest in 
the LCD group.  Furthermore, the liver to body weight ratio tended to be higher in LCD, 
constituting around 4% compared to about 3.5% in HCD, though this did not reach 
statistical significance (p = 0.055; figure 2.11).  Given the correlation between liver and 
final body weight in the LCD group, it is not surprising that the individual ratios varied in 
a manner similar to those for final body weight (figure 2.1 b), which may explain the 
lack of statistical significance.  
 Increased cytoplasmic accumulation of fatty acids, triglycerides, and cholesterol 
results in hepatic steatosis, the sine qua non of NAFLD.  Implementing a LCD or HCD 
following a H-Chol challenge was hypothesized to reduce hepatic lipid content, albeit 
through different mechanisms.  By limiting the amount of dietary carbohydrate (as 
glucose and fructose) delivered to the liver, a LCD would in effect limit pancreatic insulin 
release, thereby reducing insulin’s potent stimulatory effect on DNL and simultaneously 
increasing the oxidation and removal of fatty acids to the circulation as ketone bodies.  
In contrast, a HCD, by providing more carbohydrate and less fat to the liver, could 
reduce hepatic lipid content by increasing the production of fatty acids and triglycerides 
which in turn would be incorporated into VLDL particles for eventual egress to the 
circulation (see literature review for detailed discussion). 
 Interestingly, liver TG content was significantly greater in LCD livers (p = 0.01; 
figure 2.12) compared to HCD.  There was however, a significant reduction of liver TG 
in both LCD and HCD compared to the H-Chol group (p = 0.0005; table 2.5), indicating 
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that indeed both groups were capable of decreasing cellular TG stores.  A particularly 
intriguing observation was that in LCD animals, lower levels of liver TG tended to be 
correlated with higher plasma ketone bodies (r  = -.65, p = 0.056) while a positive 
correlation, though not significant, was observed in the HCD group (r = .45, p = 0.19).  
This could imply that the microsomal and mitochondrial oxidative systems responsible 
for generating fatty acyl-CoAs may be impaired or overwhelmed in HCD livers.  Hepatic 
levels of both TC (p = 0.034; figure 2.13 a,b) and FC (p = 0.02; figure 2.13 c,d) were 
also increased in LCD guinea pigs compared to HCD, however there was no difference 
in cholesterol ester content (p = 0.45; figure 2.13 e,f).  One should also note the 
considerable variability of individual responses in the LCD group with regard to hepatic 
cholesterol measurements when interpreting these data.  Together, these findings 
indicate that LCD livers are prone to increased retention of both cholesterol and TG 
following a H-Chol challenge.  It also appears that liver cholesterol content is a more 
important contributor to overall liver weight, at least in LCD livers as we observed a 
positive correlation between liver weight and both TC (r = .82, p = 0.007) and FC (r = 
.71, p = 0.04), but not TG (r = .38, p = 0.31).  There was no correlation between liver 
weight and hepatic TC (r = -.19, p = 0.6), FC (r = .024, p = 0.95), or TG (r = -.42, p = 
0.23) in the HCD group. 
Overall, hepatic TC content was significantly lower in both LCD and HCD when 
compared to H-Chol (p = 0.0001; table 2.5).  It should be mentioned here that in LCD 
livers TC was present in higher concentrations than TG, a finding that was also present 
in the H-Chol group, but absent in the HCD group (table 2.5). The importance of this 
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observation is currently unclear.  Lastly, the concentration of hepatic phospholipids did 
not differ significantly between either LCD or HCD (p = 0.64), however there was a 
consistent reduction of this lipid when compared to the H-Chol group (p = 0.001; table 
2.5).  The consequences of this overall reduction in PL content are as of yet unknown, 
although it is feasible that it may play a role in worsening liver pathology (see below).  
More detailed analysis of hepatic PL under these different dietary schemes is provided 
in study 3 of this dissertation.  
Six weeks of LCD or HCD resulted in similar histological grading of steatosis  
 
 As described in study 1, liver sections were evaluated for fatty infiltration and 
assigned a score based on the percentage of hepatocytes that show fatty change.  
There were no overt differences in the gross morphology of LCD or HCD livers (figure 
2.14 a) with each group containing a range of normal reddish, brown as well as swollen, 
pale livers indicative of increased lipid accumulation. Surprisingly there was no 
statistical difference between the group scores of LCD and HCD (p = 0.13; table 2.4, 
figure 2.14 b) although the overall score was slightly higher in the LCD group.  Three 
LCD livers (33%) were designated as having severe steatosis (grade 3), while zero 
guinea pigs in the HCD group displayed steatosis to this extent.  Instead, the majority of 
HCD livers displayed either minimal, grade 0 (40%) or mild, grade 1 (40%) fatty 
infiltration.  Additionally, the pattern of steatosis for both groups was predominantly 
macrovesicular with mixed microvesicular droplets present as well.  It seems likely that 
increased cholesterol deposition may also be a more important determinant of steatosis 
in the LCD group as we observed a strong positive correlation between steatosis score 
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and liver TC content (r = .75, p = 0.02).  This relationship was not present in the HCD 
group (r = .44, p = 0.205).  No statistically significant correlations were observed 
between fat score and other lipids, particularly TG, in either LCD (r = .52, p = 0.15) or 
HCD (r = -.03, p = 0.93).  
 One of the original hypotheses for this study was that both a LCD and HCD 
would successfully reduce the degree of hepatic steatosis from what was observed in 
H-Chol livers, albeit through different mechanisms.  Surprisingly, although the average 
score for LCD and HCD was lower than the H-Chol group, there was not an overall 
significant difference between groups as revealed by ANOVA (p = 0.054) (table 2.5, 
figure 2.14 c).  This result is somewhat incongruous with the earlier findings that all 
hepatic lipids were significantly reduced in the LCD and HCD compared to H-Chol 
(table 2.5). It is currently unclear as to how to interpret this result, although it does 
highlight some potential discrepancies that likely exist between biochemical data and 
pathological examination. 
Heterogeneous pathological response of livers from both LCD and HCD fed 
guinea pigs 
 
 Hepatic steatosis, as we have discussed previously, is the beginning of the 
NAFLD spectrum and sets the stage for potential development of more insidious forms 
of liver injury, including hepatic inflammation and ballooning which comprises NASH, as 
well as bridging fibrosis.  Therefore reducing the amount of lipid deposition in the liver is 
seen as potentially beneficial for improving hepatic architecture and reducing the 
possibility of various ‘second hits’ that can trigger disease progression.  We noted 
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earlier the progressive decrease of liver TG, TC, and FC (table 2.5) along with the trend 
for decreased pathological scoring of steatosis as guinea pigs were transitioned from H-
Chol to LCD or HCD (figure 2.14 c).  Therefore it is all the more surprising that there 
was actually a worsening of liver pathology in some guinea pigs of both the LCD and 
HCD groups.  While there were indeed some sections that were histologically normal, 
there were also sections that presented with more advanced histological lesions such 
as inflammation and hepatocyte ballooning (figure 2.15).  Perhaps the most striking 
observation of this study centered around the presence of advanced lesions in livers 
with mild or minimal steatosis as shown in figure 2.16.  This figure depicts a LCD liver 
with grade 1 steatosis and bridging fibrosis (panels A,C) and a HCD liver with grade 0 
steatosis and biliary hyperplasia (panels B,D).  Interestingly, there were no conspicuous 
metabolic parameters in this LCD animal that would suggest possible mechanisms for 
fibrotic development.  On the other hand, the HCD animal that presented with biliary 
hyperplasia had the highest levels of all plasma cholesterol species and plasma AST in 
the HCD group.  Another example is shown in figure 2.17 which demonstrates a pattern 
of bridging fibrosis in a HCD guinea pig with grade 0 steatosis.  Taken together these 
results may imply an inverse relationship between more advanced hepatic lesions and 
steatosis. 
Overall, administering a six week LCD or HCD intervention following a six week 
H-Chol challenge resulted in a heterogeneous pathological response in the liver; that no 
clear cut separation between LCD or HCD could be made suggests that both groups 
were equally affected by the H-Chol challenge.  It is likely that bombarding the liver with 
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copious amounts of dietary cholesterol produces some lingering cellular effects that 
proceed even when a LCD or HCD is administered.  
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Table 2.1: Dietary composition of low-carbohydrate diet (LCD) and high-
carbohydrate diet (HCD) 
 
Macronutrient LCD HCD 
 % gram % kcal % gram % kcal 
Protein 30 25 15 15 
Carbohydrate 11 9 52 54 
Fat 34 65 13 30 
Ingredient LCD HCD 
 grams grams 
Soy protein 100 60 
L-methionine 6.25 3.75 
Corn starch - 239.5 
Maltodextrin  90.5 35 
Sucrose - 274 
Cellulose 100 100 
Guar gum 25 25 
Safflower oil 194 89 
Coconut oil, 
hydrogenated 
60 28 
Soybean oil 39 18 
Mineral mix1 13.88 13.88 
Vitamin mix1 9 9 
Cholesterol  0.42 (.05%) 0.42 (.04%) 
Caloric density (kcal/g) 4.77 3.87 
1Mineral and vitamin mixes were formulated to meet the National Research Council requirements for 
guinea pigs. 
 
 
Table 2.2: Distribution of fatty acid classes in LCD and HCD 
 
Fatty Acid Class LCD HCD 
 % kcal % kcal 
SFA 17.6 8.2 
MUFA 35.8 16.4 
PUFA 11.4 5.2 
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Figure 2.1: Average initial and final body weights (a) and individual final body 
weights (b) of LCD and HCD fed guinea pigs 
 
 
Figure 2.2: Average body weight change (a) and daily food consumption (b) of 
LCD and HCD guinea pigs 
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Figure 2.3: Plasma cholesterol profile of LCD and HCD fed guinea pigs 
 
Figure 2.4: Individual TC values of LCD and HCD guinea pigs 
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Figure 2.5: Correlation between plasma TC and LDL-C in LCD and HCD (a) and in L-Chol, 
H-Chol, LCD, and HCD (b) 
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Table 2.3: Plasma characteristics of guinea pigs fed LCD or HCD for six weeks 
 
Metabolite LCD (n = 9) HCD (n = 10) p-value 
Total cholesterol 
(mg/dL) 128 + 24 73 + 9 0.059 
Free cholesterol 
(mg/dL) 43 + 8.6 23 + 3.1 0.051 
*LDL-C (mg/dL) 84 + 17 47 + 6.6 0.072 
HDL-C (mg/dL) 30 + 6 15 + 2.8 0.044* 
Triglycerides  
(mg/dL) 72 + 9.5 57 + 9.1 0.28 
Non-esterified 
fatty acids 
(mEq/L) 
0.5 + .03 0.5 + .04 0.97 
Glucose (mg/dL) 162 + 5.6 160 + 9.1 0.85 
ALT (U/L) 180 + 52.5 228 + 68.8 0.59 
AST (U/L) 424 + 114.7 500 + 203.4 0.75 
Ketones (µmol/L) 186 + 36 107 + 12 0.07 
All data presented as mean + standard error of the mean (SEM) 
Abbreviations: LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density 
lipoprotein cholesterol, ALT; alanine aminotransferase, AST; aspartate 
aminotransferase 
*LDL-C calculated according to Friedwald equation: LDL-C = TC – [HDL-C + (TG/5)] 
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Figure 2.6: Individual plasma TG (a), NEFA (b), glucose (c), and ketones (d) 
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Figure 2.7: Plasma activity level of liver enzymes in LCD and HCD guinea pigs 
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Figure 2.8: Liver glycogen content (a) and correlation with ALT in HCD (b) 
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Figure 2.9: Liver weights of LCD and HCD guinea pigs 
 
 
 
Figure 2.10: Correlation between liver weight and final body weight in LCD (a) and 
HCD (b) 
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Figure 2.11: Ratio of liver to final body weight in LCD and HCD  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 157 
 
Table 2.4: Hepatic characteristics of guinea pigs fed LCD or HCD for six weeks 
 
Liver parameter LCD (n = 9) HCD (n = 10) p-value 
Liver weight (g) 28.6 + 3.3 25.2 + 1.6 0.36 
Liver/body weight 
(%) 
3.9 + .2 3.4 + .1 0.055 
Triglycerides  
(mg/g) 7.8 + .6 5.9 + .3 0.01* 
Phospholipids  
(ug/g) 20487 + 993 21114 + 859 0.64 
Total cholesterol 
(mg/g) 9.1 + 1.2 6 + .7 0.034* 
Free cholesterol 
(mg/g) 5.9 + .8 3.4 + .6 0.02* 
Cholesterol 
esters (mg/g) 3.2 + .8 2.5 + .3 0.45 
Steatosis score 1.6 + .4 .8 + .2 0.13 
Glycogen (µg/µL) 0.011 + .003 0.022 + .006 0.12 
All data presented as mean + standard error of the mean (SEM) 
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Figure 2.12: Hepatic triglyceride content of LCD and HCD guinea pigs 
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Figure 2.13: Hepatic TC (a,b), FC (c,d), and CE (e,f) in LCD and HCD 
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Figure 2.14: Livers (a) and steatosis scoring for LCD and HCD (b) and L-Chol, H-
Chol, LCD, and HCD fed guinea pigs (c) 
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Figure 2.15: Example of inflammatory foci situated between normal hepatocytes 
(right) and steatotic hepatocytes with ballooning change (left) 
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Figure 2.16: Example of bridging fibrosis with mild steatosis (LCD) and biliary 
hyperplasia with minimal steatosis (HCD) 
 
 
 
 
 
 
 
 
Figure 2.18: Example of bridging fibrosis in HCD fed guinea pig (see following 
page) 
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Table 2.5: One-way ANOVA of plasma and liver parameters of H-Chol, LCD, and 
HCD fed guinea pigs 
Parameter H-Chol LCD HCD p-value 
Plasma     
Total cholesterol 
(mg/dL) 284 + 36.6 128 + 24 73 + 9* < 0.0001 
Free cholesterol 
(mg/dL) 99 + 10 43 + 8.6 23 + 3.1* < 0.0001 
LDL-C (mg/dL) 201 + 29 84 + 17 47 + 6.6* < 0.0001 
HDL-C (mg/dL) 72 + 11.6 30 + 6 15 + 2.8* 0.0002 
Triglycerides 
(mg/dL) 61 + 6 72 + 9.5 57 + 9.1 0.45 
NEFA (mEq/L) 0.5 + .04 0.5 + .03 0.5 + .04 0.99 
Glucose (mg/dL) 184 + 9.4 162 + 5.6 160 + 9.1 0.11 
ALT (U/L) 196 + 30.8 180 + 52.5 228 + 68.8 0.82 
AST (U/L) 472 + 72.6 424 + 114.7 500 + 203.4 0.66 
Liver     
Liver weight (g) 21.9 + 1.3 28.6 + 3.3 25.2 + 1.6 0.15 
Liver/body weight 
(%) 3.9 + .2 3.9 + .2 3.4 + .1 0.08 
Triglycerides 
(mg/g) 11.6 + 1.3 7.8 + .6* 5.9 + .3* 0.0005 
Phospholipids 
(ug/g) 27026 + 1216 20487 + 993* 21114 + 859* 0.001 
Total cholesterol 
(mg/g) 14 + 1.3 9.1 + 1.2* 6 + .7* 0.0001 
Steatosis score 1.8 + .2 1.6 + .4 .8 + .2 0.054 
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STUDY 2: Discussion 
 
 Contrary to our initial hypothesis, the current study revealed that despite 
implementing two diets (LCD and HCD) with distinct macronutrient compositions after a 
dietary cholesterol challenge period, there was an overall worsening of liver pathology 
and injury. Because no clear cut differences in the pathological response could be 
observed between LCD and HCD, this likely indicates that the six week induction phase 
of NAFLD caused by a 0.25% high-cholesterol diet overrides any potential dietary 
benefit. This is the first study to our knowledge that implemented a LCD or HCD 
intervention following cholesterol-induced NAFLD, at least in phenotypically normal 
guinea pigs. Previous studies from our laboratory have demonstrated that a LCD with 
similar macronutrient profile as the current study results in improved atherosclerosis and 
decreased arterial inflammation (14,15). We have also observed that feeding a LCD in 
conjunction with a cholesterol-enriched diet lowers hepatic cholesterol and triglyceride, 
along with mRNA levels of hepatic LDLR and HMGCR when compared to guinea pigs 
fed a HCD/cholesterol-enriched diet (16). In the first study from our lab to document 
changes in liver histology, guinea pigs fed a LCD with 0.25% cholesterol had a similar 
extent of mixed macro- and microvesicular steatosis when compared to guinea pigs fed 
a HCD and 0.25% cholesterol (13). This study noted no differences in hepatic lipid 
concentrations of cholesterol species, free fatty acids, or triglycerides, although LCD 
livers were 40% larger overall. This finding was attributable to an increased expression 
of proliferating cell nuclear antigen (PCNA), a marker of hepatocyte proliferation; these 
results suggested that during a LCD, the excess cholesterol stimulated a proliferative 
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process to accommodate the incoming cholesterol. The significance of hepatic 
cholesterol in liver regeneration has also recently been observed in more in-depth 
experiments (17).  
 A key difference in the current study as compared to previous ones using guinea 
pigs and dietary intervention is that here the LCD and HCD were consumed in 
conjunction with a low level of dietary cholesterol after being crossed over from a purely 
cholesterol-enriched diet. This may provide some insight into the results observed here. 
There were no significant differences in plasma lipids, with the exception of HDL-C, 
which was increased in LCD. This is a well-known result of carbohydrate restriction in 
both humans and guinea pigs (3). Also both groups had similar biochemical liver injury 
evidenced by circulating ALT and AST- these values were also similar statistically to 
those obtained from a H-Chol group (table 2.5) indicating a continued degree of liver 
dysfunction. LCD guinea pig livers stored more cholesterol and triglyceride when 
compared to the HCD, however no significant differences were observed in liver size or 
its relation to overall body weight. Most intriguing was that the guinea pigs with the most 
severe pathological features such as bridging fibrosis and biliary hyperplasia had some 
of the lowest steatosis scores. It seems that an inverse relationship between the extent 
of pathological lesions and steatosis exists, at least in the current study, although it is 
well understood that hepatic lipid content tends to decrease with more advanced liver 
disease.  
 Despite some study limitations that include small sample sizes, the findings of 
the current study provide the first step in understanding the contribution of dietary 
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intervention to NAFLD in guinea pigs. It also underscores the role of individual 
responses to macronutrient manipulation as the LCD group was noted to have 
pronounced variability in several parameters (see results). In fact, guinea pigs that 
responded well to LCD intervention displayed all of the features typically associated with 
carbohydrate restriction including reduced plasma triglycerides, increased HDL-C, 
reduced weight gain and decreased daily food consumption. Therefore, guinea pigs, 
similar to humans, may respond differentially to carbohydrate restriction. The fact that 
responders and non-responders can occur in the same strain of guinea pigs indicates 
some underlying genetic predisposition that has yet to be defined.   
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STUDY 3: Assessment of hepatic phospholipid and triglyceride fatty 
acid composition in response to dietary manipulation 
Abstract: 
 Livers from guinea pigs fed either low (L-Chol, 0.04%) or high dietary cholesterol 
(H-Chol, 0.25%) (n = 5-6 per group) were quantified for fatty acids (FA) in liver 
triglycerides (TG) and phospholipids (PL). H-Chol decreased the percentage of 
saturated fatty acid (SFA) (p = 0.005), particularly stearate (p = 0.003) and increased 
monounsaturated fatty acid (MUFA) (p = 0.012), particularly oleate (p = 0.014) in PL 
fractions. Similar changes were observed in the TG fraction. Despite no differences in 
the PL content of linoleic acid (p = 0.6), H-Chol PLs were significantly depleted of 
arachidonic acid both in absolute (p = 0.001) and relative terms (p = 0.004). A second 
aim was to investigate these lipid fractions in animals randomized to diets either low 
(LCD) (n =9) or high in carbohydrate (HCD) (n =10) following the H-Chol phase. There 
were no differences in the fatty composition of TG or PL with the exception of palmitate, 
which was increased in HCD PL fractions (p = 0.005). When compared to the H-Chol 
group, both LCD and HCD groups had a pronounced depletion of total phospholipid 
content (p = 0.001) and this was shown to be negatively correlated with plasma ALT (r = 
-.7, p = 0.0004) and AST (r = -.8, p = 0.0002). Compared to the H-Chol, both LCD and 
HCD also demonstrated increases in the percent of MUFA and decreases in PUFA in 
both PLs and TGs. The percent composition of omega 6 was also reduced while omega 
9 was increased in both lipid fractions compared to H-Chol. The differences in omega 6 
can be explained by a decrease in PL and TG content of linoleic acid while the increase 
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in omega 9 can be explained by increased oleate content of PL and TG. These data 
demonstrate that high dietary cholesterol increases the incorporation of unsaturated 
fatty acids in liver PL and TG, while also decreasing PL arachidonic acid. They also 
show that manipulating macronutrients has no impact on liver fatty acid composition and 
this is likely due to the lingering effects of the dietary cholesterol overload in these 
guinea pigs.  
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STUDY 3: Introduction 
 
 Phospholipids represent a specialized class of amphiphilic lipids that are crucial to 
an array of cellular functions; they provide structure and order to lipid bilayers of 
organelle membranes, serve as components of lipid signaling cascades, shelter 
hydrophobic lipids in lipoproteins and lipid droplets (LD) from the aqueous environment, 
and more recently have been shown to lend themselves towards the formation of 
triglycerides (1). 
The landscape of cellular membranes can be envisioned as a patchwork-like quilt 
of protein and lipid molecules with the latter comprising approximately 50% of total 
membrane mass. Phospholipids, cholesterol, and fatty acids dot lipid bilayers in a 
bewildering array of combinations that reflect variations in polar head groups, 
hydrocarbon chain lengths and degrees of saturation; it has been estimated that 
membranes contain more than 1,000 different phospholipid species alone (2). 
Phosphatidylcholine (PC) represents the bulk of membrane phospholipids totaling 40-
50% followed by phosphatidylethanolamine (PE) at 20-50% and phosphatidylserine 
(PS) at 10-20% (2). A responsible discussion detailing the functions and interactions of 
all membrane phospholipids is daunting, though fortunately several insightful 
commentaries exist, many of which are the prodigious work of Jean and Dennis Vance 
(3-5).  
PC commands special attention amongst other phospholipids, not least because 
it prevails as the major membrane phospholipid (40-50% of total phospholipids), 
especially in both mitochondrial (44%), and endoplasmic reticulum (40%) membranes, 
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and predominates in plasma (24% total lipid by weight). The monolayer of LDs is also 
largely composed of PC, which provides key stabilizing properties that other 
phospholipid species lack (6,7). Not surprisingly, PC is known to influence several 
aspects of hepatic lipid metabolism and is crucial for normal liver functioning. This is 
reflected in the biosynthesis of PC, which principally occurs through the Kennedy (CDP-
choline) pathway via the rate limiting enzyme, CTP:phosphocholine cytidylyltransferase 
(CT) (8). Alternatively, another pathway for PC synthesis involves the sequential 
methylation of PE via PE N-methyltransferase (PEMT). This secondary pathway is only 
utilized by hepatocytes, providing 30% of hepatic PC whereas the CT pathway 
generates the remaining 70% (1). The existence of both pathways likely ensures a 
consistent availability of PC for incorporation into membrane lipid bilayers as well as 
budding very-low density lipoproteins (VLDL) and lipid droplets, where it serves as a 
component of the phospholipid monolayer.  
As phospholipids are essential components of the milieu of cellular membranes, 
conditions in which their availability is limited may trigger cell or organ dysfunction. For 
instance, in non-alcoholic fatty liver disease (NAFLD), the liver experiences a spectrum 
of histological changes that begins with increased triglyceride accumulation (hepatic 
steatosis) and can transition to a more inflamed state known as non-alcoholic 
steatohepatitis (NASH) (9,10). One manner in which steatosis can arise is from an 
insufficiency of hepatic phospholipid availability which impairs the lipidation of 
apolipoprotein B-100 (ApoB), the major apoprotein of VLDL particles. Lipidation of apoB 
with phospholipids is a critical step for the assembly and eventual egress of VLDL 
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through hepatic sinusoids and out of the liver (11), thus under conditions of limited 
availability, improperly formed VLDL particles accumulate within the secretory pathway 
and the contained lipid accrues in the cytoplasm, triggering steatosis. In fact, one of the 
most commonly employed experimental techniques for inducing steatosis in animals is 
through the administration of a methionine and choline deficient diet (MCD), which limits 
the dietary availability of choline, the precursor to PC, thereby reducing hepatic VLDL 
secretion and causing increased hepatic triglyceride content (12). Though the MCD diet 
provides useful information with regard to intrahepatic trafficking of VLDL and produces 
very consistently pathological features of NASH, it represents a physiologically 
irrelevant scenario as limited dietary choline is a very rare occurrence to confront 
humans. Moreover, the metabolic context in which the MCD diet takes place is also very 
different from humans with NAFLD (13), as mice fed MCD do not exhibit any features of 
insulin resistance or impaired glucose metabolism (14).  
Insights into the diverse roles phospholipid metabolism plays in liver function 
have been gained through studies using genetically-targeted mouse models (15). 
Collectively the studies to date have shown fairly convincingly that PC and PE are 
involved in both steatosis as well as the transition to NASH. For example mice with a 
liver specific deletion of CT, the rate limiting enzyme of PC synthesis, were shown to 
develop steatosis on a chow-diet and when fed a high-fat diet, rapidly developed NASH 
within one week (16). Furthermore, mice genetically manipulated to lack PEMT develop 
liver failure when fed a choline-deficient diet and this is attributable to a greater than 
50% reduction in the hepatic ratio of PC to PE (17). Alterations in this ratio caused loss 
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of membrane integrity and the formation of ballooned hepatocytes, which is a seminal 
feature of NASH, demonstrating that maintenance of the PC to PE ratio may be 
involved in dictating the transition of steatosis to NASH. The authors also observed a 
similar occurrence in humans with NASH, adding to the growing list of studies that 
implicate phospholipid composition as another determinant of NAFLD severity (18). A 
well-conducted lipidomics study of human livers found a stepwise reduction in hepatic 
PC content as NAFLD severity increased. There was also a concomitant increase in the 
free cholesterol to phospholipid ratio which is significant given that in membranes the 
free cholesterol molecule situates itself between neighboring phospholipids, forming so-
called condensed complexes (19).  
The growing awareness that NAFLD occurs in the midst of numerous alterations 
to normal lipid metabolism prompted us to investigate some of the finer changes that 
might occur in specific lipid species when liver injury is present. To do this, we sought to 
identify changes in the fatty acid composition of both phospholipids as well as 
triglycerides from livers of guinea pigs with varying degrees of NAFLD. We used four 
groups of animals based on diet; a low-cholesterol (L-Chol) control group, a high-
cholesterol group (H-Chol), a carbohydrate restricted (LCD) group, and a carbohydrate-
enriched (HCD) group. Because we observed that H-Chol feeding promotes steatosis 
as well as inflammation and evidence of hepatic injury, we wanted to determine how 
changes in these two lipid fractions might help explain the degree of liver damage. We 
also observed that when guinea pigs were fed the H-Chol and then assigned to either a 
LCD or HCD, both groups had more advanced hepatic dysfunction than that observed 
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for the H-Chol. As no obvious differences were observed between the LCD and HCD in 
terms of liver injury, we focused on changes that occurred in both lipid fractions as 
potential explanations for these pathological changes. In short, we find that H-Chol 
feeding causes liver PL and triglycerides to become more unsaturated in terms of fatty 
acid composition, and also triggers a reduction in PL arachidonic acid content despite 
having similar linoleic acid content as L-Chol controls. There were no major differences 
between LCD and HCD, however both experienced a pronounced depletion of total PL 
content following the H-Chol challenge, which may help to explain the worsened liver 
pathology of these two dietary groups. 
 
 
  
 
 
 
 
 
 
 
 
STUDY 3: Methods and experimental methodology 
 
Fatty acid profile of liver PL and TG: 
 How certain dietary manipulations impact liver fatty acid metabolism in guinea 
pigs has never been sufficiently investigated.  To that end we sought to analyze the 
composition of fatty acids present in liver triglycerides (TG), a predominant storage lipid, 
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and phospholipids (PL), the major lipid constituent of membrane lipid bilayers, in guinea 
pigs fed either L-Chol (n = 6), H-Chol (n = 5), LCD (n = 9), and HCD (n = 10) for six 
weeks.  For analysis approximately 1 g of tissue from the left lobe or medial sublobe of 
the right lobe was sliced with a razor, placed in a 1.5 mL snap tube, immediately 
submerged in liquid nitrogen, and stored at -80°C until samples were ready for analysis.  
 Samples were tightly wrapped and sealed to limit exposure to light and packaged 
in dry ice on the day of shipment.  All samples were analyzed using capillary gas 
chromatography at Lipid Technologies LLC (Austin, MN).   
Capillary gas chromatography 
 Lipids were extracted from livers based on the methodology of Bligh and Dyer 
(20).  Livers were homogenized and mixed with methanol, chloroform, and water and 
lipids were extracted from the chloroform layer.  The extracts were maintained under an 
atmosphere of nitrogen and kept frozen until additional processing took place.  Prior to 
the separation of lipid classes samples were dried under a steady stream of nitrogen 
and rediluted in 50 µL of chloroform.  Next, lipid classes including total TG and PL were 
separated on commercial silica gel G plates (AnalTech, Newark, DE) with development 
of the plates occurring in a solvent system consisting of distilled petroleum ether: diethyl 
ether: acetic acid (80:20:1 by volume).  Silica gel plates were then sprayed with a 
methanolic solution (0.5% 2,7-dichlorofluorescein) in order to visualize the lipid bands 
under ultraviolet light exposure.  Desired bands were scraped into Teflon-lined screw 
cap tubes and samples were then transesterified with 10% boron trifluoride in the 
presence of excess methanol in a water bath (80°C) for approximately 90 minutes. The 
 178 
 
resultant fatty acid methyl esters were then extracted with water and petroleum ether 
and stored frozen prior to gas chromatographic analysis.  
 Fatty acid methyl ester composition was subsequently determined by capillary 
gas chromatography. First, methyl esters were blown to dryness under nitrogen and 
resuspended in hexane.  Next, fatty acid methyl esters were separated and quantified 
using a Shimadzu capillary gas chromatograph with a programmed temperature from 
190° to 240°C at 7°C/ min with a final hold of 10 min, thereby separating and measuring 
fatty acid methyl esters ranging from 12:0 to 24:1 at a detector temperature of 250°C.  
All chromatographic data was collected and processed using EZChrom software 
(Scientific Products, CA) and fatty acids were identified by comparison to authentic fatty 
acid standards and quantitated with peak area and internal standard.  Individual peaks 
that represented as little as 0.05% of fatty acid methyl esters were distinguished.  Data 
is expressed as both percent composition and absolute composition (µg/g liver). 
Statistical analysis: 
 All data were analyzed using the Prism statistical program from GraphPad 
Software version 5.0c (San Diego, CA).  Two-tailed independent student’s t-tests were 
performed when comparing the differences between L-Chol and H-Chol and between 
LCD and HCD groups.  An unpaired t-test with Welch’s correction was used when 
unequal variances were detected.  To compare differences between H-Chol, LCD, and 
HCD, a one-way analysis of variance (1-way ANOVA) was used followed by Tukey’s 
post-hoc multiple comparisons test. In the case of unequal variances as determined by 
Bartlett’s test, data were analyzed with Kruskal-Wallis test followed by Dunn’s post-hoc 
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multiple comparisons test.  All data are expressed as the mean + standard error of the 
mean (SEM).  An α-level of p < 0.05 was chosen to denote statistical significance.  
Graphical data represents the % fatty acid composition of either phospholipids or 
triglycerides.  The p value represents the ANOVA results comparing H-Chol, LCD, and 
HCD. 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY 3: Results 
 
H-Chol alters fatty acid profile of liver phospholipids and triglycerides by 
decreasing SFA and PUFA while increasing MUFA 
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 In this study we used capillary gas chromatography to analyze the fatty acid 
composition of liver phospholipids and triglycerides in guinea pigs fed four distinct diets; 
L-Chol, H-Chol, and LCD and HCD following H-Chol.    
 Looking first at hepatic phospholipids, it was evident that feeding H-Chol for six 
weeks dramatically alters the fatty acid profile from that observed in the L-Chol group.  
Table 3.1 contains the results for L-Chol and H-Chol in the phospholipid fraction and 
data is expressed as both percent composition and absolute concentration (µg/g liver).  
H-Chol feeding significantly reduced the percentage of SFA (p = 0.005) while at the 
same time increasing the percentage of MUFA (p = 0.012).  There was no difference in 
the percent PUFA content (p = 0.2), however there was a significant reduction in the 
absolute amount (p = 0.03) in H-Chol livers.  Intriguingly, there was also a marked 
reduction in highly unsaturated fatty acids (HUFA) in H-Chol samples, both in terms of 
percent (p = 0.004) and absolute levels (p = 0.001).  Overall, phospholipids in both L-
Chol and H-Chol appear to be composed primarily of SFA and PUFA as both species 
each represented around 40% of the total, with MUFA comprising between 14-17%.  
The fact that MUFA content increased with H-Chol feeding likely indicates an increase 
in hepatic SCD-1 activity to provide increased substrate for formation of certain 
phospholipid molecules.  Further substantiating the likelihood of increased SCD-1 action 
is the reduced PUFA concentration, as PUFA, specifically n3 and n6 species (see 
below) are potent inhibitors of SCD-1 expression (21).    
H-Chol phospholipids and triglycerides show decreased stearate but increased 
oleate compared to L-Chol 
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 Between L-Chol and H-Chol there were no significant differences in the 
composition of shorter chain SFA such as myristic acid.  Both were equally composed 
of palmitate and palmitoleate, two key membrane fatty acids; there was actually very 
little palmitoleate present in both groups, making up only around .5%, which indicates 
that liver phospholipids of guinea pigs do not contain notable amounts of this fatty acid.  
There was considerable accumulation of stearate within this lipid fraction and 
interestingly, this accumulation was greatest in L-Chol as feeding H-Chol resulted in 
less stearate, both as percent composition (p = 0.003) and absolute amount (p = 0.024).  
The decreased stearate in H-Chol is likely a consequence of increased hepatic SCD-1 
activity as there was evidence of increased oleate concentration in H-Chol 
phospholipids,  constituting 15% compared to 13% in L-Chol (p = 0.014).   
 Without directly measuring the enzymatic activity of SCD-1 in liver microsomes, 
many of these observations are speculative in nature.  However, given the 
preponderance of evidence detailing cholesterol’s regulation of this lipogenic enzyme 
(21,22) it is plausible, indeed, exceedingly likely that H-Chol increased the endogenous 
production of MUFAs, in particular oleate, in liver phospholipids.  Reflecting this 
possibility is the observed reduction of the stearate to oleate ratio (18:0/18:1) in H-Chol 
livers compared to L-Chol (p = 0.005).  Alterations in this ratio are known to have 
profound effects on membrane integrity and fluidity and a reduced ratio in H-Chol may 
help to, in part, explain some of the changes to liver microanatomy observed in study 1. 
H-Chol reduces phospholipid arachidonic acid content and causes a reduction in 
overall hepatic omega 6 concentration 
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 PUFAs consist of primarily omega 3 and omega 6 species and in liver tissue 
three fatty acids predominate: docosahexaenoic acid (DHA,22:6n3), linoleic (18:2n6), 
and arachidonic (20:4n6). This was true in the current study with linoleic acid being the 
major PUFA in both L-Chol and H-Chol, followed by much lower amounts of 
arachidonic, and DHA (Table 3.1).  Overall, the omega 6 content represented between 
37-39% of total phospholipid PUFA content with H-Chol displaying significantly lower 
absolute concentration compared to the L-Chol (p = 0.025).  Closer inspection revealed 
that this difference was due to lower hepatic levels of arachidonic (p = 0.001) and its 
immediate precursor, dihomo-γ-linolenic acid (DGLA, 20:3n6) (p = 0.001). Similar 
statistical differences were also evident when the data were expressed as percent 
composition (Table 3.1). Moreover, we noted a significant reduction in the arachidonic 
to linoleic ratio (20:4n6/18:2n6) (p = 0.01) in H-Chol compared to L-Chol.  The overall 
omega 3 content was similar between both groups, however we did note an increase in 
DHA within phospholipids in H-Chol (p = 0.01), the relevance of which is not currently 
clear. There was a similar ratio of omega 6 to omega 3 between groups (p = 0.14), 
although it should be noted that it was reduced in the H-Chol group. Thus, it appears 
that H-Chol feeding somehow depletes hepatic phospholipids of arachidonic acid and 
thereby reduces the omega 6 PUFA content; whether this depletion of arachidonic acid 
is due to increased phospholipase A2-mediated release from membranes or enhanced 
conversion to bioactive eicosanoids is currently unknown and requires further 
investigation. 
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LCD and HCD guinea pigs display identical changes in hepatic phospholipid and 
triglyceride fatty acid composition 
 
 We had anticipated that feeding a LCD or HCD following a H-Chol challenge 
would differentially impact the fatty acid composition of various lipid fractions based on 
the specific metabolic effects elicited by these diets. Remarkably, the fatty acid makeup 
of phospholipids were almost identical in both groups, with one notable exception being 
palmitate (table 3.2).  In the HCD group, palmitate was significantly increased 
compared to the LCD group, both when expressed as percent (p = 0.008) and absolute 
amount (p = 0.005).  This may reflect differences in the DNL pathway between LCD and 
HCD as palmitate is a major end product of endogenous fatty acid synthesis.  Why this 
difference is observed in the phospholipid fraction and why it occurs with palmitate and 
not stearate, another end product of DNL, is not presently understood.   
Phospholipid content is markedly depleted in LCD and HCD livers following a H-
Chol challenge 
 
 One of the most intriguing findings from this current study was that when 
compared to the H-Chol group, livers from guinea pigs in either the LCD or HCD had a 
pronounced reduction in total phospholipid content (p = 0.001; see table 2.5 in study 
2). Although the relevance of this finding was not further investigated, we speculate that 
this may be due to an increased membrane cholesterol content, which might disrupt 
membrane bilayers, resulting in the removal of the phospholipids themselves. Future 
studies using this same study design should address whether this is the case or if in fact 
other mechanisms are at play.  
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Table 3.1: Fatty acid composition of hepatic phospholipids in L-Chol and H-Chol 
fed guinea pigs 
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Data are represented as mean + SEM of n = 6 (L-Chol) and n = 5 (H-Chol) animals. p-
value was calculated using an unpaired, two-tailed student’s t-test with an α-level of 
0.05 considered statistically significant. ND; not detected.  
Table 3.2: Fatty acid composition of hepatic triglycerides in L-Chol and H-Chol 
fed guinea pigs 
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Data are represented as mean + SEM of n = 6 (L-Chol) and n = 5 (H-Chol) animals. p-
value was calculated using an unpaired, two-tailed student’s t-test with an α-level of 
0.05 considered statistically significant. ND; not detected.  
Table 3.3: Fatty acid composition of hepatic phospholipids in LCD and HCD fed 
guinea pigs 
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Data are represented as mean + SEM of n = 9 (LCD) and n = 10 (HCD) animals. p-
value was calculated using an unpaired, two-tailed student’s t-test with an α-level of 
0.05 considered statistically significant. ND; not detected.  
Table 3.4: Fatty acid composition of hepatic triglycerides in LCD and HCD fed 
guinea pigs 
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Data are represented as mean + SEM of n = 9 (LCD) and n = 10 (HCD) animals. p-
value was calculated using an unpaired, two-tailed student’s t-test with an α-level of 
0.05 considered statistically significant. ND; not detected.  
Figure 3.1: One-way ANOVA of liver fatty acid classes between H-Chol, LCD, and 
HCD groups 
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Figure 3.2: One-way ANOVA of major SFA and MUFA species between H-Chol, 
LCD, and HCD groups 
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Figure 3.3: One-way ANOVA of liver n3, n6, and n9 classes between H-Chol, LCD, 
and HCD groups 
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Figure 3.4: One-way ANOVA of major n3 and n6 PUFA species between H-Chol, 
LCD, and HCD 
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Figure 3.5: One-way ANOVA of n6 to n3 ratio in liver phospholipids and 
triglycerides between H-Chol, LCD, and HCD groups  
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STUDY 3: Discussion 
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 This is the first study to our knowledge that has evaluated the fatty acid 
composition of liver PL and triglyceride in guinea pigs under different dietary schemes. 
The study, in conjunction with the pathological evidence obtained from previous work 
(see study 1 and 2) might help in our understanding of NAFLD pathogenesis and how it 
occurs in guinea pigs, an animal which has yet to gain appreciable interest as a model 
for NAFLD.  
 Many aspects of hepatic lipid metabolism are affected by cholesterol status. For 
instance, increased dietary cholesterol is known to exert tremendous influence on 
stearoyl-CoA desaturase 1 (SCD-1), the enzyme responsible for the conversion of 
saturated fatty acids (SFA) to monounsaturated fatty acids (MUFA) (21). MUFA, 
primarily palmitoleate (16:1) or oleate (18:1), are the preferred fatty acid substrates for 
the synthesis of triglycerides, PL, as well as cholesterol esters, and a disruption of SCD-
1 activity, such as that which occurs in the SCD-1 null mouse (22) results in decreased 
synthesis of these molecules.  Here we observed that guinea pigs fed the H-Chol had a 
shift in the ratio of SFA and MUFA in both PL and triglyceride fractions. Specifically, 
both fractions were shown to contain a greater percentage of MUFA and this occurred 
at the expense of SFA. Oleate was shown to be responsible for the increased MUFA of 
both fractions, thus implicating SCD-1 as a likely mediator. The reason for enhanced 
SCD-1 activity under H-Chol presumably stems from an increased cellular need to 
buffer incoming free cholesterol through esterification, a process mediated by acyl-CoA 
cholesterol acyltransferase (ACAT) (23). By forming the preferred palmitoleate or 
oleate, cells then use ACAT to attach these fatty acids to the cholesterol molecule, 
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rendering it much more hydrophobic and at the same time eliminating any potential 
cytotoxic or membrane effects (24). Free cholesterol resides in close proximity to PLs 
within membranes. It is important not to underestimate cholesterol’s ability to influence 
membrane function, as has recently been shown by Andrew Brown’s group (25). In this 
study an enantiomer of cholesterol was utilized in several cell experiments and shown 
to be as effective as natural cholesterol in eliciting homeostatic responses. This was 
attributed to the specific membrane effects that cholesterol is responsible for and 
argues that cholesterol might play a much more profound role in modulating 
membranes than previously thought.  
 One of the most interesting findings was that H-Chol triggered a significant 
depletion of PL arachidonic acid. Because there was no difference between H-Chol and 
L-Chol in terms of PL linoleic acid levels (the precursor to arachidonic acid), the 
reduction cannot be attributed to a dietary deficiency of  linoleate. To us this indicates 
that the arachidonic acid contained in membrane PL of H-Chol livers underwent 
phospholipase-mediated release and was able to engage in the production of 
proinflammatory prostaglandins, thromboxanes, or leukotrienes, though we do not have 
evidence to directly support these claims at this time. It may also be the case that the 
decrease of PL arachidonic acid reflects an increased utilization of this lipid in H-Chol 
livers. Whatever the underlying mechanism(s), it was significant that this alteration has 
also been observed in humans with varying stages of NAFLD (18). Specifically, Puri et 
al (18) found that in humans with NASH, there was a significant reduction in arachidonic 
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acid content of free fatty acids, triglycerides, and importantly in PC. This again occurred 
despite no differences in linoleic acid levels between control and NASH patients.  
 Guinea pigs fed the LCD or HCD had almost identical changes in all parameters 
measured in this study, which was unexpected given the different metabolic changes 
each diet elicits. The only difference that reached statistical significance was an 
increase in the amount of palmitate within PLs of guinea pigs fed the HCD. The 
mechanistic importance of this observation is unclear. Because these animals were 
coming off of a six week dietary cholesterol challenge prior to these diets, we compared 
the responses of LCD and HCD to the H-Chol group. The results indicate that in both 
PL and triglycerides there were statistically significant increases in MUFA along with 
concomitant decreases in PUFA. An increase in oleate in both fractions was shown to 
be responsible for the elevated MUFA content of LCD and HCD guinea pigs. We should 
point out that triglycerides contained MUFA as the most predominant fatty acid specie, 
while PL was primarily composed of SFA and PUFA. When we evaluated the percent 
composition of total omega 6, the LCD and HCD groups had significantly less omega 6 
in both PL and triglyceride fractions as compared to H-Chol. This reduction in omega 6 
proved to be due to a significant reduction in PL and triglyceride content of linoleic acid 
(18:2n6) (figure 3.4 a,b).  
 As mentioned previously, cholesterol is found situated between PLs in 
membranes with its free, polar hydroxl group on the 3rd carbon facing the aqueous 
exterior and its fused steroid nucleus and methylated side chain buried deep within the 
lipid bilayer. In mammalian cells the plasma membrane contains the highest 
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concentration of cholesterol (about 17% total lipid) whereas organelles such as the 
mitochondria tend to have much lower levels (3%). The ER is home to all of the pivotal 
transmembrane proteins that are responsible for governing cholesterol homeostasis, yet 
maintains a very tight level of membrane cholesterol at a low range (3-5%). Brown and 
Goldstein recently demonstrated that the ER is remarkably sensitive to changes in 
membrane cholesterol concentration such that when the ER content exceeds 5% 
cholesterol (on a molar basis), homeostatic responses are initiated which effectively 
shut down pathways of cholesterol biosynthesis (26). So, in situations where cholesterol 
is relatively abundant such as during a dietary cholesterol challenge, it is reasonable to 
consider the potential for increased membrane accumulation, which may impact 
membrane lipid organization. We believe this occurs in the guinea pigs fed LCD or HCD 
as they were shown to be markedly depleted in total phospholipid content as compared 
to H-Chol (p = 0.001). Furthermore this reduction in PL content likely contributes to the 
advanced pathological changes in these groups as plasma ALT and AST were shown to 
be negatively correlated with total hepatic PL content (r = -.7, p = 0.0004 and r = -.8, p = 
0.0002 for ALT and AST respectively). Though we did not identify the specific PL 
species in this analysis, it seems logical that this reduction of PL might be PC, as it is 
the most abundant PL in liver cells. The fact that PC has also been seen to be reduced 
as humans transition from steatosis to NASH (18) lends credence to our findings. It may 
also be that PE is also reduced, thereby altering the PC to PE membrane ratio, which 
has been shown to be reduced in mice and humans with NAFLD (17). Maintenance of a 
proper PC to PE ratio is also critical for recovery from surgically-induced liver loss, such 
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as partial hepatectomy (PHx) (27). We should point out that in those guinea pigs with 
more advanced injury, PL content was not always reduced, indicating the involvement 
of other as of yet unknown factors. However the most severe pathological injury (biliary 
hyperplasia) occurred in the HCD guinea pig which did in fact display the lowest level of 
hepatic PL content.  
 There are several outstanding questions that emerge from this study. Where 
exactly in the liver do these changes to fatty acid composition occur? Triglycerides are 
stored in the hydrophobic cores of lipid droplets within the cytoplasm, however PLs are 
scattered throughout several organelle membranes. It would be extremely interesting to 
determine if H-Chol induces these changes we observed to a similar extent in places 
like the ER, mitochondria, or golgi. Which species of PL are involved is another question 
of significance. Because PC is the most abundant PL, we speculate that this might be 
where the bulk of these changes to fatty acid composition occur. With regard to the LCD 
and HCD groups an important question is whether the reduction in PL content is due to 
either depleted PC, PE, or a combination of both. Given the large surface area that the 
plasma membrane has, it may be that most of the depletion occurs here, although it 
may also be that organelles like the ER are experiencing a shortage of PL. To what 
extent does cholesterol accumulate in membranes? We did not measure membrane 
cholesterol content, but determining whether feeding a H-Chol diet results in membrane 
accumulation is an avenue that should be explored. It is quite possible that overloading 
guinea pig livers with cholesterol results in increased membrane accretion, which may 
oversaturate the complexing ability of cholesterol with surrounding PL. Answers to these 
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pressing questions will hopefully begin to tease apart the function of PL metabolism in 
NAFLD. Research of this kind will also likely begin to shift the attention of researchers 
towards the importance of organelle lipid composition in disease progression. Scientific 
evidence from such experiments is eagerly awaited.  
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CONCLUDING REMARKS 
 
 We have come to the conclusion of the present investigation and should reflect 
upon some of the major findings. The overarching hypothesis of this dissertation 
centered around the pathophysiological impact of excess dietary cholesterol on hepatic 
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function and in particular, how this dietary scheme has the potential to promote non-
alcoholic fatty liver disease (NAFLD) in guinea pigs, an underappreciated animal model 
in metabolic disease research. Indeed, study 1 demonstrated that feeding a cholesterol-
enriched diet caused guinea pigs to develop fatty liver and several pathological features 
observed in the more advanced stage of the disease spectrum. Several questions arise. 
Is cholesterol solely responsible for the transition of steatosis to non-alcoholic 
steatohepatitis in those affected guinea pigs? How is it that some guinea pigs in the 
cholesterol-enriched group developed steatosis and others displayed more 
inflammatory pathological features? Is there an underlying genetic component that 
makes some guinea pigs more sensitive to cholesterol-induced disease? Answers will 
only come from more in-depth studies that employ a potent mixture of genetics, 
biochemical, and pathological experiments.  
 Another hypothesis that drove the dissertation was that manipulating dietary 
macronutrients may be a potential therapeutic modality to improve histological features 
of NAFLD. Quite unexpectedly, the results from study 2 suggest this may not be the 
case as guinea pigs fed either a low-carbohydrate, high fat diet or a high-carbohydrate, 
high-fat diet developed more severe hepatic dysfunction and pathological features of 
injury. This could imply that macronutrient manipulation may be unable to rescue guinea 
pigs following cholesterol-induced injury. An interesting experiment that should be done 
in the future would be to subject guinea pigs to the dietary intervention and then place 
them on a high-cholesterol diet. It may be that one diet is more hepatoprotective, a 
consequence of the metabolic effects of specific macronutrients.  
 204 
 
 The third study provided us with some more in-depth answers when it comes to 
the lipidomic changes that a cholesterol challenge elicits. The results largely reaffirmed 
what was previously published, specifically that high cholesterol promotes an increase 
in the content of unsaturated fatty acids, both in triglycerides as well as phospholipids. 
What was particularly rewarding was the observation that arachidonic acid was 
significantly depleted in phospholipids following a cholesterol challenge, a finding that 
has been repeatedly shown in studies conducted in humans. An equally interesting 
observation was that both low and high carbohydrate diets were profoundly depleted of 
membrane phospholipids compared to the high cholesterol group. What species of 
phospholipid are depleted, and perhaps equally important, what organelles do these 
changes occur in the liver? Future experiments should begin to take a more nuanced 
approach to understand alterations in fatty acid metabolism and see how this relates to 
the pathological changes in the liver. This may indeed represent a new frontier in the 
study of NAFLD, lipid metabolism, and dietary interventions. No doubt it is an exciting 
time to be a researcher in this field. Hopefully this work along with others will result in a 
truly exciting situation, that is, potent therapeutic modalities to finally gain control over a 
disease that has, and continues to have such an overwhelming impact on much of the 
world today.  
 
 
 
 
 
 
 
 205 
 
 
 
